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Abstract 
Transglutaminase 2 (TG2; EC 2.3.2.13) has been shown to protect cardiomyocytes against 
ischaemia and reperfusion-induced cell death and to mediate cell survival in many cell types. 
Given the prominent role of PKA and PKC in cardioprotection, this study investigated 
whether TG2 was involved in the cytoprotection induced by activation of these two kinases in 
cardiomyocyte-like H9c2 cells.  
Cultured H9c2 cells were extracted following stimulation with activators of PKC (phorbol-
12-myristate-13-acetate; PMA) and PKA (forskolin; FK). Transglutaminase 2 activity was 
determined using an amine incorporating (in vitro and in situ) and a protein crosslinking 
assays. Different protein kinase inhibitors were used to determine the involvement of PKC 
and PKA in the activation of TG2 in H9c2 cells. To confirm the involvement of TG2 activity 
via PKC and PKA, TG2 specific (Z-DON and R283) inhibitors were used. Western blot 
analysis revealed the presence of TG2 and TG1 (TG2 >> TG1) protein, but not TG3. Since 
the H2O2, a major contributor to reactive oxygen species following damage was used to  
induce oxidative stress. The role of TG2 in PMA- and forskolin-induced cytoprotection was 
investigated by monitoring H2O2-induced oxidative stress in H9c2 cells. The identification of 
TG2 substrates in H9c2 cells was investigated using pull down assay coupled with proteomic 
analysis techniques.  
The PMA and FK-induced time and concentration-dependent increases in TG2 catalysed 
biotin cadaverine incorporation in H9c2 cells. Forskolin but not PMA also increased TG2 
catalysed protein crosslinking. The PKC (Ro-31 8220) and PKA (KT 5720 and Rp-8-Cl-
cAMPS) inhibitors, blocked PMA and FK-induced TG2 activity. Immunocytochemistry using 
ExtrAvidin®-FITC revealed in situ TG2-mediated biotin cadaverine incorporation into 
protein substrates following stimulation of PMA, FK and their receptor agonists. The TG2 
inhibitors Z-DON and R283 attenuated the PMA- and FK-induced increases in TG2 activity. 
Pre-treatment with PMA and FK reversed H2O2-induced cell death as judged by a MTT 
reduction assay and the release of cellular LDH. The TG2 inhibitors R283 and Z-DON 
blocked PMA and FK-induced cytoprotection. Proteomic analysis identified more than 25 
proteins that serve as intracellular substrates for TG2 following PMA and FK stimulation. 
Some of these identified proteins have already been reported as TG2 substrates, but not in 
H9c2 cells e.g. tubulin while others e.g. α-actinin have not been identified before.  
In summary, these data have shown TG2 activity to be stimulated via PKA and PKC-
dependent signalling pathways in H9c2 cells and suggest a role for TG2 in cytoprotection-
induced via these two protein kinases. 
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GENERAL INTRODUCTION 
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1. Introduction 
1.1. History of transglutaminase (Transglutaminases in cell and organisms)   
The transglutaminase (TG) enzymes were first discovered 55 years ago in mammalian 
guinea pig liver homogenates. They were shown to have the ability to catalyse the 
calcium-dependent formation of covalent bonds between small molecule amines and 
definite proteins, along with the release of free ammonia (Clarke et al., 1959; Mycek 
et al., 1959). However, when the activity of transglutaminases was explored in blood 
plasma, it was found that factor XIIIa had the ability to cross link and stabilise fibrin 
monomers as part of the blood coagulation mechanism (Pisano et al., 1969), 
establishing the idea that these enzymes are able to modify proteins and act as 
biological glues (Griffin et al., 2002). Further studies revealed different TG 
isoenzymes and nine different genes encoding for TGs were identified in mammalian 
cells, some of which have been studied at the protein level (Grenard et al., 2001). 
Different transglutaminases can be categorised by their characteristic tissue 
distribution and they can also be found together in a number of diverse tissue types 
(Grenard et al., 2001). Since the complete sequence of TG2 was characterised in 
guinea pig liver (Ikura et al., 1988), and from TG2 cDNA clone of human endothelial 
cells and mouse macrophages (Gentile et al., 1991), transglutaminases have been 
shown to be highly conserved among different species (Makarova et al., 1999) and 
widely distributed in various cell types. Examples include, endothelial and smooth 
muscle cells in arteries, veins, and mesangial cells (like smooth muscle cells that are 
usually found around the kidney-blood vessels), renomedullary interstitial tumour 
cells or differentiation of cells to enterocytes in small intestine (Thomázy & Fésüs, 
1989). In addition, catalytic activities of transglutaminase have been detected in a 
wide range of organisms, including invertebrates (Zanetti et al., 2004), unicellular 
primitive eukaryotes (Wada et al., 2002), plants (Serafini-Fracassini & Del Duca, 
2008), amphibians (Zhang & Masui, 1997), birds (Puszkin & Raghuraman, 1985) and 
fish (Lin et al., 2008). The enzymatic functions of TGs generally involve either tissue 
assembly or repair (Kim et al., 2002), making them of particular interest for 
researchers. 
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1.2. Reactions catalysed by transglutaminases 
Transglutaminases (TG; Protein glutamine -glutamyl-transferases, EC 2.3.2.13) are a 
family of Ca
2+
 dependent enzymes that catalyse the posttranslational modification of 
proteins. Once Ca
2+
 ions bind to TG catalytic core domain, a cysteine residue is 
exposed at the active site of the enzyme leading to the formation of a bond between ε-
amide (as an isodipeptide or polyamine bond) and the -carboxamide of protein bound 
glutamine residues (Lorand & Conrad, 1984). There are at least five different catalytic 
reactions known for these enzymes. These can be classified into three types; 
transamidation, deamidation (or hydrolysis) and esterification (Lorand & Graham, 
2003). In the TG transamidation reaction, acyl transfer between the γ-carboxamide 
group of a protein bound glutamine residue and the ε-amino group of a protein 
containing lysine residue results in the crosslinking of proteins (Fig. 1.1/1a). 
Moreover, incorporation of monoamines or polyamines by attachment to the γ-
carboxamide of a glutaminyl residue and acylation of lysyl residue are two more 
transamidation reactions (Fig. 1.1/1b,c). However, in esterification reactions, an 
alcohol substrate binds to protein glutamine resulting in an esterified product (Fig. 
1.1/2), while hydrolysis occurs in the presence of H2O and results either in 
deamidation through the replacement of the NH2 group with an -OH group or 
cleavage of an isopeptide bond (Fig. 1.1/3a,b; Iismaa et al., 2009).  
Additional activities have been revealed for TG2, which will be discussed later in 
section (1.3.7), including its ability to act as a G protein (Nakaoka et al., 1994; 
Prasanna Murthy et al., 1999), protein disulphide isomerase (Ferrari & Söling, 1999) 
and protein kinase (Mishra & Murphy, 2004). 
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a) Crosslinking 
b) Amine incorporation 
 
c) Acylation 
 
a) Deamidation 
 
b) Isopeptide cleavage 
 
1- Transamidation 
2- Esterification 
 
3- Hydrolysis 
 
 
Figure 1.1 Posttranslational reactions catalysed by transglutaminases 
The different TG-catalytic reactions. Shown are acceptor glutamine (Gln) residue of 
one protein (blue oval) and the lysine (Lys) donor residue another (red oval), a Gln-
containing peptide (green oval) and an alcohol substrate (grey oval). R1 and R2, 
represents the side chains in branched isopeptides. Figure modified from Lorand & 
Graham (2003).
 
+    NH3 
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1.3. Transglutaminase family members 
At least nine different genes encoding for TG isoenzymes have been identified in 
mammalian cells (Grenard et al., 2001), though only seven have been studied at the 
protein level (Table 1.1). Each TG can be characterised via its own distinctive tissue 
distribution (Grenard et al., 2001). However, they also appear in a number of diverse 
tissue types frequently in combination with other TG family members. 
Transglutaminases have particular functions in the cross linking of specific proteins or 
tissue structures. For example, blood plasma transglutaminase (Factor XIIIa) is 
essential for the formation and stabilisation of fibrin clots during haemostasis, and 
TGs 1, 3, and 5, are mostly expressed in the skin epidermis, contributing towards the 
correct formation of the cornified cell envelope (Eckert et al., 2005). Band 4.2 protein, 
which has no catalytic activity due to the absence of a catalytic core domain (Iismaa 
et al., 2009), is a component of the cytoskeleton (Aeschlimann et al., 1998). 
Transglutaminase 2 (TG2) is expressed ubiquitously and is implicated in a wide range 
of cellular processes, such as programmed cell death (Akar et al., 2007b), cell 
differentiation (Singh et al., 2003) and tumour growth (Verma et al., 2008). It has 
been suggested that TG2 may act as an apoptotic inhibitor of retinoblastoma protein 
regulation during the cell cycle (Antonyak et al., 2001; Boehm et al., 2002; Tucholski, 
2010). 
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Table 1.1 Transglutaminase enzymes family 
 
Table 1.1 Classification of TGs isoenzymes is summarised, according to their 
molecular mass, known gene location, cell or tissue localisation and biological 
functions (Lorand & Graham, 2003). 
 
 
 
TGs 
 
Molecular 
mass in 
kDa 
 
Biological function 
and/or location 
 
Gene 
location 
 
Reference 
Factor XIIIa 
Plasma 
Platelet 
 
360 
166 
 Blood clotting, angiogenesis 
and wound healing 
 
6p24-25 
1q28 
( Olaisen et al., 1985; 
Dardik et al., 2006; 
Dardik et al., 2007) 
TG 1 
(Keratinocyte 
TG, kTG) 
106 
 
Keratinocyte differentiation 
and correct formation of the 
cornified cell envelope 
14q11.2 (Yamanishi et al., 
1992; Jans et al., 
2007) 
TG 2 (Tissue 
TG, tTG, 
cTG) 
78 Apoptosis and cell 
differentiation, matrix 
stabilization, adhesion 
protein and signal 
transduction 
20q11-12 (Gentile, et al.,  1994; 
Siegel & Khosla, 
2007; Chhabra et al., 
2009) 
TG 3 
(Epidermal 
TG, eTG) 
77 Epidermal, nail and hair 
follicle differentiation 
20q11-12 (Wang et al., 1994; 
Zhang, et al., 2005; 
Cheng et al., 2008) 
TG 4 
(Prostate TG, 
pTG) 
80 Suppression of sperm 
immunogenicity & rodent 
fertility 
3q21-22 (Dubbink et al., 1998; 
Ablin et al., 2011) 
TG 5 (TG X) 81 Expressed in epithelial 
tissues and involved in 
differentiation. 
15q15.2 (Aeschlimann et al., 
1998; Thibaut et al., 
2005) 
TG 6 (TG Y) 80 Expressed in cortical and 
cerebellar neurons 
20q11 15 (Grenard et al., 2001; 
Thomas et al., 2013) 
TG 7 (TG Z) 80 Not characterized 15q15.2 (Grenard et al., 2001; 
Thomas et al., 2013) 
Protein 4.2 74 Involved in formation of 
membrane & cytoskeleton 
components of red cells and 
blood vessels. 
15q15.2 (Sung et al., 1992; 
Mouro-Chanteloup et 
al., 2003) 
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Apart from Protein 4.2, gene and protein structure of all TG family members consists 
four conserved domains; a) an amino-terminal β-sandwich, b) a core domain which 
contains a catalytic triad of cysteine (Cys), histidine, (His) and aspartate (Asp) 
residues and a transition stabilising site tryptophan (Trp), and c) two COOH-terminal 
β-barrel domains (barrel 1 and barrel 2). However, TG1 and Factor XIIIa family 
members have an additional N-terminal pro-peptide sequence that can be cleaved to 
activate the enzyme (Fig. 1.2; Lorand & Graham, 2003).  
 
 
 
 
 
 
 
 
 
Figure 1.2 Transglutaminase protein domains and genomic organisation 
Diagram shows the four structural domains of the protein, namely the NH2-terminal 
β-sandwich, two COOH terminal and α/β catalytic core domain that contain essential 
cysteine (Cys), histidine (His), aspartate (Asp) and tryptophan (Trp) residues. 
Additional pro-peptide sequences (NH2-terminal) for TG1 and Factor XIIIa are also 
indicated. Dotted lines represent the relative location of exons encoding structural 
domains. Fifteen exons (numeral) and fourteen introns of genes encoding FXIII-a and 
TG1 (starting from exon 2). Genes with 13 exons and 12 introns encode isoforms 
TG2 to TG7 and protein 4.2 (Lorand & Graham, 2003).
 
1.3.1. Keratinocyte Transglutaminase (TGK) 
Keratinocyte transglutaminase (TGK), also known as transglutaminase epidermal type 
I, is encoded in the human gene TGM1 (Phillips et al., 1992). This is a membrane-
NH2-terminal Trp, Cys, His, Asp 
 
COOH-terminal 
Pro-β- 
sandwich 
  
β- 
sandwich 
  
α/β catalytic 
core 
β-barrel 
(1) 
β-barrel 
(2) 
FXIII-A  
&TG1 
TG2-TG7 
& 
Protein4.2 
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bound transglutaminase that is able to link to the membrane by an esterified fatty acid 
(Chakravarty & Rice, 1989). This membrane anchorage region is hypersensitive to 
proteolysis by trypsin, plasmin or Ca
2+ 
and temperature dependent proteolysis, 
resulting in release of the enzyme in a soluble form (Rice et al., 1990). Moreover, 
these features are important in the formation of cross-linked envelopes at the cell 
periphery upon calcium activation during terminal differentiation of human epidermal 
cells (Thacher & Rice, 1985), and in stabilising internal structures (Rice et al., 1990). 
In addition to activation by calcium, 12-O-tetradecanoylphorbol-13-acetate (TPA) can 
activate TG1 and elevate its mRNA expression while retinoic acid down-regulates its 
expression in cultured human keratinocytes (Liew & Yamanishi, 1992). Interaction 
between TG1 and tazarotene-induced gene 3 protein leads to its activation to regulate 
keratinocyte terminal differentiation of human foreskin keratinocytes (Jans et al., 
2007). Tazarotene-induced gene 3 acts in epithelial cancer cells as a class II tumour 
suppressor to impede cell proliferation (Deucher et al., 2000) and it is play an 
important role in survival of human keratinocytes via controlling TG1 activity 
(Sturniolo et al., 2003; Sturniolo et al., 2004). The epidermis is the first physical 
barrier for the protection of organisms from pathogen invasion and dehydration 
(Candi et al., 2005). In order to exert its protective barrier function, a complex balance 
between the proliferation and differentiation components is required during the 
formation of the cornified envelope process (Terrinoni et al., 2012). Thus, any such 
mutation or abnormality in these compartments can cause skin pathogenesis. It has 
been reported that specific deletions or mutations in the TG1 gene can result in a rare 
keratinisation disorder called Lamellar ichthyosis, which is characterised by abnormal 
cornified envelope formation (Terrinoni et al., 2012).   
1.3.2. Epidermal Transglutaminase (TG3) 
Transglutaminase type 3 (TG3) is another member of the transglutaminase TG family, 
that is commonly expressed during the late stage of terminal differentiation and more 
most likely to be found in epidermis (Martinet et al., 1988; Zhang et al., 2005), hair 
follicles and nails (Martinet et al., 1988; Cheng et al., 2008), keratinocytes, and brains 
(Hitomi et al., 2001). However, it also has been suggested that TG3 has an essential 
role during early embryogenesis at the developmental stage of mouse limb bud skin 
formation (Zhang et al., 2005). 
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Similar to TG1, TG3 is involved in regulation of the cornified cell envelope through 
interacting with and mediating the crosslinking of various protein structures (small 
proline-rich proteins, involucrin and loricrin) that are important in assembly of 
cornified cell envelope during the terminal differentiation stage of skin epidermal 
cells (Kalinin, et al., 2001; Kalinin et al., 2002). In addition, TG3 enzyme is thought 
to participate in shape determination or hardening of the inner root sheath through 
crosslinking of intermediate filaments and trichohyalin protein to the inner root sheath 
cell of hair follicles and the granular layers of the epidermis that is essential for hair 
cortical cells morphogenesis (Lee et al., 1993). The molecular mass of TG3 has been 
reported to be 77 kDa in human as well as in mouse tissues (Kim et al., 1993). The 
protein can be cleaved in vitro by cathepsin L (Cheng et al., 2006) and by proteinase 
K, trypsin, and thrombin (Kim et al., 1990), into a 50 kDa N-terminal fragment, which 
is the catalytically active form, and a 27 kDa C-terminal fragment, which is the non-
catalytic form (Hitomi et al., 2003).   
Unlike TG1, no mutation in TG3 has been linked to any human disease, although the 
failure in implantation of the TG3 knockout mouse blastocyst shows that it is essential 
in the earliest stages of embryo development (Ahvazi et al., 2004). Transglutaminase 
3 has been suggested to be involved in aggregation and crosslinking of mutant 
huntingtin protein into intranuclear inclusions in patients with Huntingdon’s 
disease (Zainelli et al., 2005). It is believed that TG3 is an auto-antigenic target in 
coeliac patients with dermatitis herpetiformis, a blistering skin disease (Sárdy et al., 
2002). It is worth to note that both these transglutaminase isoenzymes have never 
been investigated in cardiomyocytes, however, TG1 but not TG3 has been shown to 
be expressed in the vena cava and aortic smooth muscle cells (Johnson et al., 2012). 
1.3.3. Transglutaminase 4 (TG4) 
An alternative name for TG4 is prostate-specific transglutaminase, since it is 
predominantly secreted in the prostate gland. However, it is also found at low levels 
in other tissue types (Gentile et al., 1995; Dubbink et al., 1998; An et al., 1999). 
Transglutaminase 4 has been shown to display GTPase and protein crosslinking 
activities in rat coagulatory gland secretions (Spina et al., 1999). These activities have 
been linked to its N-terminal end domain, which was demonstrated by the analysis of 
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different TG4 mutants (Mariniello et al., 2003). The rat dorsal prostate TG or dorsal 
protein 1 is a homologue of TG4 that has molecular mass of 62 kDa (Wilson & 
French, 1980). 
Despite the lack of studies at molecular level, TG4 has been suggested to be up 
regulated by androgens in both the rat dorsal prostate and coagulating gland 
(Steinhoff et al., 1994; Dubbink et al., 1999). The transamidation activity of TG4 has 
been shown to be important in copulatory plug formation in human and rat sperm 
cells (Williams-Ashman, 1984) and in the immunogenicity and motility of tumour 
cells (Ablin & Jiang, 2011). In addition, its expression level was reported to be 
strongly associated with the invasiveness of human prostate cancer cells (Davies et 
al., 2007) in which TG4 transfected prostate cancer cells shed increased invasiveness. 
In prostate cancer, overexpression of TG4 has a potential role in activation and 
adherence of endothelial cells and these effects were reduced when TG4 expression 
was knocked down (Jiang et al., 2009). 
1.3.4. Transglutaminases 5-7 (TGs5-7) 
Transglutaminase 5 (TGX) plays a role in cornified cell envelope (CE) formation in 
human epidermis and keratinocyte differentiation through in vitro crosslinking of the 
specific epidermal substrates loricrin, involucrin and small proline-rich proteins 
(Candi et al., 2001). During hair follicle homeostasis, TG5 was significantly 
expressed as well as TG3, which suggests that they possibly play a balancing function 
in hair follicle homeostasis, hair shaft differentiation and construction, and could also 
participate in the crosslinking of these structures (Thibaut et al., 2005). In normal 
human skin tissue, TG5 was detected in the upper layers by immunofluorescence, 
being concentrated in the spinous and granular layers, while low levels of TG5 were 
detected in the basal layer (Candi et al., 2002). Both haematoxylin-eosin and 
immunofluorescence staining techniques have revealed that over expression of TG5 
was indirectly implicated with many incidences of pathologic human epidermis 
including, psoriasis, ichthyosis vulgaris and Darier's disease (Candi et al., 2002). The 
secretion of TG5 is not restricted to keratinocytes and epidermis, it has also been 
detected in other types of human cells e.g. in erythroleukemia (a pre-leukemic state), 
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osteosarcoma (a type of bone tumour) and dermal fibroblasts (Aeschlimann et al., 
1998).  
Transglutaminase 5 as well as TG6 and TG7 have molecular weights of 
approximately 80-81 kDa (Grenard et al., 2001). Recently, physiological functions of 
TG6 have been identified; Thomas and colleagues revealed that TG6 was extensively 
expressed in neuronal cells of mouse brain and in a human carcinoma cell line 
(Thomas et al., 2013). In addition, the biochemical analysis in the same study 
indicated the possible presence of Ca
2+
 and  GDP biding sites similar to those present 
in TG2 and TG3 (Thomas et al., 2013). The involvement of TG6 in coeliac disease 
autoantibody mediated gluten ataxia has been demonstrated (Stamnaes et al., 2010). 
By exome sequencing, Wang and his colleagues identified the presence of a mutation 
in the TG6 gene in patients with familial ataxia (a genetic neurodegenerative disorder 
characterised by incoordination of gait, hands, speech and limb that affects diverse 
regions within the brain cerebellum; Matilla-Dueñas et al., 2010; Wang et al., 2010). 
In mouse cerebral cortex cells, NGF (nerve growth factor) and dibutyryl cAMP are 
both able to up-regulate TG6 expression, suggesting involvement in neural cell 
differentiation (Thomas et al., 2013). Transglutaminase 7 is mainly expressed in lungs 
and testis (Grenard et al., 2001). However, this TG isoenzyme is still not fully 
investigated. 
1.3.5. Blood plasma transglutaminase (Factor XIII)  
Factor XIII is a combination of two dimers, one contains two catalytic subunits 
(FXIIIa) and two non-catalytic subunits (FXIIIb), playing an essential role in blood 
circulation and coagulation (Schwartz et al., 1973; Lorand, 2001). The enzyme is a 
well characterised member among the TG family. In addition, genomic sequences 
have revealed the localisation of factor XIIIa in human chromosome 6 p24-25, and the 
protein encoded by this gene has a molecular weight of 83 kDa (Ichinose, et al., 1986; 
Ichinose et al., 1990). Factor XIIIb subunit has a molecular weight of 80 kDa and the 
gene encoded to this protein is located in human chromosome 1q31-32.1 (Bottenus et 
al., 1990). Factor XIII has been shown to be synthesised in the liver and placenta 
(Iismaa et al., 2009). At the cellular level, factor XIIIa is mainly expressed in 
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monocytes, hepatocytes, macrophages, platelets, and endothelial cells (Iismaa et al., 
2009). 
The activation of factor XIII by calcium ionophore in human monocytes led to the 
production of covalently cross-linked angiotensin II type 1 (AT1) receptor (which 
binds a vasopressor hormone controlling blood pressure of the cardiovascular system) 
creating homodimer in patients with atherosclerosis (thickening in arterial wall due to 
fatty material accumulation) (AbdAlla et al., 2004). Apolipoprotein E is a 
glycoprotein that is believed to play a role in cholesterol homeostasis and 
inflammatory responses associated with atherosclerotic vessels (Curtiss & Boisvert, 
2000). In Apolipoprotein E-deficient mice, the inhibition of factor XIII activity or 
release of angiotensin II prevent this crosslinking formation and thus adhesion of 
monocyte to endothelial cells, and symptoms of atherosclerosis suggested the 
involvement at the onset of atherosclerosis (AbdAlla et al., 2004). Factor XIII plays a 
role in angiogenesis (regeneration of blood vessel) of endothelial cells through its pro-
angiogenic activity (Dardik et al., 2006) and tissue repair through triggering cell 
migration and proliferation, and repressing apoptosis of monocytes and fibroblasts 
(Dardik et al., 2007). The blood plasma TG (factor XIII A) knockout animal model 
exhibited significantly reduced reproduction, and uterine bleeding was observed in 
female mouse models (Koseki-Kuno et al., 2003). In situ hybridisation for factor XIII 
revealed restricted expression in skeletal elements of zebrafish and  the inhibition of 
factor XIII activity by KCC-009 (TG2 irreversible acivicin derived inhibitor) reduces 
average vertebrae mineralisation, suggesting a vital role of factor XIII in bone 
mineralisation (Deasey et al., 2012).    
1.3.6. Protein 4.2  
Also known as human erythrocyte band 4.2, the gene encoding this protein is located 
on human chromosome 15 and the protein has a molecular weight of 72-74 kDa (Sung 
et al., 1992; Zhu et al., 1998). Protein 4.2 has been shown to be subject to fatty acid 
modification (myristylation) at an N-terminal glycine and exists at several 
cytoskeletal locations within red blood cells associated with cell membranes (Risinger 
et al., 1992). This suggests that it might play a role in growth monitoring and signal 
transduction. Protein 4.2 is one of the red cell skeleton proteins and contributes to 
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stabilising the linkages between the cytoskeleton and the erythrocyte membrane 
(Golan et al., 1996). Thus it has been implicated in haemolytic anaemia through its 
interaction with CD47 as one of Rhesus complex proteins in red blood cells 
membrane (Mouro-Chanteloup et al., 2003). Unlike the other TG family members, 
band 4.2 protein preferentially binds ATP instead of GTP (Azim et al., 1996). 
1.3.7. Transglutaminase 2 EC 2.3.2.13 
Transglutaminase 2 is probably the most interesting member of the TG for many 
reasons (Facchiano et al., 2006). It displays a number of enzymatic functions and 
many different molecules (proteins, amines, nucleotides, drugs) can acts as substrates 
for TG2. Transglutaminase 2 may act at different cellular sites for recognising these 
substrates, further extending its range of actions. It is not only present in the 
intracellular environment, as it was initially defined as “cytosolic” TG, it is also found 
in the nuclear and extracellular environments. This member of the TG family has been 
shown to catalyse some of the chemical reactions that are associated with human 
diseases, opening new pathogenic perceptions and probably new therapeutic 
approaches. Transglutaminase 2 has also been shown to be of use in biotechnological 
applications such as in pharmaceutical and food industry (Facchiano et al., 2006). The 
ability of the enzyme to crosslink a verity of keratinocyte proteins makes them one of 
the major components present in cosmetic and pharmaceutical products e.g. 
sunscreens, hair condition agents, perfume and anti-inflammatory and anti-oxidant 
drugs. In the food industry, many meat proteins are TG substrates including collagen, 
fibrin fibronectin, and the ability of the enzyme to crosslink these substrates enhances  
sausage binding and texturing (Mariniello & Porta, 2005). 
Transglutaminase 2 or tissue transglutaminase (tTG) (also known as transglutaminase 
C) is a protein-glutamine gamma-glutamyltransferase and is universally expressed in 
almost all tissues and organ-specific cell types (Iismaa et al., 2009; see section 1.3). It 
is found in endothelial cells, fibroblasts cells and smooth muscles (Thomazy & Fesus, 
1989) either outside or inside the cells. In the human genome, TG2  is encoded by the 
TGM2 gene and is located in chromosome 20q12 (Gentile et al., 1994) with a size of 
32.5kb consisting 13 exons and 12 introns  (Fraij & Gonzales, 1997; Gentile et al., 
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1991) as shown in figure 1.2. The full length of the TG2 protein is 687 amino-acids 
with a molecular weight of approximately 78 kDa.  
The x-ray α-crystal structure of TG2 has been reported previously and it has a 
complex and unique structure that makes it a multifunctional enzyme (Liu et al., 
2002). Transglutaminase 2 has two forms; inside the cell it is known as an 
intracellular TG2 and outside the cell it is known as extracellular TG2 (Fig. 1.3). 
Inside the cell, TG2 adopt a compact conformation, in which it binds to guanosine-5´-
triphosphate (GTP) and crystallises in a condition where the active site is covered 
(Liu et al., 2002). Thus, inside the cell, the normally high concentrations of GTP 
inhibit TG2´s catalytic activity, allowing the enzyme to function as a G-protein in 
membrane signal-transduction pathways by the activation of phospholipase C-δ 
(Nakaoka et al., 1994; Prasanna Murthy et al., 1999). Outside the cell, TG2 adopts an 
extended conformation in the presence of Ca
2+
 and the active site cysteine thiol group 
is displayed and interacts with the glutamine protein bond carboxamide, resulting in 
thioester intermediate formation and thus it becomes active (Griffin et al., 2002; 
Pinkas et al., 2007).  
In its active form, TG2 performs extracellular functions by binding to integrins on the 
cell surface and fibronectin in the extracellular matrix. Thus, it regulates cell 
adhesion, movement, signalling, proliferation, and differentiation (Siegel & Khosla, 
2007). However, there is evidence showing that the extracellular TG2 remains in an 
inactive form even in the presence of Ca
2+
 and that this is due to the redox 
environment that enhances the formation of disulphide bonds between cysteine 
residues (Pinkas et al., 2007; Jin et al., 2011; DiRaimondo et al., 2012).   
Transglutaminase 2 plays an important role in stabilisation of the extracellular matrix 
via its transamidation activity, which is involved in bone remodelling, wound healing 
and angiogenesis (Griffin et al., 2002). By contrast, its intracellular role is thought to 
be mainly crosslinking activity, regulating apoptosis under harsh conditions (Iismaa et 
al., 2009). However, the intracellular roles of TG2-mediated polyamine incorporation 
activity have not been fully investigated. Therefore, the aim of this study was to focus 
on the intracellular role of TG2-mediated polyamine incorporation in cardiomyocytes 
in response to protein kinase activation. 
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Figure 1.3 The crystal structures of TG2 
The N-terminal β-sandwich is shown in blue (N), and the C-terminal β-barrels in red 
(C). (A) Compact form, GDP-bound TG2. (B) Extended form, TG2 inhibited with the 
active-site inhibitor; modified from Pinkas et al., (2007). 
 
Transglutaminase 2 has been shown to have a number of additional activities, one of 
which is that of a G protein (Gh). TG2 can hydrolyse GTP to GDP and act as G 
protein in association with the plasma membrane associated α1 adrenergic receptor 
with transfer of signalling to the activation of phospholipase C (Nakaoka et al., 1994; 
Vezza et al., 1999). However, the exact biochemical mechanism is not clear but is 
thought to involve PLC-δ (Nanda et al., 2001). One more activity identified for TG2 
is protein kinase activity, through which TG2 can phosphorylate proteins such as 
retinoblastoma protein in fibroblasts (Mishra et al., 2007), histone proteins in breast 
cancer cells (Mishra et al., 2006) and p53 (Mishra & Murphy, 2006). The first paper 
published on TG2 kinase activity was reported by Mishra et al., (2004) in breast 
cancer cells,  resulting in phosphorylation of insulin-like growth factor-binding 
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protein-3 (IGFBP-3) enhancing the affinity of insulin-like growth factors (IGF)-I 
protein to bind to IGFBP-3, thus attenuating its pro-apoptotic effects (Mishra & 
Murphy, 2004). Kinase activity has also been implicated in mouse embryonic 
fibroblasts, in which protein kinase A and cAMP enhance TG2 kinase activity and 
phosphorylation, while increasing Ca
2+
 level is able to inhibit this activity (Mishra et 
al., 2007). This kinase activity has also been reported for factor XIII (Mishra & 
Murphy, 2006).  
Protein disulphide isomerase (PDI) is a member of the thioredoxin super-family 
present in the lumen of the endoplasmic reticulum (ER). It is involved in the correct 
introduction of disulphide bridges within polypeptides and correct construction and 
conformation for diverse proteins (Ferrari & Söling, 1999). Protein disulphide 
isomerase has been identified as another activity for TG2 (Hasegawa et al., 2003). 
This activity is Ca
2+
 and nucleotide independent, being modulated by oxidant and 
antioxidant concentrations (Ferrari & Söling, 1999). The discovery of this activity- 
resulted in the generation of the hypotheses that TG2 may be able to act as PDI in 
cytosol, where almost all TG2 is present, Ca
2+
 concentration is low and nucleotide 
concentration is high (Hasegawa et al., 2003). It has been reported that TG2 regulates 
the ADP/ATP transporter role in mitochondria through its PDI activity (Malorni et al., 
2009).  
1.3.7.1. Calcium-dependent activity of TG2 
In eukaryotes, Ca
2+
 is required for transglutaminase to crosslink proteins through a 
catalytically active conformation. Specific glutamic and aspartic acid residues are 
essential for Ca
2+
 binding (Josse et al., 2001). Based on TG2 sequence homology to 
blood factor XIIIa transglutaminase (see figure 1.2), Ca
2+
 binding sites on TG2 are 
primarily suggested to be between amino acids 427 and 455 (Islamovic et al., 2007). 
The majority of studies agree that TG2 has six Ca
2+
 binding sites, which are all 
located in the catalytic domain and five of them are able to influence its 
transamidation activity (Király et al., 2009). 
Crystallisation studies of factor XIIIa showed that glutamic acid (E) E490, E485, 
aspartic acid (D) D438, and alanine (A) A457 are Ca
2+
-binding sites. They are 
involved in the formation of this negatively charged site and are conserved in other  
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TG structures (Fox et al., 1999). However, in TG2, site directed mutagenesis of these 
Ca
2+
 binding sites resulted in merely decreased sensitivity to Ca
2+
 activation when 
compared to wild type TG2 (Ikura et al., 1995). Similar residues revealed in TG3 
include E448, E443, and A393 and the resolution of its crystal structure has shown 
that, when Ca
2+
 binds, a channel opens and exposes to tryptophan residues to manage 
access of the substrate to the active site (Ahvazi et al., 2002).  
The concentration of Ca
2+
 required for TG2 activation varies in vitro and in vivo. For 
example, 3-4 μM Ca2+  is required for activation of purified TG2, while more than 100 
μM is required for activation of recombinant TG2 (Lai et al., 1997). A huge Ca2+ 
concentration gradient is maintained in cells across the plasma membrane, 
approximately 100 nM inside and 2 mM outside the cell (O'Malley et al., 1999). In 
normal cellular conditions, where the Ca
2+ 
concentration is low, TG2 is maintained in 
its folded form, while under stress or signalling conditions that elevate intracellular 
free Ca
2+ 
concentrations results in the opened conformation of TG2, revealing its 
active site. These facts lead to the suggestion that TG2 is catalytically inactive in a 
normal cellular environment and it is activated under extreme or fatal conditions, such 
as in necrosis and apoptosis (Nicholas et al., 2003; Pinkas et al., 2007).   
1.3.7.2. Transglutaminase 2 substrate properties 
The recognition of proteins that act as TG2 substrates and the target amino acids on 
such proteins are of critical importance for studying TG2's biological roles in different 
cell types and tissues. A significant number of proteins have been identified as TG2 
substrates, which are listed in Table (1.2); these include extracellular and intracellular 
structural proteins, hormones, enzymes and small heat shock proteins.  
Approximately, 46 TG2 interacting proteins have been identified according to the 
Human Protein Reference online database http://genomics.dote.hu/wiki/. The 
TRANSDAB database reports 155 TG2 substrates, which are mostly located in the 
cytoplasm, in addition to five TG2 substrates involved in its kinase activity and two in 
its deamidase activity. Transglutaminases modify both lysine and glutamine residues. 
However, they are much more selective toward glutamine residues than toward amine 
donor lysine residues (Esposito & Caputo, 2005; Lorand & Graham, 2003). It has 
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been proposed that glutamine residues should be exposed at the target surface of 
protein's surface to act as a TG2 substrate. 
 Table 1.2 Transglutaminase 2 substrates 
Protein substrates Reactive site Associated disease 
Cytoskeleton proteins 
Actin 
Tau 
β-tubulin 
Vimentin 
Glutamine and lysine 
Glutamine and lysine 
Glutamine and lysine 
Glutamine and lysine 
Alzheimer's disease 
Heat shock proteins 
alpha B-crystallin 
Hsp60 
Hsp70 
Hsp90 
Lysine Neurological diseases 
Enzyme 
Aldolase 
GAPDH 
Small GTPase RohA 
 
 
Lysine 
Metabolic and endocrinology 
diseases, genetic disease 
Huntington’s disease 
Crystallins 
βB3-crystallin 
βBp (βB2)-crystalline 
Glutamine 
Glutamine 
Chronic liver disease. 
Others 
Amines 
(monoamines, 
diamines, 
polyamines): 
cadaverine, histamine, 
putrescine, serotonin, 
spermidine, spermine 
Act as amine donor  
Cytochrome C 
Collagen alpha 1(III) 
Glutamine 
Glutamine 
Chronic liver disease. 
Gluten proteins Glutamine Coeliac disease 
Fibrinogen A-α Glutamine and lysine Other autoimmune, inflammatory 
and related diseases 
The table 1.2 showing the different protein substrates, their reactive sites for 
mammalian TG2 catalysed crosslinking, and related diseases were identified in cells 
via different proteomic analysis methods. Modified from Esposito & Caputo, (2005) 
and Boros (2008).  
 
The effectiveness of glutamine as a substrate is favoured when glycine or asparagine 
precedes or follows the glutamine residue (Pastor et al., 1999). Therefore, if it is 
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located at the N- or C-terminal, or between two proline residues and it will not be 
identified as a substrate (Pastor et al., 1999). 
The sequences of different amino acids around glutamine residues were extensively 
studied to identify their effect on substrate efficiency. For example, Gorman and Folk 
(1984) studied the effect of the deletion or replacement of amino acids around 
glutamine residues from synthetic peptides derived from β-casein (Fig. 1.4; predicted 
amino acid sequences). They suggested that the positions of valine at -5, leucine at -2, 
lysine at +2, valine at +3, leucine at +4 and proline at +5 are important in determining 
the ability of a specific glutamine (Fig. 1.4a) to be a TG2 substrate (Gorman & Folk, 
1984).  
   A) 
 
  
    B) 
 
 
 
 
 
 
 
Figure 1.4 The amino acid sequences of peptides which TG2 favours for a 
substrate (predicted sequence) 
A) Preferred amino acid sequences surrounding a glutamine residue. B) Preferred 
amino acid sequences surrounding a lysine residue. 
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In addition, these amino acid sequences act as acceptor sites for TG2 in cross linking 
reactions and the adjacent glutamine residues are the most polar and highly charged 
amino acids e.g. charged residue (lysine at +2) and polar (serine at +5, glutamine at 
+2 and threonine at −3) (Aeschlimann et al., 1992). The influence of amino acids 
around lysine (Fig. 1.4b) has also been established. The modification of lysine-
surrounded sequences in α-crystallin revealed that the presence of aspartate or glycine 
amino acids before lysine had unfavourable properties on substrate reactivity, whereas 
tryptophan, proline and histidine were less unfavourable. In contrast, asparagine, 
valine, arginine, alanine, leucine, tyrosine and serine have been found to have a 
positive effect in enhancing the substrate reactivity (Grootjans et al., 1995). 
1.3.7.3. TG2 and its substrates in cellular biological functions 
Both experimental studies and mass spectrometry coupled with 
bioinformatics analysis allow better insight and understanding into potential TG2 
substrates. Many of these substrates have been shown to be involved in controlling 
cell function and to be involved in human diseases (Facchiano et al., 2006). Some of 
the cellular biological functions controlled by TG2 through its substrates are cell 
survival and death, signal transduction, cytoskeleton regulation, membrane trafficking 
and function and ECM-cell interaction and stabilisation (see the next sections).  
1.3.7.3.1. Cell death and cell survival 
Cell death and cell survival are major biological phenomena that can occur either 
voluntarily or sometimes accidentally. The molecular pathways that regulate both of 
these phenomena are evolutionarily conserved and their components can exist in 
single-cell organisms. In addition, their molecular mechanisms are complicated and 
often entangled with other cellular mechanisms, such as cell proliferation and cell 
differentiation, thus moulding a broadly related signalling network (Johnson, 2013). 
Transglutaminase has been shown to regulate the balance between cell survival and 
cell death through binding to cathepsin D (CTSD; an aspartyl protease) and 
crosslinking pro-survival proteins results in attenuated CTSD levels as well as 
apoptosis in mouse embryonic fibroblasts (Kim et al., 2013). Breakpoint cluster 
region protein (Bcr), a GTPase-activating protein for Rac which that negatively 
regulates acute inflammatory responses (Cunnick et al., 2009), was identified as a 
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TG2 substrate. Transglutaminase 2-induced aggregation of Bcr in primary human 
pulmonary artery endothelial (HPAECs) cells occurs under extreme stress conditions 
induced by a hypoxia-mimetic agent such as CoCl2 (Yi et al., 2011).  
In vivo TG2 has been shown to be able to modify retinoblastoma protein (RB: a key 
modulator of cell growth and death) in promonocytic cells undergoing apoptosis 
through polymerisation of RB protein (Oliverio et al., 1997). Furthermore, TG2 may 
crosslink the pro-apoptotic enzyme dual leucine zipper-bearing kinase modulating its 
function and enhancing its kinase activity resulting in the activation of c-Jun amino-
terminal kinase (JNK) (Robitaille et al., 2004). These data suggest that TG2 is 
involved indirectly in regulating signal-transduction cascade by modifying the activity 
of enzyme substrate itself. 
1.3.7.3.2. Signalling transduction 
Transglutaminase 2 is a GTP-binding and hydrolysing protein (G alpha h) (Nakaoka 
et al., 1994). The activation of TG2 in HeLa cells has been shown to increase 
transamidation of RhoA (a member of the low molecular weight Ras superfamily of 
G-proteins) (Bishop & Hall, 2000) and stimulate its binding to RhoA-associated 
kinase-2 (ROCK-2), thus promoting cell adhesion and the forming of stress fibres 
(Singh et al., 2001). Transglutaminase 2 can also alter the signalling function of some 
of its substrates proteins that act as a growth and differentiation factors such as 
epidermal growth factor (EGF; Antonyak et al., 2009), vascular endothelial growth 
factor receptor 2 (VEGFR-2; Dardik & Inbal, 2006), the bifunctional ectoenzyme 
human cyclic ADP ribose hydrolase (CD38; Umar et al., 1996) that is essential for 
intracellular Ca
2+
 regulation (Malavasi et al., 2008). Similarly, insulin-like growth 
factor-binding protein-3 (IGFBP-3; Mishra & Murphy, 2004), (IGFBP-1; Sakai et al., 
2001) and neurite growth-promoting factor 2 (NEGF2)  that act as heparin-binding 
polypeptide (Iwasaki et al., 1997; Kojima et al., 1997) are all growth factor proteins 
whose signalling functions can be altered by TG2.  
1.3.7.3.3. Cytoskeleton and membrane trafficking regulation 
Many TG2 substrates are involved in cytoskeletal regulation. For example, the 
activation of TG2 by Ca
2+
 allows it to crosslink and rearrange intracellular and 
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extracellular cytoskeleton adapter proteins such as radixin, ezrin and moesin (Orrù et 
al., 2003). Other examples include, the crosslinking of microtubule-associated protein 
tau and neurofilament proteins (heavy, middle and light chain) that act as pathological 
markers for Alzheimer's disease (Prasanna Murthy et al., 1999; Grierson et al., 2001) 
and cytoplasmic actin in human leukemia cells (Nemes et al., 1997). However, β-
tubulin is the best acyl donor of TG2 substrates in early embryogenesis (Maccioni & 
Arechaga, 1986). Recently, spectrin and myosin were identified as TG2 substrates in 
human intestinal epithelial cells (Orrù et al., 2003).  
Membrane trafficking is a crucial process for all aspects of cell physiology including 
cell function, growth, death, signalling and development (Di Paolo & De Camilli, 
2006). Valosin, clathrin and importin are proteins that are involved in the membrane 
trafficking processes and have been identified as TG2 substrates (Orrù et al., 2003). 
Indeed, the involvement of TG2 in cell trafficking regulation has also been described 
in Huntington's disease, since the overexpression of TG2 blocks the secretion of 
brain-derived neurotrophic factor (BDNF) from the Golgi region through formation of 
clathrin-coated vesicles containing-BDNF (Borrell-Pagès et al., 2006). 
1.3.7.3.4. ECM-cell interaction and stabilisation 
The exact mechanism by which TG2 is secreted out of the cell to the extracellular 
environment remains unknown. The normal trafficking pathway for any proteins 
requires them to have a leader sequence and usually go through the endoplasmic 
reticulum, Golgi apparatus, and plasma membrane to the extracellular space (Chou et 
al., 2011). The fact that TG2 has no leader sequence suggests that it must have a non-
classical releasing pathway (Akimov & Belkin, 2001a; Collighan & Griffin, 2009). 
Recent studies proposed that the membrane trafficking of TG2 and its biological 
activity were linked to its binding to cell-surface heparan sulphate proteoglycans such 
as syndecan-4 (Scarpellini et al., 2009). However, other studies have suggested the 
involvement of TG2 crosslinking activity in its secretion outside smooth muscle cells 
through the microparticles (van den Akker et al., 2012). Another study strongly 
believes that this trafficking is heavily linked to a specific sequence within the β-
sandwich domain of TG2 structure (Chou et al., 2011).  
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The ability of TG2 to be secreted out of the cell, where high Ca
2+ 
concentration can 
activate it and allow it to stabilise and crosslink ECM proteins, makes this a fertile 
area for researchers to investigate. Some of the critical TG2 substrates identified 
within ECM proteins are fibronectin, laminin and collagen (Mosher, 1984). Several 
laboratories have shown that the majority of TG2 protein is localised in ECM and on 
the plasma membrane in different cell types and tissues (Zemskov, et al., 2006). 
Depending on cell types, TG2 can enzymatically (posttranslational modification of 
ECM) (Akimov & Belkin, 2001b), or non-enzymatically (cell adhesion, migration and 
growth) (Akimov & Belkin, 2001a) function at these locations. This can be either by 
crosslinking various ECM proteins or by non-covalent modulation of cell-ECM 
interactions with growth factors, consequently,  regulating  β1 and β3 subfamilies of 
integrins (Akimov et al., 2000), cell adhesion molecules of the 
immunoglobulin superfamily (Hunter et al., 1998), heparan sulphate proteoglycan e.g. 
syndecan-4 (Zemskov et al., 2006; Telci et al., 2008),  platelet derived growth factor 
receptor (Zemskov et al., 2009) and VEGFR-2 (Dardik & Inbal, 2006). 
1.3.7.4. Transglutaminase 2 in disease states 
Transglutaminase 2 has been implicated in numerous pathological conditions, such as; 
inflammatory diseases, neurodegenerative disorders (Hoffner & Djian, 2005), 
diabetes (Bernassola et al., 2002) some cancers (Mangala & Mehta, 2005) and 
autoimmune disorders (Molberg et al., 2000). The involvement of TG2 and its 
substrates in these diseases will be discussed below.  
1.3.7.4.1. Gluten sensitivity diseases 
The catalytic function of TG2 results in posttranslational modifications of proteins 
that are thought to contribute to the generation of autoantibodies such as those in 
gluten sensitivity disease or coeliac disease (CD). Coeliac disease is an autoimmune 
disorder with a genetic element caused by dietary exposure to gluten from barley, 
wheat, and rye flour (Di Sabatino & Corazza, 2009). Some gluten proteins are 
resistant to gastrointestinal proteases, which result in the accumulation of immuno-
toxic peptides in the lower intestine and thus the triggering of inflammatory responses 
(Matysiak-Budnik et al., 2008). Thereby, the immune system attacks villous atrophy 
(of the small intestinal mucosa) which results in villous flattening in chronic diarrhoea 
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and malabsorption of food (Matysiak-Budnik et al., 2008). A covalently cross-linked 
bond between the gliadin peptide and TG2 itself has been reported in this disease 
(Sollid et al., 1997). In this process, TG2 acts as a hapten-carrying gliadin in a manner 
that an elicits immune response and generates autoantibodies. Transglutaminase 2 
modifies specific gluten peptides-sequences through its deamidation activity; the 
modified epitope generated binds efficiently to DQ2 of a HLA receptor of intestinal 
cell lines (Fleckenstein et al., 2002). This immune complex is recognised by 
circulating T cells, generating autoantibodies (IgA) against TG2, which is commonly 
used as a diagnostic marker for coeliac disease (Dieterich et al., 1997; Koning et al., 
2005). The role of TG2 in coeliac disease is not only in triggering auto-antigen and in 
modifying gliadin pathogenic epitope generation, but it also has a further role in 
regulating lymphocyte migration and controlling the early immune response stages of 
coeliac disease (Maiuri et al., 2005). 
1.3.7.4.2. Neurodegenerative diseases 
Transglutaminase 2 activity has been implicated in the pathogenesis of a number of 
neurodegenerative diseases. Protein aggregation in damaged neural tissue is the major 
characteristic linked with these diseases. For example, Alzheimer’s disease (AD) is 
associated with the destruction of nerve tissues in the cortex and hippocampus of 
brain (responsible for memory) (Graeber et al., 1998). Abnormal clusters of senile 
plaques and tangles are the main cause of cell death and tissue loss in AD patients 
(McKhann et al., 1984). The aggregation of β-amyloid has been shown to be 
associated with extracellular senile plaques that block signals between neural cells 
(Glenner & Wong, 1984; Masters & Beyreuther, 2006), while aggregation of hyper-
phosphorylated tau proteins was linked with the formation of neurofibrillary tangles 
that disrupt cell nutrients (Buée et al., 2000; Lee et al., 2001). It has been 
demonstrated that almost all neurofilament polypeptides act as substrates for TG2 
promotes its cross linking function (Miller & Anderton, 1986; Grierson et al., 2001). 
Many different studies have confirmed that TG2 is involved in the aggregation of tau 
protein and tangles through its crosslinking activity (Appelt & Balin, 1997; 
Halverson, et al., 2005; Wilhelmus et al., 2009).  
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Huntington's disease (HD) is another neurodegenerative disorder characterised by 
choreia (abnormal and writhing movements of limbs and facial muscles) and decline 
in mental processes and functions. Huntington's disease is caused by a dominant 
mutation, which occurs in an autosomal gene huntingtin (htt). This mutation results in 
over repeating of CAG trinucleotide in the first exon of the htt gene, which results in a 
long polyglutamine (polyQ) expansion at the N-terminus of huntingtin (Andrew et al., 
1993). The role of TG in this disease is not clear, some studies hypothesised that TG2 
protein cross linking-activity may contribute to the formation of the aggregated 
proteins (Gentile et al., 1998; Cooper et al., 1999). Moreover, polyglutamine has been 
found to be an excellent substrate for TG2 (Kahlem et al., 1996) and, based on this 
finding, further studies revealed significant increases in TG2 expression and activity 
in HD brain (Cooper et al., 1999; Cooper et al.,  2002). Another study by Karpuj et al. 
(2002) confirmed these findings using a non-specific TG2 inhibitor (cystamine) in 
animal models of HD. It was found that the formation of the aggregated proteins was 
inhibited and the survival rates were improved (Karpuj et al., 2002). However, a study 
in human neuroblastoma SH-SY5Y cells revealed that TG2 was not involved in HD 
protein aggregation as mutant truncated huntingtin aggregation protein was present in 
the absence of TG2 (Chun, et al.,  2001). It is clear that more work is needed to reveal 
the exact role of TG2 in this disease. 
1.3.7.4.3. Inflammation and tumour progression 
Transglutaminase 2 has been implicated in the main phases of inflammation and 
tumour progression processes, including ECM homeostasis, cell adhesion, cell 
migration, apoptosis and angiogenesis (Kotsakis & Griffin, 2007). Inflammation is a 
response of the immune system to cell or tissue-infection, injury or any other stress 
(Medzhitov, 2010). This can result in severe pathological conditions, such as those, 
which appear with cancer and degenerative fibrotic diseases. The inflammatory 
process is usually involved in tissue repair and wound healing (Kiritsy & Lynch, 
1993). Transglutaminase 2 has been shown to be involved in the initial phases of 
inflammation and the wound healing process. For example, during the initial phase of 
cell damage, the release of cytokines and growth factors has been shown to regulate 
TG2 synthesis (Verderio et al., 2004). An increase in TG2 synthesis was observed in 
response to the cytokines interleukin IL-1β and tumour necrosis factor TNF-α in rat 
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brain astrocytes (Monsonego et al., 1997). Transglutaminase 2 has been shown to 
promote inflammation by activating the nuclear factor kappa B (NF-κB) cascade in 
tissue macrophages in the brain (Lee et al., 2004).  
The involvement of TG2 in the wound healing processes, its expression and 
crosslinking activity were also shown to be associated with tissue fibrosis and 
scarring. A lot of research has focused on the relevance of TG2 in fibrosis in different 
organs, including liver (Mirza et al., 1997; Grenard et al., 2001), renal tissue (Skill et 
al., 2001; Johnson et al., 2003), lung (Griffin, et al., 1978), and heart (Small et al., 
1999). Transglutaminase 2 can directly bind to cell-surface heparin sulphate chains 
which promote Arg-Gly-Asp (RGD)-independent cell adhesion mechanism, with the 
subsequent activation of protein kinase C, focal adhesion kinase (FAK) and 
extracellular signal-regulated kinase (ERK) (Telci et al., 2008).  
Inflammatory responses and TG2 expression play an essential role during different 
cancer phases (initiation, progression, invasion and spreading). Chronic expression of 
TG2 may induce cell growth, survival and allow accumulation of oncogenic 
mutations, and consequently tumour progression (Mehta & Han, 2011). Several 
studies have implicated up-regulation of TG2 expression in carcinomas including 
pancreatic (Akar et al., 2007; Cheung et al., 2008), breast (Mehta et al., 2004), 
glioblastoma (Yuan et al., 2005; Yuan et al., 2006) and skin tumours (Fok et al., 
2006). The over expression of TG2 in carcinomas was linked with its anti-apoptotic 
role (Boehm et al., 2002) and chemotherapeutic drug resistance (Kim et al., 2006). 
The expression of TG2 in pancreatic cancer cells has been connected with activation 
of FAK, Akt, and NF-kB signalling pathways and inhibition of the ability of the 
phosphatase and tensin homologue located on chromosome 10 (PTEN) gene to  act as 
a tumour suppressor gene (Verma et al., 2008). The mediation of these oncogenic 
signalling pathways by TG2 possibly causes resistance to chemotherapy and amplifies 
invasiveness of cancer cells. A study in mouse pancreatic cancer has suggested that 
inhibition of TG2 by small-interfering RNA (siRNA) can be used as a therapeutic 
approach to improve pancreatic cancer treatment (Verma et al., 2008). 
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1.3.7.4.4. Heart diseases 
Various heart cells abundantly express TG2 including endothelial smooth muscle 
cells, cardiomyocytes and vascular cells (Thomazy & Fesus, 1989). A large number 
of research studies have pointed to the critical roles of TG in cardiac biology and 
pathophysiology. Transglutaminase has been cited to be involved in regulation of 
myocardium growth, fibrosis and wound healing (Sane et al., 2007). Away from its 
enzymatic activity, TG2 likely influences hypertension (high blood pressure) of 
vascular smooth muscle cells by enhancing vasoconstriction (Janiak et al., 2006). In 
this case, TG2 stimulates the binding of RhoA/ROCK-2 kinase and auto-
phosphorylation of ROCK-2 (Rho-associated coiled-coil containing protein kinase) 
through direct binding between cell surface TG2 and fibronectin (Janiak et al., 2006).  
The crosslinking activity of TG2 has been shown to contribute to inward remodelling 
(a reduction in lumen diameter of vessels) of arteries. Rat blood flow inward 
remodelling was lowered when TG2 was inhibited via exposure to nitric oxide, 
whereas it was increased by retinoic acid treatment to enhance TG2 expression 
(Bakker et al., 2005). This could be a novel therapeutic target for chronic 
vasoconstriction or any inward remodelling pathogenesis. Another study by Engholm 
et al. (2011) in spontaneously hypertensive rats (SHR) has shown that inhibition of 
TG2 with cystamine results in reduction of inward remodelling (Engholm et al., 
2011).  
Transglutaminase 2 has been shown to be linked to cardiac hypertrophy. Cardiac 
hypertrophy (heart enlargement) is one potential risk factor associated with heart 
failure and ischaemic heart disease (Shiojima et al., 2005). Up-regulation of the TG2 
gene has been reported in cardiac hypertrophy and cardiac failure in rat models (Iwai 
et al., 1995). In failing human heart tissue of both ischaemic and dilated 
cardiomyopathy, GTP-binding and TG2 activities were decreased while TG2 protein 
levels were increased in dilated heart (Hwang et al., 1996). In transgenic mouse 
models, GTP-binding and TG2 over-expression regulate activation of cyclooxygenase 
(COX-2) (Zhang et al., 2003). The up-regulation of the COX-2 gene was linked to 
cardiac failure (Abassi et al., 2001) and cell survival (Adderley & Fitzgerald, 1999). 
Therefore, TG2-mediated COX-2 activation may differentially modulate 
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cardiomyocyte death or survival. Recently, Li et al. (2009) demonstrated that TG2 
over-expression, but not its activity, was implicated in hypertrophic agonist-induced 
(endothelin (ET) 1) cardiac hypertrophy, which suggests the involvement of TG2 in 
signalling activity (Li et al., 2009). 
Atherosclerosis is a condition in which plaques (accumulation of fatty substances) 
build up on and thicken arterial walls (Ismail & Peden, 2011). Since inflammation has 
been shown to play a significant role in this disease (Libby, 2006), the involvement of 
TG2 in its inflammation process may be an important factor. The presence of TG2 in 
human coronary artery was reported (Sumi et al., 2002) and isodipeptide epsilon 
(gamma-glutamyl) lysine crosslinking generated by TG2 was isolated from rabbit 
atherosclerotic aorta (Bowness et al., 1994). In aorta of cholesterol-fed rabbits, TG2 
protein levels and activity were increased (Wiebe et al., 1991). Leukocytes or white 
blood cells have been the main source of TG2 in atherosclerotic injuries. In vitro, 
macrophage TG2 expression induces apoptotic cell clearance and decreases 
atherosclerotic lesion size in vivo (Abedin et al., 2004).  
In the case of ischaemic /reperfusion injury (where the return of blood to ischaemic 
damaged tissue results in more damage), the infarct size was shown to be increased in 
TG2 knockout mouse heart, combined with a serious failure in ATP level (Szondy et 
al., 2006). This suggests the action of TG2 at a mitochondrial level under 
physiological conditions. It has been previously shown that TG2 over-expression 
hyperpolarises mitochondria and drives cells to apoptosis (Grazia Farrace et al., 
2002).  
1.3.7.5. Apoptotic and anti-apoptotic role of TG2  
Various experimental systems have established the involvement of TG2 in apoptosis 
(Piacentini et al., 1991). In the majority of cells, TG2 protein is barely detectable and 
its messenger RNA is transcribed as a signal of apoptosis (Nagy et al., 1997; Verderio 
et al., 1998). Over-expression of TG2 has been largely used as a specific marker of 
cells undergoing the apoptosis process. This could be because its over expression 
drives cells to suicide, as clones resistant to TG2 transfection show greatly reduced 
cell growth in vitro (Piredda et al., 1997) and in vivo (Piacentini et al., 1996). Since 
TG2 crosslinking activity is inhibited by GTP, the aggregation of its protein substrates 
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in cells should not necessarily correlate with its crosslink activity (Fesus et al., 1991; 
Melino & Piacentini, 1998). A study by Fabbi et al., (1999) established that the loss of 
TG2 crosslink activity during apoptosis is due to cleavage by caspase-3 (Fabbi et al., 
1999), which is a member of the cytosolic aspartate–specific cysteine protease family 
(Alnemri et al., 1996). However, the activation of TG2 via Ca
2+
 in dying cells results 
in the irreversible accumulation of an insoluble cross-linked protein scaffold that 
stops the leakage of intracellular macromolecules (Piredda et al., 1997; Melino & 
Piacentini, 1998). This insoluble protein scaffold could stabilise the integrity of cells 
undergoing apoptosis before phagocytosis clearance, consequently preventing the 
release of harmful components such as nucleic acids, lysosomal enzymes etc., that 
elicit inflammatory responses (Knight et al.,  1993). 
Transglutaminase 2 has been shown to have both pro- and anti-apoptotic roles that 
depend on cell stimulation and the cell type (Antonyak et al., 2001; Antonyak et al., 
2002; Gundemir & Johnson, 2009). One possible anti-apoptotic role is the ability of 
TG2 to prevent the degradation of retinoblastoma protein (a tumour suppressor that 
acts to prevent cell growth) and thus sustain its anti-apoptotic role during cell death 
(Boehm et al., 2002; Milakovic et al., 2004). In contrast, TG2 has been reported to 
promote the release of cytochrome C and Bax (an apoptosis regulator) through 
conformational changes using its BH3-like (Bcl-2 homology) domain (Rodolfo et al., 
2004). In addition, the induction of TG2 has been shown to be paralleled to down-
regulation of Bcl-2, but is not affected by its inhibition (Melino et al., 1994). The 
overexpression of TG2 inhibited apoptotic cell death induced by Ca
2+
 overload 
through Bax suppression, which in turn decreased activation of caspase-3 and -9, 
secretion of cytochrome C, and mitochondrial permeability transition (Cho et al., 
2010). This revealed the protective and anti-apoptotic role of TG2 in diseases 
involving Ca
2+
 overload. 
As TG2 transamidation activity is strongly dependent on the concentration of 
intracellular Ca
2+
, its activity is also linked to the apoptotic process by inhibiting the 
release of DNA and intracellular proteins from dying cells (Fesus et al., 1991). 
Moreover, Ca
2+ 
overload induced cell death and apoptosis triggering was detected in 
cells under hypoxic or oxidative stress conditions (Orrenius et al., 2003). However, 
the disruption of Ca
2+
 homeostasis in cells can affect other enzymes that are Ca
2+
-
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dependent, such as endonuclease, phospholipases and calpain which are all involved 
in cell injury and death (Dong et al., 2005). Therefore, the exact apoptotic and anti-
apoptotic role of TG2 are still unclear and need further investigation. In addition, 
because of the multiple functions of TG2 and its ability to take part in signal 
transduction, different roles in apoptosis have been suggested that depend on the type 
of cell and stress involved (Fesus & Szondy, 2005). 
In human neuroblastoma SH-SY5Y cells, different types of stress stimuli have 
displayed a variable effect on apoptotic processes, in which staurosporine and osmotic 
stress treatments caused a significant increase in caspase-3 activity and apoptotic 
nuclear changes, in combination with induction of TG2 transamidating activity, 
whereas heat shock stress did not (Tucholski & Johnson, 2002). This suggested that 
apoptotic and anti-apoptotic effects of TG2 are not constant in identical cell types. 
1.3.7.6. Protective role of TG2 
Despite the fact that TG2 is involved in diseases processes, it also plays a protective 
role in some diseases. Transglutaminase 2 elicited liver protection against hepatitis C 
virus in which its expression and localisation at in the ECM were decreased in the 
advanced stages of fibrosis in hepatitis C virus-infected patients (Nardacci et al., 
2003). In addition, carbon tetrachloride induced liver injury in TG2 knockout mice 
failed to clear necrotic tissue in comparison with wild-type mice, suggesting its role in 
protection was through tissue stabilisation and repair. In neuroblastoma cells, TG2 
overexpression induced by retinoic acid or staurosporine elevated apoptosis via 
crosslinking of glutathione S-transferase P1-1, histone H2B and β-tubulin (Piredda et 
al., 1999). Conversely, TG2 activation by retinoic acid-induced differentiation 
inhibited apoptosis in human promyelocytic leukemia (HL60) cells, while 
monodansylcadaverine (MDC; an inhibitor of TG2) eliminated this protective effect 
(Antonyak et al., 2001). This suggested an important role of TG2 enzymatic function 
in cells under differentiation and stress condition. In the same context, retinoic acid 
treatment inhibited cell death caused by TNF-α and this effect was also abolished by 
MDC in SH-SY5Y human neuroblastoma cells (Kweon et al., 2004). It is already 
known that treatment of cells with retinoic acid results in the activation of the pro-
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survival protein phosphatidylinositol 3-kinase (PI3K)–Akt and that this requires TG2 
induction and activation (Antonyak et al., 2002).  
The involvement of TG2 and its substrates in membrane-mediated glucose-stimulated 
insulin secretion in rat pancreatic islets has been reported (Gomis et al., 1989) to be 
induced by retinoic acid or vitamin A (Driscoll et al., 1997). The aggregation and 
internalisation of insulin receptors have been linked to cells or tissues that display 
high levels of TG2-crosslinking activity, e.g. human fibroblasts (Baldwin, et al., 
1980). The TG2 knockout mice show a high level of glucose concentrations 
correlated with decreases in TG2 activity compared to wild-type animals. The 
knockout mice show a decrease in glucose-stimulated insulin release, suggesting a 
role for TG2 in glucose regulation and metabolism processes (Bernassola et al., 
2002).  
There is a strong relationship between deficits in glucose-induced insulin secretion 
resulting in mitochondrial dysfunction through the loss of ATP production (Maechler 
& Wollheim, 2001), and involvement of TG2 in mitochondrial hyperpolarisation 
(change in mitochondrial membrane voltage) (Grazia Farrace et al., 2002). Szondy 
and colleagues linked this relationship to a cardioprotective role of TG2 against 
ischaemia and reperfusion-induced cell death. They found that the deletion of TG2 
lead to a major drop in ATP production along with significant increase in the infarct 
size (Fig. 1.5), suggesting the involvement of TG2 catalytic activity in the 
posttranslational modification of some essential mitochondrial regulatory proteins 
(Szondy et al., 2006). In the SH-SY5Y neuroblastoma cell line, up-regulation of TG2 
selectively decreases the oxygen and glucose deprivation (OGD) -induced hypoxia 
inducible factor 1 (HIF1) and thus protected cells from OGD induced cell death. The 
protective role of TG2 here is due to interaction with HIF1β and prevention of the 
formation of the heterodimeric form of (HIF1) which consists from HIF1α and HIF1β 
(Filiano et al., 2008) and is thought to be responsible for activation of pro-apoptosis 
genes (Filiano et al., 2010). Transglutaminase 2 protected NIH3T3 fibroblasts from 
glucose deprivation (GD)-induced apoptosis in WT TG2 mice and it was more 
effective in the presence of 5 µM retinoic acid that results in up-regulation of TG2 
expression and GTP binding activity (Antonyak et al., 2003). 
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Figure 1.5  Protective role of TG2 in heart tissue 
The figure shows the limitation in infarct size in heart of WT mice in comparison 
to TG2-/-after ischaemia/reperfusion. Adapted from Szondy et al., (2006).
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proteins expression of potential biomarkers for AAAs (TNF-α; matrix 
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1.4. Myocardial cell injury and cell death  
Many different types of myocardial cell injury and cell death are triggered in response 
to pathological processes associated with oxidative stress, ischaemic reperfusion or 
other cardiac diseases. Such injuries can induce necrosis, apoptosis and more recently 
autophagy. Necrosis is evident when cells or subcellular organelles are swelling via 
cell membrane disruption (Trump et al., 1997). Since ischaemic reperfusion injury 
alters the cells from reversible to irreversible mode, a severe defect in membrane 
permeability develops that permits the uncontrolled flow of Ca
2+
, alterations in 
electrolyte channels and loss of Mg
2+
/K
+ 
ions, resulting in the swelling of cytoplasm, 
mitochondria and other organelles (Buja, et al., 1993; McCully et al.,  2004). This 
results in physical defects, such as holes in the cell membrane and fractures due to the 
cells swelling. Moreover, the release of cellular components in and around tissues 
activates the inflammatory response and neutrophil influx that could lead to damage 
of neighbouring cells. 
Apoptosis is another type of cell death (see section 1.6) that is dependent on energy to 
eliminate the damaged cells without triggering an inflammatory responses (Elmore, 
2007). Apoptosis has been known as a process that can be provoked by external 
stimuli that are either physiological or pathological (Kettleworth, 2007). The 
importance of the pathogenic process of apoptosis is well established in the 
development of myocardial disease therapies. This involves caspase pathway 
activation by Fas (apo1)/TNFR-1 signalling (Kaufmann & Hengartner, 2001) such 
pathway is blocked by the ubiquitin-like protein (sentrin) (Okura et al., 1996). During 
apoptosis, many different gene products are regulated, including an inner 
mitochondrial protein (bcl-2), p53 and c-myc a member of an oncogene family 
(Hoffman & Liebermann, 2008). 
In addition, mitochondria contribute to the apoptosis process (Fig. 1.6), being altered 
via free radicals or other pathological processes resulting in release of cytochrome C 
that binds to the apoptotic protease (Apaf-1). This leads to cell death through 
generation of apoptosomes that activate both caspase and apoptotic pathways 
(Iliodromitis et al., 2007). Over expression of bcl-2 (anti-apoptotic protein), which is 
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located in mitochondrial membranes is responsible in the blockage of such a pathway 
(Hetts, 1998; Marani et al., 2002). Apoptosis results in shrinking of cells, which is due  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 The mitochondrial death pathway  
The schematic diagram outlining the mitochondrial death pathway in response to 
pathological processes associated with ischaemia reperfusion injury and oxidative 
stress. The translocation of pro-apoptotic Bax to the mitochondrial membrane 
promotes mitochondrial transition pore opening and thus cytochrome c release. Cyt C 
binds to apoptotic protease (Apaf-1/dATP) in turn this leads to cell death through 
generation of apoptosomes that activate caspases and trigger apoptosis. Anti-apoptotic 
Bcl-2 can prevent Bax and mitochondrial membrane association. Scheme modified 
from Iliodromitis et al., (2007).
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to activation of TG2 (see section 1.3.7.5) and protease, producing cytoplasmic protein 
crosslinking (Nemes et al., 1996; Szondy et al., 1997; Grabarek et al., 2002). The 
activation of TG2 in cells undergoing apoptotic death results in the irreversible 
accumulation of a cross-linked protein scaffold that stops the leakage of intracellular 
macromolecules (Piredda et al., 1997; Melino & Piacentini, 1998). Consequently, 
rapid phagocytoses are triggered without the elicitation of inflammatory responses 
(Falasca et al., 2005).  
The autophagy induction has been shown to be associated with up-regulation of the 
mitochondrial pro-apoptotic protein BNIP3 in glioma cells (Daido et al., 2004). 
Autophagy has been shown to have a key role in cellular homeostasis or clearance of 
damaged organelles, cellular response to stress conditions (Levine, 2005), cancer 
(Liang et al., 1999), neurodegenerative disorders (Yuan et al., 2003), and 
cardiomyopathy disorders (Shimomura et al., 2001). Moreover, BNIP3 has been 
shown to be involved in ischaemic reperfusion injury, mediating the up-regulation of 
autophagy as a protective response in HL-1 cardiac cells thus, inducing mitochondrial 
dysfunction (Hamacher-Brady et al., 2006).  
1.5. Protein kinases in ischaemic/ pharmacological preconditioning  
Over the past 20 years, a significant body of research has focused on ways to prevent 
or block irreversible ischaemic injury associated with heart disease or cardiac surgery. 
It is known that brief periods of ischaemia before reperfusion (ischaemic 
preconditioning; IPC) is an effective mechanism that is capable of protecting the heart 
from myocardial ischaemic injury (Murry et al., 1986). Pharmacological 
preconditioning (PPC) acts as an alternative approach for IPC, in which 
cardioprotective  effects are triggered pharmacologically (Kloner & Jennings, 2001). 
A number of pharmacological preconditioning agents have been identified, including 
agonists of G protein-coupled receptors (GPCRs) such as the adenosine A1 receptor 
(Yellon & Downey, 2003). 
Reversible protein phosphorylation plays a key role in signal transduction pathways 
and a growing number of protein kinases have been shown to be involved in IPC and 
PPC including protein kinase C (PKC), (Yoshida et al., 1997; Hassouna et al., 2004), 
mitogen-activated protein kinases (MAPKs) and protein kinase B (PKB; or Akt) 
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(Armstrong, 2004; Hausenloy & Yellon, 2004). The three major MAPK families (p38 
MAPK, extracellular signal-regulated kinases (ERK1 and ERK2) and c-Jun N-
terminal kinases (JNK1 and JNK2)) and PKB are triggered in response to both 
ischaemia and reperfusion (Armstrong, 2004; Hausenloy & Yellon, 2004). It is 
commonly acknowledged that PKB and ERK1/2 are cardioprotective and trigger anti-
apoptotic survival pathways, whereas p38 MAPKs and JNK are thought to stimulate 
cell death (Abe et al., 2000; Sugden & Clerk, 2001). Nevertheless, there is also 
evidence that p38 MAPK and JNK are implicated in cardioprotection (Dougherty et 
al., 2002; Steenbergen, 2002). Protein kinase B, ERK1/2 and p38 MAPK have been 
reportedly involved in PPC and IPC (Dana et al., 2000; Punn et al., 2000; Brar et al., 
2002; Chanalaris et al., 2003). In addition to serine/threonine kinases (PKC, PKB, and 
MAPKs), non-receptor tyrosine kinases including Src, Bmx and Janus kinases (JAKs) 
are implicated in cardioprotection (Vondriska et al., 2001; Bolli et al., 2003; Zhang et 
al., 2004).  
1.6. Protein kinase A and protein kinase C  
In a variety of eukaryotic genomes, protein kinases account for ~2 % of genes and are 
found to be one of the major families of proteins (Manning et al., 2002). Up to 30 % 
of human cellular proteins are under the control of protein kinases that are considered 
to act as major regulatory mechanisms directing the basic cellular processes and 
signal transduction of complex pathways (Ficarro et al., 2002; Manning et al., 2002). 
By mass spectrometric analysis of protein phosphorylation, it has been revealed that 
the majority of cellular mechanisms are regulated by the reversible phosphorylation of 
proteins on more often with serine, threonine, and less on tyrosine residues (Mann et 
al., 2002).  
Protein kinase A and protein kinase C both belong to the AGC family of protein 
kinases (Pearce et al., 2010). These kinases are a group of enzymes that chemically 
modify a specific protein at its serine and threonine residues transferring the terminal 
phosphate group of ATP to protein bound serine, threonine or tyrosine residues in an 
action called phosphorylation. Activation of these kinases results in phosphorylation 
of target proteins (substrates) and regulates their enzymatic activity, localisation and 
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function, thereby, orchestrating almost all the essential aspects of cellular function 
and processes in living organism (Cohen, 2000).  
1.6.1. Protein kinase A: Structure, function and regulation 
The heterotetrameric form of protein kinase A is an inactive state of the enzyme 
composed of two subunits, a catalytic subunit which contains the ATP binding 
domain and a regulatory binding domain. The regulatory subunit also contains two 
domains, one to bind cyclic AMP and the other to inhibit the active subunit of PKA. 
Following G-protein-coupled GPCR activation, adenylyl cyclase is activated in 
downstream signalling. This results in the production of cAMP, which in turn binds to 
PKA regulator subunits and releases the catalytic subunits to phosphorylate target 
proteins (Taylor et al., 1990). PKA-kinase anchor proteins control the subcellular 
localisation of the enzyme and up to 50 different types of these multidomain 
scaffolding proteins have been reported and all can localise PKA to particular 
subcellular organelles (cytoskeleton, plasma membrane, Golgi apparatus, 
mitochondria, ion channels, and centrosomes) within different cell types (Wong et al., 
2002).   
Protein kinase A modulates various biological functions in cells and this depends on 
the type of stimulator (hormones and GPCRs) and cell type. For example, the 
activation of PKA through the stimulation of β- adrenergic receptor by the hormone 
adrenaline in cardiomyocytes results in glucose production and phosphorylation of 
glycogen phosphorylase and acetyl- CoA carboxylase (Rang, et al., 2003). In contrast, 
the activation of PKA with catecholamine also stimulates β- adrenergic receptor in the 
same cells resulting in Ca
2+
 repositioning at the sarcoplasmic reticulum and 
phosphorylation of phospholamban (Rang et al., 2003). The activation of PKA can 
enhance cardiac myocytes by phosphorylation of troponin I/C, L-type Ca
2+ 
channel 
and phospholamban which serve to control Ca
2+ 
concentration and myofilament 
sensitivity to Ca
2+ 
(Xiang & Kobilka, 2003; De Arcangelis et al., 2008). Protein 
kinase A is also known to be involved in gene regulation. For example, 
phosphorylation of cAMP response-element binding protein (CREB) by PKA allows 
it to initiate the transcription of Pax3 (paired box gene) and Myf5 (myogenic 
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regulatory factor 5) associated genetic factors involved in muscular tissue formation 
(Chen et al., 2004). 
Immunocytochemistry analysis of rat brain and cultures of brain cells has revealed the 
accumulation and localisation of protein kinase A in the Golgi-centrosomal area and 
microtubule-organising centres thus suggesting the involvement of PKA in 
metabolism regulation, cellular mobility/trafficking and microtubule stability (De 
Camilli et al., 1986). Protein kinase A has also been shown to mediate pancreatic β-
cell proliferation stimulated by exendin-4 making it a potential therapeutic target for 
treating inadequate β-cell mass in both diabetes types (Song et al., 2008).  
1.6.2. Protein kinase C: Structure, function and regulation 
Protein kinase C is a crucial enzyme in the biochemical mechanism of signal 
transduction and is implicated in a variety of cellular functions (Nishizuka, 1986). The 
activation of phospholipase C (PLC) through Ca
2+ 
ionophore exposure can directly 
cleave inositol phospholipids to produce inositol phosphates and diacylglycerol 
(DAG) necessary for PKC activation (Huang & Cabot, 1990; Peterson & Walter, 
1992). Over 10 protein kinase C isozymes have been identified (conventional PKCα, 
PKCβI/II and PKCγ; novel PKCδ, PKCε, PKCη and PKCθ and a typical PKCζ and 
PKCλ/ι) based on differences in their crystal structure and cofactor regulation 
(Nishizuka, 1995; Parker & Murray-Rust, 2004). These PKC isoforms require Ca
2+
 
alone or Ca
2+
 and diacylglycerol (DAG) for activation. This serine/threonine kinase is 
activated by production of DAG in response to Gq protein–coupled receptor 
activation by α-adrenergic agonists, autocrine factor endothelin and angiotensin II 
(Dorn II & Brown, 1999; Robu et al., 2003). Immunofluorescence and Western 
blotting analyses of NIH 3T3 fibroblasts revealed that after activation of PKC by 
phorbol ester 12- O-tetradecanoylphorbol-13-acetate (PMA), PKCδ, PKCγ and PKCη 
were localised at the Golgi apparatus while PKCα PKC-βII, PKCε accumulated in the 
endoplasmic reticulum, the cytoskeleton and nuclear membranes, respectively 
(Goodnight et al., 1995). These different locations usually occur due to binding of 
isoenzymes to specific scaffold proteins. For example, RACK1 can bind to active 
PKC isoform, modifying its signalling activity and trans-locating it to a particular 
subcellular region (Schechtman & Mochly-Rosen, 2001).  
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Some of these scaffold proteins (plakophilins) are specific to one PKC isoenzyme 
(PKCα) that regulates cell junction assembly (Bass-Zubek et al., 2008). While others 
can bind to and localise many kinase isoenzymes such as AKAP12, which localises 
both PKCα and PKC βII (Piontek & Brandt, 2003). In addition, AKAP79 can localise 
and maintain the function of protein phosphatase-2B, PKA and PKC in 
neuromuscular junctions (Perkins et al., 2001). All PKC isoforms have a critical role 
in a multitude of cell biological functions. For example, PKCα has been shown to be 
involved in cell growth, division, differentiation, adhesion and apoptosis (Dempsey et 
al., 2000; Parker & Murray-Rust, 2004). Furthermore, PKCα can act as immuno-
regulator through T cell-interferon production (Pfeifhofer et al., 2006). Protein kinase 
Cγ has been linked to brain functions associated with learning and memory, while 
PKCε has been shown to play a role in GABA receptor function in brain (Brose & 
Rosenmund, 2002). 
1.6.3. Cardioprotection mediated by PKA and PKC  
The protective role of PKC has been well studied and characterised in models of 
ischaemic preconditioning against ischaemic injury (see section 1.5). The protein 
kinase C isozyme PKCε has been shown to be critical in prompting of ischaemic and 
anaesthetic cardioprotective effects (Liu et al., 1999; Toma et al., 2004). The 
desflurane-induced preconditioning in ischaemia and reperfusion heart tissue by 
activation of PKCε was shown to be in correlation with ERK activation and infarct 
size limitation (Toma et al., 2004). Other studies reported an association with the 
activation of PKCδ, PKCε, as well as Src family protein tyrosine kinase with 
ischaemic preconditioning in response to isoflurane treatment of intact rat heart. This 
was in correlation with PKC activation of upstream transduction events including 
mitochondrial ATP–sensitive potassium channel-opening and reactive oxygen species 
production (Ludwig et al., 2004). A study by Zatta et al., (2006) proposed the 
involvement of PKC in post-conditioning (brief repetition of the early moments of 
reperfusion induce cardioprotection) that results in reduction of cardiomyocyte 
damage (Zatta et al., 2006).  It is also believed that the protective effect of PKC could 
be due to permeability transition pore (mPTP) blocking in cardiac mitochondrial 
function (Baines et al., 2003). Conversely, PKCδ  activation has been linked with 
ischaemic reperfusion injury, since the inhibition of this PKC isozyme by selective 
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PKCδ inhibitor (δV1-1) enhanced cardioprotection effects and reduced reperfusion 
injury in isolated perfused rat heart (Inagaki et al., 2003).  In addition, rapid 
translocation and accumulation of PKCδ has been observed in the mitochondria of 
reperfusion heart in association with superoxide anion generation and apoptosis 
induction (Churchill & Szweda, 2005). Activation of PKA and PKC both are part of 
the cardioprotective properties of exendin-4 (peptide drug acting as glucagon-like 
peptide-1 (GLP-1) important in controlling levels of glucose in blood), which also 
protects myocardium from acute ischaemic–reperfusion injury (Hausenloy & Yellon, 
2008; Hausenloy & Yellon, 2012).  
Protein kinase C (PKC) and cAMP-dependent protein kinase (PKA) are two major 
mediators of signal transduction pathways associated with ischaemic preconditioning 
and pharmacological preconditioning induced cardioprotection. Figure 1.7 represents 
the protective mechanisms mediated by activation of PKA and PKC induced by the 
pharmacological preconditioning agent (exenatide) against ischaemia–reperfusion 
injury. Many potential cardioprotective signalling pathways elicit in responses to 
exenatide as pro-survival signalling cascades PI3K–Akt and adenylyl cyclase-cAMP–
PKA), ROS generation, endothelial nitric oxide synthase, and PKC translocation 
(Hausenloy & Yellon, 2008; Hausenloy & Yellon, 2012). These signalling cascades 
can exert cardioprotective effects through a number of vital cellular mechanisms such 
as glucose up-take, mPTP inhibition, apoptosis reduction and production of 
cardioprotective gene factors (Hausenloy & Yellon, 2012). Volatile anaesthetic agents 
may also induce cardioprotection mediated by PKA and PKC signal transduction 
activation (Frässdorf et al., 2009). 
Similarly, chronic morphine treatment exerts cardioprotective  phenotype mediated by 
a PKC-independent pathway involving Gs coupled (stimulated 
adenylyl cyclase) protein, PKA and β-adrenergic receptors, whereas acute morphine 
induced preconditioning is mediated by Gi coupled (inhibited adenylyl cyclase) G-
protein and PKC (Peart & Gross, 2006). In the case of ischaemic preconditioning, 
PKA activation in combination with p38 MAPK can provide a dual role in 
cardioprotection (Makaula et al., 2005). Interestingly, in the same study the activation 
of PKA by forskolin (FK; preconditioning-mimetic agent) prior to ischaemia reduces 
the infarct size whereas the non-selective PKA inhibitor H-89 when given to perfused 
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rat heart half an hour before global ischaemia-reperfusion, also decreases the infarct 
size and improves post-ischaemic function.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 The cardioprotective mechanisms mediated by PKA and PKC  
 
Shown is a schematic diagram representing the protective mechanisms mediated by 
activation of PKA and PKC induced by ischaemic preconditioning/ischaemic post-
conditioning or pharmacological preconditioning agents against ischaemia–
reperfusion injury. 
 
Although downstream signalling of PKA activation remains unclear, a study in intact 
dog heart suggested that the protective effect of PKA could be through attenuation of 
calpain-dependent degradation of sarcolemmal proteins (Inserte et al., 2004). Another 
study showed that protective effects of PKA appeared to be correlated with inhibition 
of small GTPase Rho and its kinases (Sanada et al., 2001). 
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1.7. Protein kinases and their cellular link with TG2? 
Protein kinases are one of the most important protein families (Huston & Krebs, 1968; 
Manning et al., 2002), since the majority of cellular proteins undergo phosphorylation 
by protein kinases, which can directly control many basic cellular processes and 
signal transduction pathways (Ficarro et al., 2002; Manning et al., 2002). Protein 
kinase A and PKC are both involved in posttranslational modification of proteins 
mainly through phosphorylation that can result in regulation of specific protein 
enzymatic activity, localisation and function (Cohen, 2000).  
As posttranslational modification of proteins by phosphorylation plays a critical role 
in the regulation of their cellular functions (Walsh, 2006; Pearce et al., 2010). 
Similarly, TG2 is a ubiquitous enzyme that mediates posttranslational modifications 
of protein, and protein-protein interactions (Fesus & Piacentini, 2002; Lorand & 
Graham, 2003). Transglutaminase 2 is able to crosslink or activate a variety of 
signalling molecules involved in cell death, cell survival and cell proliferation. For 
instance, the activation of TG2 and its transamination activity was shown to modulate 
regulation of RhoA, ERK1/2, JNK1, and p38 MAP kinases in neuronal differentiation 
(Singh et al., 2003). Transglutaminase 2 catalysed reactions have been shown to 
modulate posttranslational modification of retinoblastoma gene product (pRB) 
playing a role in programing cell death (Oliverio et al., 1997). At the molecular level, 
TG2 overexpression modulates the phosphorylation and activation of the cyclic AMP-
response element (CRE)-binding protein, an event that contributes to neuronal 
differentiation (Tucholski & Johnson, 2003). Both over-expression and activation of 
TG2 enhances cAMP levels and thus, PKA activation, consequently exerting its pro-
apoptotic role in tumour development (Caraglia et al., 2002). Alpha-(1B)-
adrenoreceptor facilitated intracellular Ca
2+
 signalling was reported to be mediated by 
the interaction of TG2 with phospholipase C (PLC)-δ 1 (Kang et al., 2002) . Although, 
TG2 can modulate signal transduction of different proteins either through 
posttranslational modification or through protein-protein interaction, the exact 
mechanisms by involved remains unresolved. This could be due to the protein 
phosphorylation events, which are responsible for the activation of different signalling 
pathways simultaneously.  
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Transglutaminase 2 possesses multiple enzymatic activities (including a kinase 
function; see section 1.2), and has been shown to be activated by PKA (Mishra et al., 
2007). It has been reported that PKA phosphorylate TG2 at serine-216 (Ser
216
) residue 
facilitating protein-protein interaction, increasing its kinase activity and inhibiting its 
transamidation activities (Mishra & Murphy, 2006; Mishra et al., 2007). A more 
recent study suggests that this phosphorylation is also mediated by the activation of 
the NF-kB and its inhibition of PTEN protein has a critical role in tumour invasiveness 
(Wang et al., 2012). Transglutaminase 2 expression has been shown to be regulated 
by PKCδ activation in pancreatic cancer cells, which in turn inhibit a type II, 
programmed cell death (autophagy), reflecting the important role of PKC and TG2 
expression in mediating autophagy (Akar et al., 2007).  
Although activation of TG2 has been linked to PKC and PKA in some cell lines (Akar 
et al., 2007), it has not yet been investigated in the rat H9c2 cardiomyocyte derived 
cell lines. In addition, TG2 has many enzymatic activities, not all of which have been 
investigated.  For example, its crosslinking activity was extensively studied in many 
cells and tissues with respect to its involvement in disease processes (Ruan & 
Johnson, 2007; Sane et al., 2007) or in protection from diseases (Datta et al., 2006; 
Munezane et al., 2010). However, the polyamine incorporation activity of TG2 and its 
role in modulating biological cellular functions has had less consideration from 
scientific researchers. The intracellular role of TG2 was restricted to its crosslinking 
activity and apoptosis regulation in response to different stressors (Iismaa et al., 
2009). As the role of TG2-mediated polyamination of intracellular proteins had not 
been fully investigated, the focus of this current study was to determine the 
intracellular role of TG2-mediated polyamine incorporation in H9c2 cells in order to 
address this gap in TG research. 
1.8. Cardiomyocytes function and properties 
Cardiac diseases remain the major causes of death word wide, more than three million 
of them occur after age sixty (Mendis et al., 2011). However, atherosclerosis and 
diabetes are precursors that begin earlier in life making an advanced prevention of 
cardiac diseases essential from childhood (McGill et al., 2008). The heart is an 
important organ responsible in the supply of different organs with oxygen and 
nutrition needed through pumping blood in blood vessels by repeated contacting and 
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relaxing of its cardiac muscles and associated connective tissues (Ganong & Barrett, 
2005; John, 2011). In mammalia, the heart composes of four chambers derived from 
the mesoderm layer that differentiated later to form mesothelial pericardium. This 
forms the layer that coats the outer area of the heart, while the endothelium layer coats 
the inner area of the heart and also forms lymphatic and blood vessels (van Wijk et 
al., 2007). A network of cardiac neurons is also present in the heart to generate and 
conduct electrical action potential (Ganong & Barrett, 2005; John, 2011).   
Two different types of cells exist in the heart including cardiomyocytes and cardiac 
pacemaker cells that are responsible for generating and transferring of the electric 
impulses from cell to cell (Klabunde, 2011). Cardiomyocytes are cardiac muscle cells 
that compose of a long chains of cardiac-contractile units (sarcomeres) forming 
myofibrils (Bird et al., 2003). Two types of myofibril filaments are found in 
sarcomeres; thick filaments composed of myosin proteins and thin filaments 
composed of actin proteins (Severs, 2000). Actin and alpha-actinin proteins are bound 
to Z-discs that form borders of sarcomeres. Myosin proteins have a long fibrous tail 
with a spherical head that has actin and ATP binding sites and is usually hidden by 
tropomyosin proteins. In the presence of Ca
+2
, the tropomyosin conformation is 
altered and myosin head exposed and bound to actin results in the sliding of thin and 
thick filaments over each other and causes cardiac myocytes contraction (Alberts et 
al., 2002). In contrast, binding of myosin to ATP results in dissociation of actin and 
myosin causes cardiomyocyte relaxation (Solaro & Rarick, 1998; Alberts et al., 
2002).   
Cardiomyocytes are similar to skeletal muscles cells with one nucleus and contain a 
large number of mitochondria allowing high and rapid production of ATP (Olivetti et 
al., 1996). Both atria and ventricles are made up from cardiomyocytes that enable 
them to flexibly stretch by shortening and lengthening  their fibres, a function that is 
critical for proper heart beating (Severs, 2000).Vimentin and desmin are two main 
components present in cytosol of cardiomyocytes that are responsible for holding 
cellular organelles and giving more flexibility to the cells (Sampayo-Reyes et al., 
2006).  Adult cardiomyocytes have a cylindrical shape and it has been shown that the 
shape of cardiomyocytes affects their electrical properties as arterial myocytes (Munk 
et al., 1996). Different cardiac cells are connected to each other with gap conjunctions 
44 
 
that permit different ions (Na
+
, K
+
 and Ca
2+
) to diffuse into the cells which facilitates 
cellular depolarisation and polarisation (Martini, 2007).   
The mechanism of excitation-contraction coupling is tightly controlled by calcium 
concentration and handling, however, mishandling and uncontrolled calcium in 
myocytes has been shown to be the major causes of contractile dysfunction and 
cardiac dysrhythmia in pathophysiological disorders (Pogwizd et al., 2001). Calcium 
concentration and handling are regulated by sarcoplasmic reticulum (SR), upon 
member depolarisation, the Ca
2+
 enters the cells through voltage-gated L-type calcium 
channels, activated ryanodine receptors on the sarcoplasmic reticulum results in 
release of Ca
2+
 in a process called calcium-induced calcium release (CICR) (Bers, 
2002). The increase of intracellular calcium concentration allows cardiomyocyte 
filaments to contract, where decline of it results in relaxing (Bers, 2002). This later 
can be achieve by transport Ca
2+
 out of cells through four different pathways 
including mitochondrial Ca
2+
 uniporter, sarcolemmal Na
+
/Ca
2+
 exchange, 
sarcolemmal Ca
2+
 -ATPase and SR-Ca
2+
 -ATPase (Bers, 2000). It has been shown 
that the major removal of calcium (~70 %) from cytosol is through SR Ca
2+
 -ATPase 
pump, in rabbit ventricular myocytes (Bassani et al., 1994). 
 
The amount of Ca
2+
 entry through voltage-gated L-type calcium channels is limited 
by calmodulin binding to C-terminal of Ca
2+
 channel itself (Peterson et al., 1999). In 
addition, SR Ca
2+
 release has a negative feedback on voltage-gated L-type calcium 
channels influx (Sipido et al., 1995). The Na
+
/ Ca
2+
 exchange also contributes in Ca
2+
 
influx mode either by elevating Na
+
 e.g. blockage of  Na
+
/K
+
-ATPase via digitalis 
glycosides drug or by inhibition of voltage-gated L-type calcium channels and 
activation of SR Ca
2+
 release (Dipla et al., 1999). The sensitivity of cardiomyocytes 
toward Ca
2+
 is decreased by high phosphate and Mg
2+
 concentrations or by acidity 
environment of cells, as in ischaemic condition. Moreover, the activation of β-
adrenergic receptors can reduced cardiomyocytes Ca
2+
 sensitivity, where caffeine and 
certain inotropic drugs can reversed this effect (Santana et al., 1998).  
Β-adrenergic receptors also contribute in cardiac contraction-relaxation in which they 
stimulate activation of GTP-binding protein (Gs) that turns to activate adenylyl 
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cyclase to produce cAMP-induced PKA activation (Greenstein et al., 2004). The later 
kinase results in phosphorylation of many proteins that are essential for excitation–
contraction coupling mechanism including, myosin binding protein C, 
phospholamban, L-type Ca
2+
 channels, ryanodine receptor, and troponin I (Bers, 
2002). For example, the phosphorylation of troponin I and phospholamban by PKA 
accelerates the reuptake of Ca
2+
 by SR and thus dissociation of it from myofilaments 
results in myocardial relaxing. While phosphorylation of RyR2 by PKA at ser2809 
results in dissociation of peptidyl-prolyl cis-trans isomerase (FKBP12.6) from the 
receptor and elevating open probability of RyR2 Ca
2+
 channel (Marx et al., 2000; 
Wehrens et al., 2003). The activation of Β-adrenergic receptors have shown to be 
associated with heart failure where phosphorylation level of RyR2 by PKA is high 
(Marx et al., 2000). Hyperphosphorylation of RyR2 by PKA induced disassociation of 
RyR2/FKBP12.6 complex (Marx et al., 2000) and leakage of Ca
2+
 in canine heart 
failure model (Ono et al., 2000). 
In cardiomyocytes, the phosphorylation of RyR2 by calcium/calmodulin-dependent 
protein kinase II (CaMKII) activates RyR2 Ca
2+
 channel in manner independent of 
FKBP12.6. This effect showed in parallel with elevation of heart rate and Ca
2+
 release 
(Wehrens et al., 2004). Inositol (1,4,5)-trisphosphate (InsP3) are able to induce Ca
2+
  
release from SR in cardiomyocytes (arterial cells), however the level of Ca
2+
  release 
is lower and has less potential action  than  those release by (CICR) (Lipp et al., 
2000). Although, α1- adrenergic and muscarinic agonists can trigger InsP3 production 
and contractile force, this effect is mediated mainly by PKC activation rather than 
InsP3 (Wu et al., 2006). 
1.9. Cardiomyocytes cell culture  
Many potential strategies have been developed to address the threat of heart diseases. 
The use of animal models by scientific researchers has helped in understanding the 
underlying causes of cardiac diseases (Dhein et al., 2005; Gross, 2009). This method 
is used to to overcome several ethical concerns associated to the usage of human 
tissue.  In addition, cultures of cardiomyocytes have been used as simple model for 
studying the alterations that occur at the cellular level under different conditions. 
Cardiomyocytes were isolated from both murine and rodent animals. Culturing 
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cardiomyocytes have been increased in the last decade due to the convenience, 
flexibility and economic advantages that they have over whole-animal heart 
experiments (Mitcheson et al., 1998). These also help in elimination of the 
contamination of other cell types such as, endothelium and fibroblast cells that can 
reduce the effects of experiments on a specific target cells types (Diaz & Wilson, 
2006). Many different studies prefer pure cardiomyocytes including, cell signalling 
mediated ischaemia and preconditioning, subcellular components and toxicity-based 
studies (Dhein et al., 2005; Gross, 2009). The culture of primary cardiomyocytes has 
been applied for different cardiac conditions include myocardial ischemic, 
hypertrophy, heart failure and arrhythymias (Dhein et al., 2005).  
Although primary cardiomyocyte cultures have many advantages, some drawbacks 
have also reported for them includes heterogeneous properties, inconsistent results 
and low reproducibility are often low in toxicity tests (Astashkina et al., 2012). In 
addition, primary cardiomyocytes are limited by shorter culture duration and suitable 
control is need for experiments (Louch et al., 2011). Therefore, alternative strategies 
have been developed to minimise these limitations. These alternative strategies are 
directed to develop immortalised cardiomyocyte cell lines that are able to proliferate 
and maintain differentiated phenotype in culture (White et al., 2004). AT-1 is the first 
cardiomyocyte cell line which was derived from atrial tumour of transgenic mouse. 
These cells have some difficulty to deal with, they must use as a primary cells because 
they need serial propagation, they are not suitable for passaging or recovering from 
cryopreserved stocks (Lanson et al., 1992). Therefore, HL-1 cell lines have been 
generated from AT-1and many aspects have improved. These cell lines can be serially 
passaged and can be also be recovered from frozen stocks. The HL-1 cardiomyocyte 
lines that can contract and display an adult cardiomyocyte-like pattern and similar 
expression of cardiac-specific receptors and proteins (Claycomb et al., 1998). 
Moreover, they have been employed for studying cardiac pathology, cellular 
signalling, electrophysiology, toxicology, cell cycle, apoptosis and calcium regulation 
(Strigun et al., 2012; White et al., 2004). 
The cardio-myoblast H9c2 cell line, is embryonic progenitor cells derived from 
neonatal rat heart, has been widely used as an in vitro model as it displays a 
biochemical and electrophysiological properties similar to those that appear in both 
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cardiac and skeletal tissues (Sardão et al., 2007). Although, the H9c2 cells are non-
beating cells but they have many aspects identical to primary cardiomyocytes making 
them a useful model for cardiovascular researchers to investigate the cellular and 
molecular processes involved in hypertrophy, toxicology, differentiation, and 
apoptosis (Pereira et al., 2011; Watkins et al., 2011). The H9c2 cells have preserved 
many components of hormonal and electrical signalling pathways that exist in adult 
cardiomyocytes (Hescheler et al., 1991). The ability of H9c2 cells to divide in 
comparison to terminal-differentiated cardiomyocyte makes them as an animal-free 
alternative (Koekemoer et al., 2009). 
The role of TG2 in cardioprotection is limited to molecular regulation where its 
biological activities still need further research. The TG2-catalyzed posttranslational 
modification of the substrate proteins, through incorporation of monoamines or 
polyamines, can modify the physical-chemical features of the substrates (Fesus & 
Piacentini, 2002; Park et al., 2010; Gundemir et al., 2012), hence playing a crucial 
role in controlling their biological activity. Some of these targeted TG2 substrates 
mentioned above (section 1.3.7.3) are cytoskeleton proteins, heat shock proteins, 
transport proteins etc. that may also play an essential role in cardiomyocytes function. 
These TG2 substrates have never been investigated in cardiomyocytes and none has 
been linked to its cellular function. Therefore, this study investigated for the first time 
the modulation of TG2 in cardiomyocytes in response to phorbol-12-myristate-13-
acetate (PMA) and forskolin (FK) treatments and the affected target TG2 substrate 
proteins.  
Since it is clear that TG2, PKC, and PKA play distinct role in mediating 
cardioprotection during ischaemia-reperfusion injury, it was important to assess the 
possible relation between these protein kinases and TG2 in cardiomyocytes. The 
present study investigated whether TG2 activity was modulated by PKC and PKA 
activation in H9c2 cardiomyocyte-like cells. This would helps to determine whether 
the PKC and PKA signalling cascades were involved in modulating TG2-mediated 
cytoprotection and facilitate identification of targeted proteins. Thus, this study 
hypothesis that TG2 can modulate its protective effect in the heart via activation of 
PKA and PKC. 
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Main aim  
The overall aims of this study were to investigate the modulation of TG2 activity in 
response to protein kinase A and protein kinase C activation in cardiomyocytes, and 
its role in cytoprotection.  
The specific aims were: 
 To investigate the effect of PMA and FK as PKC and PKA activators 
respectively on TG2 cellular protein level and activities in the H9c2 
cardiomyocyte cell line. 
 To study the effect of protein kinase inhibitors on TG2 activity and cellular 
protein level in H9c2 cardiomyocyte cell line. 
 To investigate the ability of H9c2 cellular proteins to act as substrates for 
endogenous TG2-catalyzed polyamine incorporation reactions before and after 
treatment with PMA and FK. 
 To study the effect of protein kinase activators and inhibitors on purified 
guinea pig liver TG2 activities. 
 To characterise the effect of oxidative stress on TG2 activities and protein 
level before and after PMA/FK induced cytoprotection in H9c2 cells. 
 To detect and identify the targeted TG2 substrates in the H9c2 cardiomyocyte 
cell line in response to PMA and FK and their protective effect against H2O2. 
 To analyse the data and write up the PhD thesis.   
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MATERIAL AND METHODS 
 
 
 
 
 
 
 
 
 
50 
 
2. Materials and Methods 
2.1. Material  
2.1.1. Cell culture reagents 
Dulbecco's modified eagle’s medium (DMEM), foetal calf serum, trypsin (10X), L-
glutamine (200 mM), penicillin (10,000 Uml
-1
)/streptomycin (10,000 gml-1) were 
purchased from BioWhittaker Ltd., Lonza, UK, Phosphate buffered saline (PBS) and 
serum-deficient DMEM (Gibco) were obtained from Life Technologies (Invitrogen, 
UK). 
2.1.2. Plastic ware 
All sterile plastic ware was tissue culture treated and supplied by Sarstedt, UK.  
Cryotube vials (Nunc brand products), supplied by Merck Ltd., UK.  Nunc Lab-Tek II 
CC2 Chamber was supplied by Thermo Fisher Scientific Inc, UK. T75 flask, 6 well 
plates, 24 well plates, 96 well plates, cells scraper supplied by Sarstedt, UK.   
2.1.3. Inhibitors 
2.1.3.1. Protein kinase inhibitors 
Chelerythrine, Gö 6983 ({2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-
(1H-indol-3-yl) maleimide}), H-89, and Ro-31-8220 ({3-[1-[3-(amidinothio) propyl-
1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleimide bisindolylmaleimide IX, 
methanesulfonate}), KT 5720 and Rp-8-Cl-cAMPS were purchased from  
Calbiochem, UK. 
2.1.3.2. Transglutaminase inhibitors 
The irreversible TG2 inhibitor Z-DON (Benzyloxycarbonyl-(6-Diazo-5-
oxonorleucinyl)-L-Valinyl-L-Prolinyl-L-Leucinmethylester) Z-DON-Val-Pro-Leu-
OMe) was obtained from Zedira (GmbH, Germany). R283 (1,3-dimethyl-
2[(oxopropyl)thio]imidazolium) was synthesized by Dr I Coutts at Nottingham Trent 
University, UK. 
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2.1.3.3. Protease and phosphatase inhibitors 
Protease inhibitor cocktail, phosphatase inhibitor 2 and 3 cocktails were obtained 
from Sigma-Aldrich Company Ltd., UK. 
2.1.4. Transglutaminase substrates 
Casein and N′,N′-dimethylcasein were obtained from Sigma-Aldrich Company Ltd., 
UK. Biotin-TVQQEL was purchased from Pepceuticals, UK. Trifluoroacetic acid salt 
(biotin-X-cadaverine) (5-(((N-(biotinoyl)amino)hexanoyl)amino) pentylamine, 
trifluoroacetic acid salt) and biotin-cadaverine (N-(5-aminopentyl)biotinamide, 
trifluoroacetic acid salt) were ordered from Invitrogen, UK. 
2.1.5. Agonist and antagonist  
N6-cyclopentyadenosine (CPA) or isoproterenol (ISO) 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX) adenosine A1 receptor antagonist were obtained from 
Sigma-Aldrich Company Ltd. UK. Phorbol-12-myristate-13-acetate (PMA) was 
purchased from Tocris Bioscience, UK and Forskolin (FK) was ordered from Sigma-
Aldrich, UK. 
2.1.6. Antibodies 
2.1.6.1. Primary antibodies  
Primary antibodies that have been used in this study are listed in table (2.1) including 
working dilutions for both Western blotting and immunocytochemistry techniques. 
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Table 2.1 Primary antibodies and working dilutions required for Western 
blotting and immunocytochemistry techniques 
 
Antibody 
Working dilution 
(Western blotting) 
Working dilution 
(immuno-
cytochemistry) 
 
Company/Catalogue 
number 
Mouse GAPDH 
(monoclonal) 
1:200 N/A Santa Cruz 
Biotechnology, UK. 
(sc-32233) 
Mouse CUB-7402 
(monoclonal) 
1:1000 N/A Abcam, UK (ab2386) 
Mouse anti-α-tubulin 
(B512) (monoclonal) 
1:2000 1:20 Sigma-Aldrich, UK 
(T9026) 
Mouse anti-TGase 1 
(monoclonal) 
1:1000 N/A Abcam, UK 
(ab167657) 
Rabbit anti-TGase 3  
(polyclonal) 
1:1000 N/A Abcam, UK (ab27001) 
 
Mouse anti-
phosphotyrosine 
(monoclonal) 
1:1000 N/A Cell Signalling 
Technology Inc, UK 
(9411) 
Mouse anti-
phosphothreonine 
(monoclonal) 
1:1000 N/A Cell Signalling 
Technology Inc, UK 
(9391) 
Mouse Anti-
phosphoserine 
(monoclonal) 
1:1000 N/A Cell Signalling 
Technology Inc, UK 
(9606) 
Mouse anti-phospho-
specific ERK1/2 
(Thr
202
/Tyr
204
) 
(monoclonal) 
1:2000 N/A Sigma-Aldrich, UK 
(E7028) 
Mouse anti-pAKT 
(monoclonal) 
1:2000 N/A Cell Signalling 
Technology Inc, UK 
(4051) 
Rabbit anti (MAO-B) 
(monoclonal) 
1:1000 1:20 Abcam, UK 
(ab125010) 
Mouse anti-Calnexin 
(AF18) 
(monoclonal) 
1:1000 1:20 Santa Cruz 
Biotechnology, UK. 
(sc-23954) 
Mouse anti-α-actinin 
(monoclonal) 
1:1000 1:20 Sigma-Aldrich, UK 
(A5044) 
Rabbit anti-active 
caspase3 
(monoclonal) 
1:5000 1:10 Cell Signalling 
Technology Inc, UK 
(9664) 
Mouse anti-lamin 
(polyclonal) 
1:2000 N/A Sigma-Aldrich, UK 
(L1293) 
Mouse anti-TG2 (ID10)   
monoclonal  
1:200 N/A antibodies (Griffin, 
School of Biomedical 
and Natural Sciences, 
NTU), 
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2.1.6.2. Secondary antibodies 
Secondary antibodies that have been used in this study are listed in table (2.2) 
including working dilutions for both Western blotting and immunocytochemistry 
techniques. 
Table 2.2 Secondary antibodies and working dilutions required for Western blotting 
and immunocytochemistry techniques 
 
Antibody 
Working dilution 
(Western blotting) 
Working dilution 
(immuno-
cytochemistry) 
Company/ 
Catalogue number 
peroxidase-
conjugated
®
ExtrAvidin 
1:5000  N/A Sigma-Aldrich, UK 
(E2886) 
anti-mouse IgG-HRP 1:5000 N/A Sigma-Aldrich, UK 
(A4416) 
anti-rabbit IgG-HRP 1:5000 N/A Sigma-Aldrich, UK 
(A0545) 
ExtrAvidin®-FITC N/A 1:200 Sigma-Aldrich, UK 
(E2761) 
anti-mouse-Alexa 568  N/A 1:200 Molecular Probes 
(Invitrogen, UK) 
(A-11031) 
anti-rabbit-Alexa 568 N/A 1:200 Molecular Probes 
(Invitrogen, UK) 
(A10042) 
2.1.7. Chemical reagents  
Ammonium persulphate (APS), bromophenol blue, bicinchoninic acid (BCA), 3-((3-
cholamidopropyl) dimethylammonium)-1-propanesulfonate (CHAPS), copper (II) 
phthalocyanine, β-mercaptoethanol,  iodoacetamide, mineral oil, sodium hydroxide 
(NaOH), sodium chloride,  tris (hydroxymethyl) aminomethane, triton X-100, 
TWEEN
®
80, urea are from Sigma-Aldrich, UK. AccuGel™ 29:1 acrylamide, 
electrophoresis running buffer (10x), electrophoresis transfer buffer (10x), protogel
® 
resolving buffer (4x), protogel
®
stacking buffer are from Geneflow, UK. Acetone, 
dimethyl sulfoxide (DMSO), ethanol, glacial acetic acid, glycerol, methanol, sodium 
azide, sodium phosphate dibasic, sodium phosphate monobasic are all from  Fisher 
Scientific, UK. Dithiothreitol (DTT), bovine serum albumin (BSA), sodium dodecyl 
sulphate (SDS) are from Melford Laboratories Ltd., UK. Carrier ampholytes (Bio-Rad 
Laboratories Ltd., UK), enhanced chemiluminescence reagent (ECL) and Brillant 
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Blue R-250 Protein Gel Stain are from Uptima, Interchim, France, N,N,N’,N’-
tetramethylethylenediamine (TEMED) (National Diagnostics, USA)  and blueye 
prestained protein ladder (Geneflow Limited., UK). 
2.2. Methods 
2.2.1. Cell Culture 
All cell culture was carried out using aseptic techniques and all cells were grown in 
T75 culture flasks. H9c2 cell line (rat neonatal ventricular myocytes) was obtained 
from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). 
They were cultured in DMEM, supplemented with 2 mM of L-glutamine, 10 % (v/v) 
(FCS) foetal calf serum (Biosera, UK), 100 μgml-1 of streptomycin and 100 Uml-1 of 
penicillin. Cells were grown in a humidified atmosphere of 5 % (v/v) CO2 at 37°C 
until 80 % confluence was reached. The medium was removed and the cells were 
rinsed by adding 10 ml of sterile phosphate buffered saline (PBS) and then they were 
incubated with 2 ml of (1x) trypsin (Lonza, UK). The cell flask was then incubated 
for 2-3 min at 37°C and monitored under the light microscope at (100x) magnification 
(Olympus CK40-SLP, Japan). A ten ml of medium was added to the flask, the cells 
were removed and then centrifuged at 5000 xg for 5 min using Sanyo Harrier 18/80 
refrigerated centrifuge (Sanyo Gallenkamp, UK) at 25°C. The pellets were re-
suspended in 1 ml of medium. The cell suspensions were split and divided into four 
fresh flasks. The rate of H9c2 cell growth was also measured by counting cells (see 
section 2.2.2) every day for 7 days. 
2.2.2. Cells count 
The amount of viable cells was determined prior to any treatment. Trypan blue 
exclusion assay a method described previously by Wang (2006) was used to estimate 
viable cell count. The H9c2 cell pellets were re-suspended in 1.0 ml of medium that 
was prepared during sub-culturing (section 2.2.1); 10 μl of cell re-suspension was 
mixed with 10 μl trypan blue dye. This mixture was pipette onto an Improved 
Neubauer haemocytometer (Camlab, UK) (0.1 mm depth, 400 mm
-2
) and the cells 
were counted in the four (0.1 mm
3
) corner squares, including those touching the left 
and bottom wells using a light microscope at (100x) magnification (Olympus CK40-
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SLP, Japan). The cell density per ml was then calculated according to the following 
formula;  
Cell density = cell number (mean from four fields) x 10
4
 x dilution factor 
2.2.3. Cell treatments 
The steps for each treatment incubation are shown in figure 2.1   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The flow diagram represents experimental incubation steps for 
different treatments 
 
A) Protein kinase activators treatment in presence (2) or absence (1) of  TG2  
inhibitors. 
B) Oxidative stress-induced cell death: PMA and FK-induced cytoprotection in 
presence (2) or absence (1) of  TG2  inhibitors. 
C) Protein kinase activators treatment in presence (2) or absence (1) of  protein 
kinase inhibitors. 
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2.2.3.1. Protein kinase activators treatment 
In various experiments, H9c2 cells were treated at 80 % confluence with or without 1 
µM phorbol-12-myristate-13-acetate (PMA; Tocris Bioscience, UK) or 10 μM 
Forskolin (FK; Sigma, UK) (from a 10 mM stock solution that was dissolved in 
dimethyl sulfoxide (DMSO) and further diluted with DMEM. For time courses 
experiments, cells were treated with either PMA or FK for 1, 5, 10, 20 & 40 min. In 
other experiments, cells were also incubated for 5 min with different concentrations of 
PMA (0.005, 0.010, 0.032, 0.05, 0.100, 0.3161 and 1.000 µM) or B) FK (0.100, 0.30, 
0.50, 1.00, 3.02, 5.01 and 10 μM). Control cells were also treated with the appropriate 
volume of DMSO equal to PMA and FK volumes that was also compared to cells 
untreated (with DMEM). Changes in H9c2 cell morphology were monitored and 
visualised using an inverted light microscope (Olympus CKX31SF, Philippine). 
2.2.3.2. Protein kinase inhibitors treatment 
All protein kinase inhibitors were obtain from Calbiochem, UK and prepared as a 10 
mM stock solutions dissolved in DMSO and further diluted with DMEM to obtain 
various final concentrations. 
Cultures of H9c2 cells (80 % confluent) were pre-incubated in DMEM medium with 
or without  the kinase inhibitors (5 µM Gö 6983 {2-[1-(3-dimethylaminopropyl)-5-
methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide} a protein kinase C inhibitor, 10 μM 
RO-31-8220 {3-[1-[3-(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-
yl)maleimide bisindolylmaleimide IX, methanesulfonate} a protein kinase C inhibitor, 
1 µM chelerythrine chloride a protein kinase C inhibitor, 1 µM H-89 dihydrochloride 
5 μM KT 5720 and 50 μM Rp-8-Cl-cAMPS  a protein kinase A inhibitor  for 30 min. 
Medium containing different inhibitors was removed and replaced with medium 
containing 1 µM PMA or 10 μM FK and incubated for 5 min. Control cells were 
treated also with the appropriate volume of DMSO equal to each drugs volumes (the 
vehicle-treated control). Cells untreated (with DMEM) served as control. 
2.2.3.3. Oxidative stress-induced cell death: PMA and FK-induced cytoprotection 
H9c2 cells in fully supplemented DMEM were pre-treated for 5 min with 1 µM PMA 
or 10 μM FK prior to 2h exposure to 600 M H2O2. Where appropriate, cells were 
also treated for 1h with the TG2 inhibitors Z-DON (Z-DON-Val-Pro-Leu-OMe) (150 
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μM) or R283 1,3-dimethyl-2[(oxopropyl)thio]imidazolium (200 μM) before the 
addition of PMA or FK. Medium containing PMA/FK and TG2 inhibitors was 
removed and replaced with fresh fully supplemented DMEM prior to H2O2 treatment. 
2.2.4. Determination of H9c2 morphological change 
Coomassie blue staining for morphological change detection is a method described by 
Mochizuki & Furukawa (1987). To observe the cell morphological change, H9c2 cells 
were plated in 24-well flat bottomed plates (25,000 cells per well) and allowed to 
recover for 24h in fully supplemented DMEM. They were then exposed to different 
treatments as described previously (section 2.2.3.3). Growth medium was aspirated 
from the H9c2 cells using vacuum. Cells were rinsed twice with 500 μl of chilled PBS 
flowed by fixation for 10 min with 500 μl per well of ice-cold 90 % (v/v) 
methanol/PBS. Fixing solution was removed by aspiration and cells were stained for 
~10 min at room temperature (25°C) in 0.25 % (w/v) Coomassie blue stain in 25 % 
(v/v) ethanol, 10 % (v/v) glacial acetic acid aqueous solution. Cells were rinsed twice 
in distilled water to remove excess stain and left to air-dry. In order to determined 
morphological change, cells were observed using an inverted light microscope at 
(100x) magnification and digital images were captured on a Canon PC 1200 camera. 
2.2.5. Cell extraction   
Cultures of H9c2 cells were rinsed twice with 2 ml of chilled PBS, lysed with 500 μl 
of ice-cold lysis buffer containing; 50 mM Tris-HCl pH 8.0, 0.5 % (w/v) sodium 
deoxycholate, protease inhibitors 5 mg ml
-1
 with or without 10 mg ml
-1
 phosphatase 
inhibitors cocktail 2 and 3 (Sigma, UK). Cell lysates were scraped and clarified by 
centrifugation at 4°C for 20 min at 14000 xg (Scientific Laboratory, UK). 
Supernatants were collected in new sterile 1.5 ml Eppendorf tubes (Fisher Scientific, 
UK) and stored in at -20°C. 
2.2.6. Acetone precipitation 
The proteins solubility could be dropped and precipitated and this could be induced 
by reducing the effective dielectric constant of the media. This was usually achieved 
by adding a water-soluble solvent with a small relative permittivity (dielectric 
constant), such as acetone, to an aqueous solution of protein (Jiang et al., 2004). This 
method was used when sample concentration was required.  In brief, nine volumes of 
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ice cold (-20C) acetone were added to the sample, vortex mixed for 15 seconds and 
left overnight to precipitate at -20C. The samples were centrifuged at 300 xg for 20 
min at 4C, the supernatant was removed and the pellet was air dried for 20 min at 
20C. The pellet was subsequently suspended in an appropriate volume of buffer. 
2.2.7. Protein estimation 
Bicinchoninic acid (BCA) protein assay was based on the method of Stoscheck (1990) 
using a kit from Sigma (Poole, UK) was used to estimate protein concentration in 
H9c2 extracts. Kits contain; 1 % (w/v) bicinchoninic acid solution (reagent A), 4% 
(w/v) copper (II) sulphate pentahydrate (reagent B) and protein standard solution 
(bovine serum albumin). Reagent C was prepared by mixing reagent A with reagent B 
at 50:1 ratio. Bovine serum albumin (BSA) protein standards were prepared in a range 
of 0–1 mg ml-1 in an appropriate volume of buffer. In a 96-well plate (Nunc), a 
volume of 25 μl of either BSA protein or unknown sample were incubated with 200 μl 
of reagent C at 37C for 30 min. The absorbance of the samples was measured at 570 
nm using a plate reader (Expert 96, Scientific laboratory, UK) and a calibration graph 
was plotted for protein range 0-1 m gml
-1
.  
2.2.8. Subcellular fractionation  
To determine subcellular distribution of TG2 in H9c2 cells, H9c2 cells were sub-
fractionated.  H9c2 cells were grown T125 culture flasks and then treated with 1 µM 
PMA or 10 μM FK (section 2.2.3.1). After which they were lysed with 500 μl of 
subcellular fractionation buffer of 20 mM HEPES (pH 7.4) containing; 250 mM 
sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA and 1 mM EGTA and freshly 1 
mM DTT and (10 μl) 10 mg ml-1 phosphatase inhibitors cocktail 2 and 3  were added.  
The plates were scraped immediately and cells lysate were transferred to 1.5 ml 
eppendorf tubes and placed in ice. Cells lysate was homogenised and passed through a 
25 Ga needle (10x) using a 1 ml syringe, and incubated in ice for 20 min. The nuclear 
pellet was centrifuged out at 720 xg for 5 min and supernatant was transferred to a 
new 1.5 ml microfuge tube. The pellet was then washed (1x) by subcellular 
fractionation buffer and centrifuged again at 720 xg for 10 min. The washing buffer 
was removed and pellet was re-suspended in lysate buffer (section 2.2.5). The 
supernatant was centrifuged at 10,000 xg for 20 min to separate the crude 
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mitochondria. The pellet was then washed as was with nuclear pellet and re-
suspended in lysate buffer. The supernatant was centrifuged for a further 1h at 80,000 
xg to isolate the mixed microsomal fraction. The pellet was washed as before and re-
centrifuged for further 45 min. The ER pellet was re-suspended in the same buffer as 
used for the above fractions. The supernatant (containing cell cytosol) was subjected 
to acetone precipitation (section 2.2.6) and the precipitated pellet was re-suspended in 
lysate buffer. Protein concentration was then determined for subcellular fractions 
(section 2.2.7). The subcellular fractions were analysed by Western blotting (section, 
2.2.12) using monoclonal antibodies to TG2 (Cub7402), calnexin (Sigma, UK), lamin 
and α-tubulin (B512) (Sigma, UK). 
2.2.9. Transglutaminase activity 
2.2.9.1. In vitro TG2 activity 
Transglutaminase activity was monitored by two different assays; 
2.2.9.1.1. Biotin cadaverine-incorporation assay 
The assay was performed as the method described by Slaughter et al., (1992) with 
modifications of Lilley et al., (1998). Briefly, 96 well microtitre plates (Maxisorp 
Nunc, UK) were coated overnight at 4°C with 250 μl of N′,N′-dimethylcasein (5 ml of 
10 mg ml
-1
 in 50 ml of 100 mM Tris-HCl, pH 8.0). After discarding the unbound 
protein the plate was washed with pure water and blocked with 250 μl of 3 % (w/v) 
BSA in 0.1 M Tris-HCl, pH 8.5 and incubated for half an hour at 37°C. The plate was 
washed and 20 μl of biotin-cadaverine (25 mg ml-1 stock in 50 mM Tris-HCl pH 8.0) 
and 5 μl of β-mercaptoethanol (Sigma, UK) were freshly added to both 10 ml of 6.67 
mM calcium chloride or 13.3 mM EDTA dissolved in 100 mM Tris-HCl pH 8.0. For 
each well 150 μl of these buffers were added separately and 50 μl of samples or 
diluted standard TG2 (Guinea pig liver TGase; Sigma, UK) (1 mg ml
-1
; standard TG2 
that was prepared in 50 mM Tris–HCl, pH 8.0, and stored in aliquots at -80°C) along 
with negative control (100 mM Tris buffer). The plate was then incubated for an hour 
at 37°C and washed as before. Then, a volume of 200 μl of 100 mM Tris-HCl pH 8.0 
containing 1:5 dilution of ExtrAvidin
®
 peroxidase was added to each well and the 
plate was incubated at 37°C for 45 min then washed as before. The plate was 
developed with 200 μl of developing buffer (75 μl of 10 mg ml-1 TMB and 1.5 μl of 3 
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% (v/v) hydrogen peroxide were added to 10 ml of 100 mM sodium acetate, pH 6.0) 
that was freshly made and incubated at room temperature for 5-15 min. The reaction 
was terminated by adding 50 μl of 5 M sulphuric acid. The absorbance was read at 
450 nm using a plate reader (Expert 96, Scientific laboratory, UK). One unit of 
transglutaminase activity was defined as a change in absorbance of 0.01 at 450 nm per 
hour. The specific activity of TG in different samples was calculated as follow;  
Average signal of calcium in three wells – Average signal of EDTA in three wells X 
100 / 2.216 (equation of purified TG activity standard curve of biotin cadaverine-
incorporation) / protein concentration of sample.   
2.2.9.1.2. Biotin-TVQQEL crosslinking assay   
The assay was performed according to the method of Trigwell et al., (2004) with 
minor modifications. Briefly, casein (sodium salt) was dissolved in 10 mM Tris-HCl 
pH 8.0, at 5 mg ml
-1 
and stored in aliquots at -20°C until required. Microtitre plate 96 
wells (Maxisorp Nunc, UK) were coated and incubation overnight at 4°C with casein 
at 1.0 mg ml
-1
 in 100 mM Tris-HCl, pH 8.0 (250 μl per well). Wells were washed two 
times with distilled water, before the addition of 250 μl of blocking solution (100 mM 
Tris-HCl, pH 8.0 containing 0.1 % (w/v) BSA. The plate was incubated at 37°C for 
1h. The wells were washed as before; then 150 μl of reaction buffer (100 mM Tris–
HCl (pH 8.5) containing; 5 μl of β-mercaptoethanol (Sigma, UK), 5 μl biotin-
TVQQEL (Pepceuticals, UK) (25 mg ml
-1
 stock in 50 mM Tris-HCl pH 8.0) and 
either 6.7 mM  CaCl2 or 13.3 mM EDTA were added to each well. The reaction was 
started by the addition of 50 μl of extract samples or diluted standard TG2 to each 
well and allowed to proceed for 1h at 37°C. The reaction development and 
termination were performed as described in (section 2.2.8.1.1). The specific activity 
of TG in different samples was calculated as follow;  Average signal of calcium in 
three wells – Average signal of EDTA in three wells X 100 / 2.269 (equation of 
purified TG activity standard curve of Biotin-TVQQEL crosslinking) / protein 
concentration of sample.   
2.2.9.2. In situ TG2 activity 
H9c2 cells were seeded on 8-well chamber slides (Thermo Fisher Scientific, UK) at 
density of (1.5 ×10
4
 cells/well) and cultured for 24h in fully supplemented DMEM. 
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The medium was then removed and adherent cells gently washed with PBS and slides 
incubated for 4h with 1 mM biotin-X-cadaverine (5-(((N-
(biotinoyl)amino)hexanoyl)amino) pentylamine, trifluoroacetic acid salt) (1:100 (v/v) 
in DMEM). Cells were then treated for 1h with the TG2 inhibitors Z-DON (Z-DON-
Val-Pro-Leu-OMe) (150 μM) before the addition of either 1 µM PMA or 10 μM FK 
for 5, 10, or 20 min. Following stimulation, cells were fixed with 3.7 % (w/v) 
paraformaldehyde in PBS for 15 min at room temperature and permeabilised with 0.1 
% (v/v) Triton-X100 in PBS for 15 min at room temperature. Each step was followed 
by (3x) 5 min washes with PBS. Finally, cells were blocked with 3 % (w/v) BSA for 
1h at room temperature and transamidated and cross-linked cadaverine substrates 
detected by 1:200 (v/v) ExtrAvidin®-FITC (green fluorescence; Sigma-Aldrich, UK). 
Nuclei were stained with blue fluorescence (DAPI; Invitrogen, UK) and viewed at 
(400x) magnification using fluorescence microscope (Olympus BX51, Japan).  
2.2.10. Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecylsulphate-polyacrylamide gel electrophoresis was performed by the 
method described by Laemmli (1970) with modifications. For making 10.0 % (SDS-
PAGE) in 10 ml, the resolving gel was prepared by combining 3.38 ml acrylamide 
(AccuGel 29:1 30 %; National Diagnostic, USA), 4 ml distilled water, 2.5 ml of (4x) 
resolving buffer (National Diagnostic, USA), 100 μl of freshly made 10 % (w/v) 
ammonium persulphate (APS) and 15 μl N,N,N’,N’-tetramethylethylenediamine 
(TEMED) were mixed in a beaker and poured quickly into the gel casting mould and 
2 cm below the bottom of the comb was left for the stacking gel. The bubbles that 
were generated were removed by overlaying with water. This was left for 30 min until 
the gel was polymerized completely. For making 10 ml stacking gel, 1.3 ml 
acrylamide, 6.1 ml distilled water, 2.5 ml of (4x) stacking buffer (National 
Diagnostic, USA), 100 μl of 10 % (w/v) APS and 40 μl TEMED were mixed in 
beaker and poured quickly into the gel casting assembly upon the resolving gel and 
left for 30 min to completely polymerize. For 50 μg protein sample, 20 μl of (4x) 
sample buffer were added to 60 μl of extracted protein and boiled for 5 min; after 
cooling the denatured samples were loaded in gel wells along with 3 μl of molecular 
weight standards Precision Plus Protein standards (Bio-Rad, UK). Using the Bio-Rad 
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(Bio-Rad Laboratories, USA) apparatus, the gel was subjected to electrophoresis at 
175 v for one hour. 
2.2.11. Agarose gel electrophoresis  
2.2.11.1. Preparation and casting 
The mini gel-casting tray (Bio-Rad Laboratories, Hercules, USA) was rinsed with 95 
% (v/v) ethanol and dried. The gel-casting tray was then assembled and the comb 
level was adjusted so that it resets with a few mm of space between the comb teeth 
and the casting tray. The 2.5 % (w/v) agarose gel was prepared by mixing 2.5 g of 
agarose powder (Bioline Reagents Ltd., UK) in 100 ml of (1x) TBE buffer (89 mM 
Tris, 89 mM boric acid, 2 mM EDTA, pH of 8.3) that was made freshly from (10x) 
TBE buffer. The mixture was melted in microwave for 2-3 min with frequently gentle 
mix until no particles appear. When the melted agarose gel was cold down to ~40°C, 
a 5 μl of SYBR Safe DNA gel stain (Life Technologies, Invitrogen, UK) was added. 
A 50 ml of melted agarose gel was poured into the casting tray and was left for 10-15 
min until the gel was solidifying completely. 
2.2.11.2. Loading and running the agarose gel  
A 5 µl of loading dye (Bioline Reagents Ltd., UK) was added to each sample. 
Samples were mix and briefly centrifuged. A casting tray containing the agarose gel 
into the electrophoresis chamber and the (1x) TBE (Tris-Borate-EDTA; 
electrophoresis buffer) was gradually added to the chamber until the buffer just 
covered the gel. Samples along with 5 µl DNA ladder day (Bioline Reagents Ltd., 
UK) were loaded and the gel was run at 100 v for 1h or till the dye has migrated to 
within ¾ of the length of the gel.  
2.2.12. Western blot analysis  
To investigate the presence of TGs and phosphoproteins, the protein extracts (50 μg 
per lane) and 100 nmol standard TG2 were separated by 10 % (w/v) SDS-PAGE 
(section 2.2.9) and transferred onto a nitrocellulose membrane by using the wet-
transferring system (Bio-Rad Laboratories, Hercules, USA) as described by Towbin et 
al. (1979). The membrane was blocked with 3 % (w/v) skimmed milk powder in TBS 
containing 0.1 % (v/v) Tween-20 and probed with (1:1000, v/v) anti-phosphotyrosine, 
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anti-phosphothreonine, anti-phosphoserine, (1:2000, v/v) phospho-specific ERK1/2, 
(ID10) monoclonal antibodies, anti-TG2 (TG 100), anti-TG2 (CUB 7402) anti-TG1 or 
anti-TG3. Horseradish peroxidase-conjugated anti-mouse IgG, Horseradish 
peroxidase-conjugated anti- rabbit IgG, Horseradish peroxidase-conjugated anti- goat 
IgG and goat anti-mouse IgG Horseradish peroxidase-conjugated were used as 
appropriate secondary antibodies. Immunoreactive proteins were detected by 
enhanced chemiluminescence (ECL). The ECL detection was performed using the 
Fujifilm Intelligent dark box system (Fujifilm, UK) according to the manufacturer’s 
instructions one volume of ECL reagent A and two volumes of ECL reagent B were 
mixed to a final volume of 1 ml.  Mixed ECL substrate was spread well and incubated 
with blotted nitrocellulose membrane for one minute.  Excess ECL substrate was then 
drained off using filter paper, the nitrocellulose was placed directly into the dark box 
and chemiluminescence was detected following the manufacturer’s instructions. Band 
intensities were quantified by densitometry (Adobe Photoshop CS4). The histogram 
within the software reported the intensity for each band. This was divided by GAPDH 
band intensity (normalisation) and then relative intensity to control was calculated 
(normalised intensity / control intensity X 100).   
2.2.13. Stripping and reprobing of Western blots 
Stripping and re-probing of western blots was carried out as described by Kaufmann 
et al., (1987) with modifications. Membranes were submerged in stripping buffer (100 
mM β-mercaptoethanol, 2 % (w/v) SDS, 62.5 mM Tris-HCl at pH 6.7) and incubated 
for 30 min at 50C.  The membranes were then washed twice for ten min in TBS-
Tween. The membranes were then blocked and probed as described in (section 
2.2.11). 
2.2.14. Two-dimensional gel electrophoresis  
Two-dimensional electrophoresis was carried out according to Nirmalan et al., (2004). 
The proteins that were extracted from H9c2 treated cells were acetone precipitated, 
and the proteins pellet was dissolved in rehydration buffer containing; 8 M urea, 4% 
(w/v) CHAPS, 50 mM DTT, 0.2 % (v/v) carrier ampholytes, 0.0002 % (w/v) 
Bromophenol Blue. In the first-dimension isoelectric focusing, an equal amount of 
protein was loaded on immobilized pH gradient (IPG) strips with a pH range of 3 to 
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10 and focused with a Protean isoelectric focusing cell (Bio-Rad Laboratories, 
Hercules, USA). For second-dimension, the IPG strips were equilibrated for 15 min 
with 10 % (w/v) DTT (as a reducing agent to break disulfide bonds) in 10 ml of an 
equilibration buffer (50 mM Tris base, pH 8.8, 6 M urea, 30 % (v/v) glycerol and 2 % 
(w/v) SDS) and for further 15 min with 25 % (w/v) iodoacetamide (to prevent any 
reformed disulfide bonds) in the equilibration buffer. Each IPG strip was loaded onto 
a gel of the appropriate percentage of acrylamide, sealed with 1 % (w/v) agarose, and 
polyacrylamide gel electrophoresis was performed as describe in section (2.2.10). 
After electrophoresis, the proteins were fixed and visualized using PlusOne silver 
staining kit (GE Healthcare life science, UK) according to the manufacturer’s 
suggested protocols (section 2.2.16). Gels were imaged in Biomolecular Imagers 
(FLA 7000, FUJIFILM, life sciences, UK). 
2.2.15. Phosphorylated protein and total protein stains 
In order to evaluate phosphorylation events in H9c2 after different treatments, cell 
lysates of treated cells were assayed for protein concentration using  the BCA assay 
(section 2.2.7), denatured with (4x) SDS sample buffer at 95°C for 5 min and 
separated by 10 % SDS-PAGE (section 2.2.10). To visualise proteins, electrophoresed 
gels were stained with 0.2 % (w/v) Coomassie blue (Uptima, Interchim, France) and 
then destained with ddH2O. However, to visualise phosphoproteins, the gel was 
stained with Pro-Q
®
Diamond phosphoprotein gel stain (Invitrogen, UK) and 
subsequently with SYPRO
®
Ruby Protein Gel Stain (Invitrogen, UK) to quantify the 
total proteins and to determine the ratio of phospho protein to total protein ratio. The 
method was performed according to the supplemented protocol of Invitrogen 
Detection Technologies. Briefly, the separated proteins were fixed with ~100 ml of 
fix solution (freshly prepared from 50 % (v/v) methanol, 10 % (v/v) acetic acid and 
made up to 100 ml ddH2O) for 1 hour at R/T. The gel was washed with ~100 ml of 
ultrapure water for (3x) 10 min and was stained with 60 ml of Pro-Q
®
Diamond 
phosphoprotein gel stain with gentle agitation in the dark for ~90 min. To visualize 
the gel, it was destained with 80–100 ml of destain solution (50 ml of 1 M sodium 
acetate, pH 4.0, 750 ml of ultrapure water, and 200 ml of acetonitrile) for (3x) 30 min 
at R/T, with protection from light. Each gel was washed twice with ultrapure water at 
R/T for 5 min per wash. Then the gels were imaged in a Biomolecular Imagers (FLA 
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7000, FUJIFILM, life sciences, UK). For total-protein stain, the gel was rinsed with 
ultrapure water twice for 5 min and then incubated directly in 60 ml of 
SYPRO
®
Ruby-gel stain solution for 24 h with protection from light. To visualize the 
gel, it was destained with 80 ml of wash solution (freshly prepared from 10 % (v/v) 
methanol, 7 % (v/v) acetic acid and made up to 100 ml ddH2O) for (3x) 30 min at 
R/T. The gels were then scanned in a Biomolecular Imagers (FLA 7000, FUJIFILM, 
life sciences, UK). 
2.2.16. Silver stain 
After resolving protein in 1D or 2D gel, the proteins were visualised by silver stain 
(PlusOne
™
Silver Staining Kit, Protein, GE Healthcare, UK). The method was 
performed according to the GE Healthcare protocol, briefly; the polyacrylamide gels 
were fixed with ~250 ml of fix solution (freshly prepared from 40 % (v/v) ethanol, 10 
% (v/v) acetic acid and made up to 250 ml ddH2O) for 2 hours R/T. These after which 
the fixation solution was removed and replaced by 250 ml of sensitizing solution 
containing; 35 % (v/v) ethanol, 5 % (w/v) sodium thiosulphate, 0.8497 M  sodium 
acetate, 25 % (w/v) glutaraldehyde and up to 250 ml ddH2O and  left in shaking for at 
least 30 min. The gel was washed with ~100 ml of ultrapure water for (3x) 10 min. 
The gel was stained with 250 ml 2.5 % (w/v) silver nitrate solution with gentle 
agitation in the dark for ~90 min. The silver solution was removed and gel rinsed 
twice in distilled water for one minute each time. To visualise the gel, a 250 ml of 
developing solution containing; 0.239 M sodium carbonate, 37 % (w/v) formaldehyde 
and made up to 250 ml ddH2O were added and left shaking for 2 to 5 min. When the 
bands or spots reach a desired intensity, gel was then transferred to stopping solution 
containing; 39.22 mM EDTA-Na2•2H2O in 250 ml ddH2O. Each gel was washed 
twice with ultrapure water at R/T for 5 min per wash. Then gels were imaged in 
Biomolecular Imagers (FLA 7000, FUJIFILM, life sciences, UK). Subsequently, the 
gels were analysed by Progenesis SameSpots software, UK. 
2.2.17. Biotinylation and fractionation of TG2 substrates  
Biotin-X-cadaverine (5-(((N-(biotinoyl)amino)hexanoyl)amino) pentylamine, 
trifluoroacetic acid salt) represents the acyl-acceptor probe for TG2 (Ruoppolo et al., 
2003), was used for labelling TG2 substrate proteins in PMA treated H9c2 cells. 180 
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mM stock of Biotin-X-cadaverine was prepared at 0.1 mg ml
-1
 in DMSO, 10 μl of 
which were further diluted in 2 ml of complete DMEM medium to reach final 
concentration of 1 mM and pre-incubated with H9c2 monolayers in T75 flasks for 4h. 
After discarding the labelling medium and washing with PBS, H9c2 cells were then 
treated with 1 µM of PMA in fresh medium for 5 min and proteins were extracted as 
described earlier (section 2.2.5). CaptAvidin
®
agarose sedimented bead suspension 
(Invitrogen, UK) was then used to isolate the bound biotinylated ligands (Fig. 2.2) as 
follows; 200 μl CaptAvidin beads were suspended in 800 μl biotin-binding buffer (50 
mM citrate phosphate buffer, pH 6.0) and mixed well. Cell lysate proteins (500 μg) 
were re-suspended in 500 μl of biotin-binding buffer and incubated with 100 μl 
CaptAvidin beads overnight at 4°C with gentle agitation. Samples were centrifuged at 
3000 xg for 15 min and unbound material (supernatant) was collected. CaptAvidin 
beads were washed with 10 mM Tris-HCl, pH 8.0 and centrifuged at 3000 xg for 3 
min and the supernatant was collected (this step was repeated twice). The biotinylated 
polypeptides were released from the beads using 50 mM sodium bicarbonate pH 10 
buffer and boiling in 30 μl of SDS sample buffer for 5 min at 95°C (section 2.2.10). 
The bound and unbound material were resolved in 4-15 % gradient gel (Bio-Rad, UK) 
followed by Western blotting (section 2.2.12) and probing with HRP-
conjugated
®
ExtrAvidin-peroxidase to detect TG2 substrate proteins.  
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Figure 2.2 The flow diagram represents fractionation steps of acyl-acceptor 
binding TG2 substrates 
As scheme in figure 2.1, H9c2 cells were pre-incubated with 1 mM biotin-X-
cadaverine for 4h in culture hood. After different treatment biotin labelled proteins in 
cells lysate was subjected to pull down assay in which CaptAvidin
®
agarose 
sedimented beads suspension was used to isolate the bound biotinylated (biotin-
cadaverine labelled) proteins. Biotinylated proteins were then recovered by 
centrifugation and released from the agarose beads with 50 mM sodium bicarbonate 
buffer pH 10. 
 
2.2.18. Dot blot  
To detect biotinylated (biotin-cadaverine labelled) proteins in culture medium after 
different treatments, the culture medium and proteins from biotinylated experiment 
(section 2.2.17) was subjected to dot blot. The nitrocellulose membrane was placed 
inside the manifold of a 96 well dot–blot system (Bio-Rad Laboratories, Hercules, 
USA). An equal amount (10 μg) of proteins of each sample was spotted onto the 
nitrocellulose membrane and then was allowed to dry for 2 hours at room 
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temperature. The nitrocellulose membrane was removed from the dot–blot apparatus 
and treated as previously described in (section 2.2.12). The nitrocellulose membrane 
was probed with HRP-
 
ExtrAvidin
®
peroxidase to detect TG2 substrate proteins. The 
biotinylated proteins were visualised by ECL as described in (section 2.2.12). 
2.2.19. Measurement of proteins serving as substrates for TG2 in the presence of 
calcium and EDTA 
The ability of cellular proteins to act as substrates for endogenous TG2-catalysed 
polyamine incorporation reactions was investigated as described previously by Singh 
et al. (1995). Briefly, cell extracts containing equal amounts (200 μg) of proteins were 
incubated in 100 μl of 100 mM Tris-HCl (pH 8.5) buffer containing; 1 mM biotin 
cadaverine and 5 mM of either CaCl2 or EDTA (background control). The reaction 
mixture (50 μl) was removed at different time points and directly mixed with (4x) 
sample buffer to stop the reaction. The reaction mixtures were separated by SDS-
PAGE (section 2.2.10) and transferred on to nitrocellulose membrane filters. The 
membrane was probed with HRP-
 
ExtrAvidin
®
peroxidase and biotinylated amine 
incorporation detected by enhanced by ECL as described in (section 2.2.12). 
2.2.20. Immunoprecipitation  
Protein G-Sepharose beads 4 fast flow (Amersham Biosciences AB, 
Uppsala Sweden) were washed twice and re-suspended in lysis buffer. Total cell 
lysate protein (500 μg) of Biotin-X-cadaverine labelled sample was pre-clarified by 
incubation with 50 μl protein G-Sepharose beads for 1 hour at 4°C with gentle 
rotation using rotating wheel mixer (Stuart Scientific Blood Tube Rotator SB1, 
Jencons- PLS, UK) and beads were spun down by centrifugation at 3000 x g for 2 min 
at 4°C. The supernatants were transferred to a fresh tube and beads were discarded. 
The pre-clarified lysates were incubated overnight with 1μg of anti-α-actinin mAb 
(Sigma, UK) antibody at 4°C with gently rotation. After incubation overnight, the 
lysates were mixed with 90-100 μl of protein G-Sepharose beads and incubated one 
again overnight, at 4°C with gently rotation. The beads were spun down by 
centrifugation at 3000 xg for 2 min at 4°C and the supernatant was removed. The 
beads were washed 3x with lysis buffer and centrifuged for 2 minutes at 3000 xg. 
Bound proteins were eluted from beads with 4x sample buffer and analysed by 
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Western blotting (section 2.2.11). To confirm α-actinin as TG2 substrate proteins, the 
immunocomplex proteins were resolved in 10 % SDS followed by Western blotting 
(section 2.2.12) and probing with HRP-conjugated
®
ExtrAvidin-peroxidase. 
2.2.21. Cell viability measurement 
2.2.21.1. MTT assay 
In order to identify the viability of cells in response to different treatments, the 
tetrazolium salt, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltertra-zolium bromide 
MTT assay was performed. This assay measured the reduction of MTT compound by 
mitochondrial succinate dehydrogenase (Denizot & Lang, 1986). This reaction only 
occured in metabolically active cells. Briefly, the 80 % confluent H9c2 cells were 
cultured in 24 wells plates overnight, at a density of (25,000 cells per well). At the 
end of each treatment period, a volume of 50 μl (1:10 in DMEM) of 5 mg ml-1 MTT 
(Sigma, UK), was added to each well and the plate was incubated at 37°C for 2h. 
After the medium was removed, 500 μl of DMSO was added to each well to dissolve 
the formazan. The magnitude of the reduction reaction was determined by monitoring 
the absorbance of the solubilised formazan product at 570 nm using a plate reader 
(Expert 96, Scientific laboratory, UK). The MTT data was expressed as percentage of 
control (untreated cells). Data calculated as follow; average of the four wells 
absorbance of each sample / average of the four wells absorbance of control sample 
X100. 
2.2.21.2. Lactate dehydrogenase (LDH) assay 
The death of H9c2 cells in response to H2O2 and different treatments was evaluated 
by a lactate dehydrogenase assay (LDH), a method as described previously (Decker & 
Lohmann-Matthes, 1988). Cardiomyocytes H9c2 cells were grown in 96-well plates 
at a density of 1×10
5
 cells/ml (5,000 cells per well) overnight. Following H2O2 
exposure the activity of lactate dehydrogenase (LDH) released into the culture 
medium was detected colourimetrically using the CytoTox 96
®
Non-Radioactive a 
cytotoxicity assay kit (Promega, UK). The LDH assay was performed according to the 
manufacturer’s instructions. Briefly, after each treatments exposure the cell culture 
plate was centrifuged for 5 min at 1000 xg using the plate centrifuge 5430 (Eppendorf 
AG, Germany) and 50 μl of medium was transferred to a 96 wells flat bottomed micro 
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plates and 50 μl of assay mixture of LDH was added to each well. The cell culture 
plate was protected from light and incubated at 25°C for 30 min. The reaction 
mixtures were stopped by 50 μl of the provided kit stop solution and the absorbance 
recorded at 490 nm. The amount of LDH released into the medium was expressed as 
percentage of control (untreated cells). Data calculated as follow; average of the four 
wells absorbance of each sample / average of the four wells absorbance of control 
sample X100. 
2.2.22. Caspase-3 activity 
The induction of apoptosis in H9c2 cells in response to H2O2 and different treatments 
was evaluated by a colorimetric caspase-3 assay as described by Sordet et al. (2002) 
with minor modifications. After each treatment exposure, cells were rinsed twice with 
2 ml of chilled PBS, lysed with 500 μl of ice-cold caspase lysis buffer of 50 mM 
HEPES (pH 7.4) containing; 5 mM CHAPS and 5 mM DTT (Sigma, UK). Cell 
lysates were scraped and clarified by centrifugation at 4°C for 20 min at 14000 xg 
(Sigma, UK). The supernatant (75 μl) were loaded into 96-well plates. The reaction 
started by the addition of 20 mM HEPES, pH 7.4, 2 mM EDTA, 0.1 % (w/v) CHAPS, 
5 mM DTT and 100 μM caspase-3 peptide substrate Acetyl-Asp-Glu-Val-Asp p-
nitroanilide (Ac-DEVD-pNA; Sigma, UK) to each wells. After one hour incubation at 
37°C, the absorbance of the p–nitroanilide (pNA) release correlating to caspase-3 
activity was read at 405 nm using a plate reader (Expert 96, Scientific Laboratory, 
UK). The enzyme activity is expressed as a percentage increase over control.  Cells 
treated with 1 µM staurosporine (STS) for 2 hours, were used as a positive control. 
2.2.23. DNA fragmentation assay 
Genomic DNA fragmentation is a consequence of apoptosis cell death, a method 
described previously and modified by Zhou et al., (1998) and Lee (2001) determined 
fragmented DNA after treatment cells with harmful agents. Briefly, H9c2 cells were 
plated out at density of 50,000 cells/ml in sterile 6 well culture dishes and incubated 
for a further 24h to allow recovery. Cells were subjected to oxidative stress-induced 
cell death/ PMA and FK-induced cytoprotection as described previously (section 
2.2.3.3). The monolayer was rinsed twice with 2 ml of chilled PBS, lysed with 200 μl 
of ice-cold lysis buffer of 0.2 % (w/v) Tris-HCl (pH 8.5) containing; 10 mM NaCl, 1 
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mM EDTA, and 1 % (w/v) SDS. After adding 0.1 mg ml
-1
 of proteinase K (Sigma, 
UK), the cell lysates were then incubated at 60°C for 2h. The reaction was stopped by 
adding 0.3 M sodium acetate into the cell lysates and incubated on ice for 30 min. The 
cell lysates supernatants were clarified by centrifugation at 4°C for 15 min at 20,000 
xg (Scientific laboratory, UK). The resultant supernatants were transferred to a new 
sterile tubes and the DNA was precipitated by the addition of five volumes of ice cold 
(-20C) 100 % (v/v) ethanol and incubated overnight at -20C. After centrifugation 
for 30 min at 20,000 xg, DNAs pellet was washed again with 70 % (v/v) ethanol, re-
suspended in 100 μl of distilled water supplemented with 0.2 mg ml-1 of RNase A 
(Sigma, UK) and incubated at 55C for 1h. The DNA fragmentation was then 
detected by loading 20 μg of DNA into 1.5 % (w/v) agarose gel (section 2.2.11). The 
DNA bands were visualised under UV light.  
2.2.24. Immunocytochemistry analysis 
H9c2 cells were seeded on 8-well chamber slides (Thermo Fisher Scientific, UK) at 
density of (1.5 ×10
4
 cells/well) and cultured for 24h in fully supplemented DMEM. 
The medium was then removed and adherent cells were gently washed with PBS and 
slides incubated (or not) for 4h with 1 mM biotin-X-cadaverine (1/100 in DMEM). 
Cells were then treated with 1 µM PMA or 10 μM FK for 5 min. The stimulation cells 
were fixed with 3.7 % (w/v) paraformaldehyde in PBS for 15 min at room 
temperature and permeabilised with 0.1 % (v/v) Triton-X100 in PBS for 15 min at 
room temperature. Each step was followed by (3x) 5 min washes with PBS. Finally, 
cells were blocked with 3 % (w/v) BSA for 1h at room temperature. For 
mitochondrial detection, cells were incubated with rabbit anti-monoamine oxidases B 
(MAO-B) mAb, and anti-rabbit-Alexa568 secondary antibody (red). Endoplasmic 
reticulum (ER) was detected by mouse anti-calnexin (AF18) antibody mAb and the 
cytoskeleton was detected by mouse anti-α-actinin antibody mAb and both were 
visualised by anti-mouse-Alexa568 secondary antibody (red) (Molecular probes, 
Invitrogen, Carlsbad, CA). Active caspase-3 was detected by rabbit anti-active 
caspase-3 antibody mAb (Cell Signalling, UK) and visualised by anti-rabbit-Alexa568 
secondary antibody (red). Nuclei were stained with DAPI (blue) and the slide viewed 
at (400x) magnification using fluorescence microscope (Olympus BX51, Japan). 
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2.2.25. Messenger RNA detection and quantification 
2.2.25.1. Reverse transcription polymerase chain reaction 
To detect and semi-quantify protein expression of TG2 after PMA and FK exposure, 
reverse transcription polymerase chain reaction (RT-PCR) was conducted. Total RNA 
was extracted from control and treated cells using a RNeasy Mini isolation Kit 
(Qiagen, UK) according to the manufacturer's protocol. The concentration and purity 
of RNA in each samples was determined by NanoDrop ND-2000c spectrophotometer 
(Thermo Scientific, Labtech, UK). For RT-PCR, specific primers for TG2 and 
GAPDH were designed using Primer3 software that yielded products spanning exon-
intron boundaries to ensure that products were derived from mRNA only. MyTaq 
One-Step RT-PCR Kit (Bioline Reagents Ltd., UK) was used to reverse transcribe 
RNA to cDNA ready for PCR amplification. Briefly, a mixture of 12.5 μl 2xMyTaq 
One-Step Mix, 1 µl of 10 μM of both forward and reverse primers (Table 2.3), 0.5 μl 
RiboSafe RNase Inhibitor, 0.25 μl reverse transcriptase, 2.5 µl RNA and ddH2O in a 
total volume of 25 μl. Amplification was performed using the Platinum PCR 
SuperMix (Invitrogen, UK). RT-PCR condition was carried out as follow; 1 cycle for 
reverse transcription at 45°C for 20 min, 1 cycle for polymerase activation at 95°C for 
1 min followed by 40 cycles at 95°C for 10s (denaturation), 60°C for 10s (annealing), 
72°C for 30s (extension) and a final extension at 72°C for 10 min. The PCR products 
along with the DNA ladder (Bioline Reagents Ltd., UK) were analysed by 2.5 % 
(w/v) agarose gel (Bioline Reagents Ltd., UK) electrophoresis and visualized with 
SYBR Safe DNA gel stain (Life Technologies, Invitrogen, UK) under UV light. The 
densitometry values of the bands were quantified and analysed using (Adobe 
Photoshop CS4). The expression of GAPDH was used to normalize variable template 
loading. 
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Table 2.3 Table shown forward and reverse primers for TG2 and GAPDH used 
in this study  
mRNA Oligo name Sequence Amplicon 
size (bp) 
Company 
TG2 NM_019386.2for  
 
NM_019386.2rev 
AGCCAACCACCT
GAACAAAC 
CAGGGTCAGGTT
GATGTCCT 
226 Eurofins 
MWG 
operon, 
USA 
GAPDH NM_017008.4for  
 
NM_017008.4rev 
GAGAAGGCTGGG
GCTCAC 
GTTGTCATGGAT
GACCTTGGC 
186 Sigma, UK 
 
The table 2.3 shows the primers' size, sequences and companies.
 
2.2.25.2. Quantitative polymerase chain reaction 
2.2.25.2.1. Reverse transcription 
After total the RNA was extracted from control and treated cells as described in 
(section 2.2.25.1) 2 µg total RNA was reverse transcribed into DNA using 0.5 µg of the 
random hexamer primers (Oligo (dT)), ddH2O was added to give a final volume of 15 
µl. The samples were then heated using UNO-Thermoblock to 70°C for 5 min to melt 
secondary structures. Samples were then immediately put on ice and a mixture of 5 µl 
of moloney murine leukemia virus (M-MLV, 5x) reaction buffer (Promega, UK), 1 µl 
of 40 mM deoxynucleotide triphosphates (dNTP’s), 0.7 µl RNasin ribonuclease 
inhibitor, 1 µl M-MLV reverse transcriptase and 2.3 µl ddH2O in a total volume of 25 
μl.  Samples were mixed gently and incubated for 80 min at 40°C in a water bath. After 
incubation, samples were finally heated using an UNO-Thermoblock to 95°C for 5 min 
and immediately stored at -20°C ready for qRT PCR.  
2.2.25.2.2. Quantitative RT-PCR 
QRT-PCR was set up into PCR tubes using Sybr Green SuperMix (Applied 
Biosystems, UK) following manufacture’s protocol described. An equivalent volume 
(0.5 µL) of cDNA was used as the template for PCR using (0.5 µL) gene-specific 
primer sets for both TG2 and GAPDH and added to ﬁnal volume of 12.5 µL. In cases 
of non-template controls (NTC), cDNA template was substituted with ddH2O. 
Thermocycling conditions used for qPCR were one cycle for polymerase activation at 
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95°C for 10 min, followed by 40 cycles at 95°C for 15s (denaturation), 60°C for 30s 
(annealing), 72°C for 30s (extension) and a final extension at 72°C for 10 min. 
Thermocycling was applied using a Bio-Rad MiniOpticon System (Bio-Rad 
Laboratories, UK). Samples were run on a qRT-PCR Thermal Cycler. Samples were 
run in duplicate and repeated at least 3 times to ensure validity of results, which were 
then analysed using as delta Ct (DCt) equation. Cycle threshold (Ct) was calculated 
using supplied software and the transcript abundance of TG2 relative to transcript 
abundance of GAPDH were calculated and used to determine changes in TG2 mRNA 
expression.  
2.2.26. Sample preparation for MALDI-TOF Mass spectrophotometry analysis   
The protein bands were excised from 4–15% precast polyacrylamide gel (Mini-
PROTEAN
®
 TGX
™
 Precast Gel, Bio-Rad, UK; Fig. 2.3). 
2.2.26.1. In gel digestion with trypsin  
2.2.26.1.1. Gel fragment preparation 
Protein bands from 1D gel or protein spots from 2D gel were excised using a sterile 
scalpel and placed into a low protein-binding microfuge tube (LoBind, Eppendorf) 
and were cut it into 1 mm pieces. Gel pieces were washed with >10 volumes of 
Millipore water (~200 μl) for 30 seconds, to wash out any acetic acid. 
2.2.26.1.2. Destaining and dehydrating 
For Coomassie blue staining, gel pieces were destained two times for 5 min until 
colourless with 200 μl of 100 mM ammonium bicarbonate ((NH4)HCO3) and 50 % 
(v/v) methanol. For silver staining gel pieces were destained by a freshly prepared 1:1 
solution of 100 mM sodium thiosulphate (Na2S2O3) and 30 mM potassium 
ferricyanide (K3Fe(CN)6). The reaction was stopped and silver ions were removed by 
washing twice for 2 min with 500 μl of ultra-pure water. Gel pieces were dehydrated 
for 15 min at 37°C with 200 μl of 50 mM (NH4)HCO3 in 50 % (v/v) acetonitrile. The 
dehydration solution was removed and 100 % (v/v) acetonitrile was added for 30s or 
until the gel pieces shrunk and became white.  
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Figure 2.3 The flow diagram represents the identification of TG2 substrate 
proteins’ protocol used for mass spectrophotometry 
The proteins were extracted from the gel by dehydration and hydration methods 
(section 2.2.26), following with trypsin digestion. Samples were directly analyzed by 
LC-MSMS.
 
2.2.26.1.3. Rehydrating 
Dehydrated gel pieces were rehydrated in 200 μl of 5 mM (NH4)HCO3 for 5 min and 
then an equal amount of 100 % (v/v) acetonitrile was added and incubated with gentle 
shaking for further 15 min. This solution was removed and the gel pieces were once 
more covered by 100 % (v/v) acetonitrile and mixed until gel pieces shrank. 
Acetonitrile was removed and gel particles were dried by pipetting excess liquid. Gel 
particles rehydrated by adding 200 μl ultra-pure water. 
2.2.26.1.4. Trypsin digestion 
After the water was removed from the gel particles, proteins in gel were digested with 
trypsin over night at 37°C in 20 μl digestion solution containing; 200 ng trypsin gold 
(Promega, UK) in 100 mM (NH4)HCO3. The reaction was terminated by adding 1 % 
76 
 
(v/v) trifluroacetic acid (TFA) and mixed for 5 min. Digested proteins were recovered 
by centrifuging for 10 min at max speed ~8000 xg (Scientific Laboratory, UK). 
Supernatant containing digestion solution transfer to a new tube, and sample was 
ready for LC-based mass analysis. This was carried out in the John van Geest Cancer 
Research Centre at Nottingham Trent University, Bruker Daltonics were analysed 
using LC-MALDI-TOFTOF (UltrafleXtreme, Bruker Daltonics, Germany). LC-
fractions were controlled using WARP-LC software (version 3.2, Bruker Daltonics) 
and FlexControl software (version 3.3, Bruker Daltonics). Data acquired were 
searched against rat (Rattus norvegicus) in SWISSPROT using MASCOT (version 
2.3 server, Matrix Science).  
2.2.26.2. Peptide purification 
The digested peptides were purified by ZipTip-C18 column (Millipore, UK), Zip-Tips 
are pipette tips that contain 0.5 µl volume immobilized chromatography media (C18, 
resin) attached at their distal end that used for clean-up before spotting onto MALDI 
plate. A P20 pipetter was set to 10 μl for the Zip-Tips and the Zip-Tip was washed 5 
times with 0.1 % (v/v) trifluroacetic acid (TFA) in acetonitrile, followed with 5 times 
wash with 0.1 % (v/v) TFA in 1:1 acetonitrile: water. The Zip-Tip was equilibrated 
twice with 0.1 % (v/v) TFA in water and digested peptides were passed through the 
Zip-Tips repeatedly by pipetting in and out to bind the sample to the resin. This was 
followed by wash three times with 0.1 % TFA and 5 % (v/v) methanol in water to 
remove unbound material. The sample was eluted directly from the Zip-Tip in 3 µl in 
80 % (v/v) acetonitrile through 15 aspirating and dispensing cycles. A 1.0 µl of eluted 
sample was mixed with 1.1 µl of matrix, typically alpha-cyano-4-hydroxycinnamic 
acid in 0.1 % (v/v) TFA 80 % (v/v) acetonitrile and spotted in triplicate on the 
MALDI-TOF sample plate.  
Statistical analysis 
All graphs were prepared using Graph Pad Prism software, while statistical analysis 
of data was performed by both One way ANOVA following by "Tukey's Multiple 
Comparison Test“, Dunnett comparison test" , and Two way ANOVA for group 
comparison. Results represent mean ± SEM and p-value less than 0.05 were 
considered statistically significant.  
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CHAPTER III:  
IN VITRO MODULATION OF TG2 ACTIVITY BY PKC 
AND PKA 
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3. Introduction 
Transglutaminase 2 has been known as a molecular “Swiss army knife” that have 
multiple enzymatic functions which include transamidation, protein kinase and 
protein disulphide isomerase activity (Gundemir et al., 2012). It also acts as a G-
protein, which is independent of its transamidation activity, mediating signal 
transduction pathways prompted by the G-protein coupled receptor family such as the 
1B-adrenergic receptor (Nakaoka et al., 1994). Interestingly, the activity of TG 
family members can be regulated by protein kinases. For example, TG2 
phosphorylation by PKA increases its kinase activity but inhibits in transamidating 
activity (Mishra et al., 2007). The protein crosslinking activity of TG1 is activated by 
phorbolester that induced PKC and ERK1/2 activation (Bollag et al., 2005). In 
addition, TG2 expression in pancreatic cancer cells has been shown to be regulated by 
PKCδ, which in turn inhibit a type II programmed cell death (autophagy) (Akar et al., 
2007). This revealed the important role of PKC in mediating autophagy and TG2 
expression. Phosphorylation of TG1 (Ser
-82
 and Ser
-85
) by PKC has already been 
demonstrated in keratinocytes (Chakravarty, et al., 1990; Rice et al., 1996). Overall, 
these observations suggest that both PKA and PKC-dependent signalling pathways 
can regulate the activity and expression of specific TG isoenzymes.  
The activation of both PKC and PKA is involved in cardioprotection mechanisms 
stimulated by different agents. The translocation of PKCε from cytosol to membrane 
can trigger cardioprotection effects stimulated by ischaemic preconditioning (see 
section 1.5) or anaesthetic, such as activation of pro-survival proteins ERK1/2 and 
reduction in ischaemic cell injury (Liu et al., 1999; Toma et al., 2004). Other protein 
kinase C isoenzymes  (PKCδ, PKCε) are involved in ischaemic heart preconditioning 
in response to isoflurane treatment in which their activation is associated with 
upstream transduction events including; mitochondrial KATP channel-opening and 
reactive oxygen species production (Ludwig et al., 2004; Frässdorf et al., 2009). 
Volatile anaesthetic agents and chronic morphine application may also induce 
cardioprotection mediated by PKA and PKC signalling transduction activation (Peart 
& Gross, 2006). The activation of PKA in combination with p38 MAPK can provide a 
dual role in cardioprotection (Makaula et al., 2005). Although the mechanism of 
downstream signalling of PKA activation remains unclear, it is believed that the 
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protective effect of PKA appears to be correlated with inhibition of the small GTPase 
Rho and its kinases (Sanada et al., 2001). 
Phorbol ester is a natural extracted from croton oil californicus and it is frequently 
used in cell culture as a PKC activator  (Saitoh & Dobkins, 1986). In addition, it has 
been reported to stimulate PKC dependent signalling pathways involved in ischaemic 
preconditioning, which facilitates activation of cardioprotective ATP-sensitive 
potassium channels, facilitating the induction of larger sarcolemma KATP channel 
currents (Nishizuka, 1995). Forskolin is a natural product extracted from the Coleus 
forskohlii herb and it is widely used in medical research (Pradeep et al., 2006). 
Forskolin acts as an adenylyl cyclase activator, which increases the turnover of cyclic 
adenosine monophosphate (cAMP; Morimoto et al., 2001). Forskolin has been shown 
to inhibit colon cancer cell growth (McEwan et al., 2007) and improve heart function 
(Roth et al., 2002). It has also been used to simulate PKA to mimic ischaemic 
preconditioning (Makaula et al., 2005).  
PKC and PKA are two major mediators of signal transduction pathways associated 
with ischaemic preconditioning and pharmacological preconditioning induced 
cardioprotection (Yellon & Downey, 2003; Sanada et al., 2011). Interestingly, TG2 
has been shown to mediate cardioprotection against ischaemia and reperfusion-
induced cell death by regulating ATP synthesis in cardiomyocytes (Szondy et al., 
2006). Similarly, increased TG2 expression protects neuronal cells from oxygen and 
glucose deprivation-induced cell death (Filiano et al., 2008). Given the emerging role 
of TG2 in cardioprotection coupled with is regulation by protein kinases associated 
with cardioprotection, one of the aims of this study was to investigate the regulation 
of TG2 by PKA and PKC in the H9c2 rat embryonic cardiomyoblast-derived cell line 
(Kimes & Brandt, 1976).  
The H9c2 cells are derived from embryonic rat heart tissue (Kimes & Brandt, 1976) 
and are extensively used as an in vitro model for investigating and studying 
cardioprotection events since they display similar morphological, biochemical and 
electrophysiological properties to primary cardiac myocytes (Hescheler et al., 1991). 
Although the regulation of TG isoenzymes by PKA and PKC has been studied in 
other cell lines (Bollag et al., 2005; Mishra et al., 2007), the regulation of TG2 has not 
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been investigated in this cardiomyocytes cell lines. Therefore, the primary aims of this 
study were to investigate; the activation of TG2 in response to phorbol-12-myristate-
13-acetate (PMA; a PKC activator) and forskolin (FK; a PKA activator).  
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3.1. Aim 
The main aim of the work presented in this chapter was to determine the effects of a 
phorbol ester (PMA; a protein kinase C activator) and forskolin (FK; protein kinase A 
activator) of on TG2 activity and its protein level in rat embryonic cardiomyoblast-
derived cell line (H9c2).  
3.2. Methods  
As described in chapter 2 of this study (section 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
da
y 
1
da
y 
2
da
y 
3
da
y 
4
da
y 
5
da
y 
6
da
y 
7
0
1.0×10 6
2.0×10 6
3.0×10 6
Days in culture
C
e
ll
 d
e
n
si
ty
3.3. Results 
3.3.1. H9c2 cell in culture  
To determine the cell growth characteristics of H9c2 rat embryonic cardiomyoblast-
derived cell line, a standard growth curve was generated (section 2.2.1). 
A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 3.3.1 The photograph and growth curve of H9c2 in culture. 
H9c2 cells were plated in equal density of 5 x 10
5 
cells per 75 flask cultured in 
DMEM media of complete condition supplemented with 10 % FBS. A) Photograph of 
H9c2 cells during seven days culturing were monitored under the inverted light 
microscope at (100x) magnification. Scale bar 100 µm. B) H9c2 growth curve of 
seven days and cells density (cell number) was determined using haemocytometer. 
Data points represent the mean ± SEM of 4 determinations from 3 independent 
experiments of three different passage numbers. 
 
Figure 3.3.1 shows a photograph and growth curve of H9c2 in culture of seven days. 
As shown in Figure 3.3.1A, the H9c2 cells exhibited spindle fibroblast-like shape that 
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rapidly attached to culture flask walls in the first day after of culturing. Many gaps 
were observed at this day with fewer connected cells. Cells showed rapid division and 
proliferation during the following two days and they form a monolayer in which cells 
become connected to each other with fewer gaps. In days 4-6, cells reached 100 % 
confluence and the flask becomes crowded. In days 6-7, the colour of culture media 
changed (yellowish) due to pH drop and some dead cells start floating.  
As shown figure 3.3.1B, the H9c2 cells density after 24 hours (day one) culturing was 
similar or less to the starting density ~ 4 x 10
5
 cells. However, in the two following 
days of culturing, the cells density was shown to gradually increase (doubling time). 
At day four, significant increase approximately 4 fold (~ 3 x10
6
) in the cells density 
was observed and this shown to be steady for 2 more days followed with decline. 
3.3.2. The effect of protein kinase activators on biotin cadaverine incorporation 
TG2 activity 
To study transglutaminase activity in H9c2 cells in response to PMA and FK 
treatments, H9c2 cells were treated with 1 µM PMA (Ertracht et al., 2011; Aggeli et 
al., 2008; Reilly et al., 1998) or 10 μM FK (Leung et al., 2007) for different 
incubation times. The cells were then subjected to TG2 biotin cadaverine 
incorporation assay as described in methods (section 2.2.9.1.1).  
3.3.2.1. Time dependent effects  of PMA  and  FK on biotin cadaverine 
incorporation TG2 activity 
A time course exposure of H9c2 cells to PMA or FK showed a statistically significant 
transient increase (n = 3, **p < 0.01) in TG2 catalysed biotin cadaverine 
incorporation peaking at 5 and 10 min exposure to PMA and 1 and 5 min exposure to 
FK (Fig. 3.3.1). However, significant decreases (n = 3, **p < 0.01) were observed 
after 10 min incubation in cell treated with PMA. In contrast, cells that were treated 
with FK showed a gradual decrease after this time point returning to basal levels. 
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Figure 3.3.2 Time dependent effects of PMA and FK on cadaverine 
incorporation TG2 activity 
H9c2 cells were incubated with A) 1 µM PMA or B) 10 μM FK for the indicated time 
periods, harvested and lysed with 0.1 M Tris buffer containing protease and 
phosphatase inhibitors. The cell lysates were clarified by centrifugation and subjected 
to biotin cadaverine incorporation assay. Data points represent the mean ± SEM TG2 
specific activity from 3 (A) or 4 (B) independent experiments. Data analysis of 0 min 
(control) vs. PMA or FK incubation time was performed using "Dunnett comparison 
test"  where statistical significance was accepted at **p < 0.01 or *p < 0.05. Purified 
guinea pig liver was used as positive control and the mean ± SEM of TG2 activity 
was 19.72±2.37 units mg
-1
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3.3.2.2. Concentration dependent effects of PMA and FK on biotin cadaverine 
incorporation TG2 activity 
A) 
 
 
 
  
B) 
 
 
 
 
 
 
Figure 3.3.3 Concentration dependent effects of PMA and FK on biotin 
cadaverine incorporation TG2 activity 
H9c2 cells were treated for 5 min with various concentrations of A) PMA (0.005-1 
µM) or B) FK (0.05-10 μM) were harvested and lysed with 0.1 M Tris buffer 
containing protease and phosphatase inhibitors. The cell lysates were subjected to 
biotin cadaverine incorporation assay. Control cells were treated with the appropriate 
volume of DMSO equal to PMA and FK volumes for 5 min and no significant 
differences compared to control-unstimulated. Graph plotted using Nonliner 
regression curve fit, "log(agonist) vs. response". Data points represent the mean ± 
SEM TG2 specific activity from 3 independent experiments. Data analysis of control 
vs. PMA or FK different concentration was performed using "Dunnett comparison 
test" to compare control vs. FK. Statistical significance was accepted at ***p < 0.001, 
**p < 0.01 or *p < 0.05. Purified guinea pig liver was used as positive control and the 
mean ± SEM of TG2 activity was 24.73 ± 3.20 units mg
-1
.  
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Since an increase in TG2 activity was observed at an early incubation time, cells were 
treated with different concentration of PMA and FK for 5 min and subjected to biotin 
cadaverine incorporation assay. A gradual increase in TG2 activity was observed with 
increasing PMA (Fig. 3.3.3A) or FK concentrations (Fig. 3.3.3B). 
3.3.2.3. Effect of phosphatase inhibitors on biotin cadaverine incorporation 
TG2 activity  
In order to determine if phosphatase inhibitors have an effect on transglutaminase 
activity, two different extractions were made for cells treated with PMA, one in the 
presence and one in absence of phosphatase inhibitors. These different samples were 
subjected to enzyme assay. 
In H9c2 cells with or without phosphatase inhibitors, the specific activity of TG2 
initially increased. Cells that were extracted without adding phosphatase inhibitors 
showed a significant increase (n = 3, **p < 0.01) after (5 min) over untreated cells (0 
min) (Fig. 3.3.4). This transient increase decreased over the 40 min incubation period. 
In contrast, cells that were extracted with buffer containing (50 μM) phosphatase 
inhibitors showed maximum increase (n = 3, **p < 0.01) in 10 min followed by a 
decrease. However, two-way ANOVA analysis (Table 3.3.1) indicated phosphatase 
inhibitors had no effect on the ability of PMA to induce TG2 activity (P-value = 
0.8957). Moreover, P-values for the interaction and PMA incubation time is less than 
0.0001, which shows that interaction between phosphatase inhibitors and PMA 
incubation time has a statistically significant impact on the TG2 catalysed biotin 
cadaverine incorporation reaction. The presence of phosphatase inhibitors results in 
prolonging of TG2 activity until 10 min incubation and shown significant increase (10 
min; n = 3, ***p < 0.001) in this time point compared to phosphatase inhibitors 
untreated sample at the same time point. 
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Table 3.3.1 Two-way ANOVA analysis of the effect of phosphatase inhibitors  
 
 
 
 
Figure 3.3.4 Effect of phosphatase inhibitors on the activation of TG2 by PMA  
H9c2 cells were incubated with 1 µM PMA for the time indicated, then harvested and 
lysed with 0.1 M Tris buffer containing proteases and with  (Brown bars; + 
phosphatase inhibitors) or without (Blue bars; - phosphatase inhibitors) phosphatase 
inhibitors. The cell lysates were subjected to biotin cadaverine incorporation assay. 
Data points represent the mean ± SEM TG2 specific activity from 3 independent 
experiments. ).  ***P < 0.001, "- Phosphatase inhibitors vs. + Phosphatase inhibitors " 
using Two-way ANOVA following by "Bonferroni post-tests". (B) Table 3.3.1 
shown the Two-way ANOVA output indicating the use of phosphatase inhibitors has 
no significant effect on the results (P-value = 0.8957). However, interaction between 
phosphatase inhibitors and PMA incubation time has statistically significant impact 
(***p <0.001) on the TG2 catalysed biotin cadaverine incorporation reaction. Two-
way ANOVA showed significant effect of PMA incubation (F= 51.11, dF=5, 24, 
***p < 0.001), no statistical significant of the phosphatase inhibitors (F= 0.02, dF =1, 
24, p<0.89) and statistical significant of the interaction of PMA incubation/ 
phosphatase inhibitors (F = 18.70, dF =5, 24, ***p < 0.001).
 
   Two-way ANOVA 
Source of Variation  % of total 
variation  
P  
Interaction  25.07  P <0.001  
phosphatase inhibitors  0.00  0.8957  
PMA incubation time  68.50  P <0.001  
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3.3.3. The effect of protein kinase activators on TG2 protein crosslinking 
activity 
Transglutaminase 2 activity in H9c2 cells was assayed in the presence of PMA or FK 
using protein crosslinking activity assay (Trigwell et al., 2004) via the acyl-donor 
probe biotin-TVQQEL (Ruoppolo et al., 2003) as describe in methods (section 
2.2.9.1.2) . Data analysis indicated a significant increase (n = 4, *p < 0.05) in TG2 
mediated protein crosslinking activity in H9c2 cells that were treated with FK (Fig. 
3.3.5B). This increase was observed at 20 min incubation time. In contrast, cells that 
were treated with PMA did not show significant changes in TG2 protein crosslinking 
activity (Fig. 3.3.5A). 
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Figure 3.3.5 Time dependent effects of PMA and FK on TG2 protein 
crosslinking activity 
H9c2 cells were incubated with A) 1 µM PMA or B) 10 μM FK at the times indicated, 
then harvested and lysed with 0.1 M Tris buffer containing protease and phosphatase 
inhibitors. The cell lysates were subjected to TVQQEL-crosslinking assay. Data 
points represent the mean ± SEM TG2 specific activity from 4 independent 
experiments. Data analysis of 0 min (control) vs. PMA or FK incubation time was 
performed using "Dunnett comparison test" where statistical significance was 
accepted at *p < 0.05.
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3.3.4. The effect of PKA and PKC inhibitors on TG2 activity stimulated with 
PMA and FK in H9c2 cells  
In order to confirm whether activation of PKC or PKA were associated with PMA or 
FK-stimulated TG activity in cardiomyocytes, inhibitors for these kinases were tested. 
H9c2 cells were pre-incubated with different protein kinase inhibitors before 
treatment with PMA or FK (section 2.2.3.2 and fig. 2.1C) and then cells lysed 
subjected to biotin cadaverine incorporation assay (section  2.2.9.1.1).  
Data of this study suggest that both treatments showed a significant decrease in TG2 
catalysed biotin cadaverine incorporation in the presence of different protein kinase 
inhibitors (Fig. 3.3.6). A 50 % decrease relative to protein kinase activator treated 
cells, returned the activity to a value not significantly (p > 0.05 different from the 
control (untreated cells) level. However, apart from chelerythrine chloride, cells that 
were treated with protein kinase inhibitors alone showed no change in TG2 activity 
(Fig. 3.3.6D).  
A) 
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Figure 3.3.6 The effect of PKA and PKC inhibitors on TG2 activity stimulated 
with PMA and FK in H9c2 cells 
H9c2 cells were pre-treated for 30 min with the PKC inhibitors Go 6983 (5 µM), Ro 
31-8220 (10 μM), chelerythrine (1 µM) and the PKA inhibitor H-89 (1 µM) prior to 
stimulation for 5 min with A) 1 µM PMA, B) 10 μM FK for 5 min or D) without. C) 
The effect of PKA inhibitors KT 5720 (5 μM) and Rp-8-Cl-cAMPS (50 μM) on TG2 
activity stimulated with PMA and FK. Cell lysates were subjected to biotin 
cadaverine incorporation assay. Data points represent the mean ± SEM TG2 specific 
activity from 5 independent experiments. Data analysis of (A, B & C) was performed 
using "Bonferroni's multiple comparison test" to compare control vs. either PMA or 
FK and later to protein kinase inhibitors. Data analysis of (D) was performed using 
"Dunnett comparison test" to compare control vs. protein kinase inhibitors. Statistical 
significance was accepted at ***p < 0.001, **p < 0.01, *p < 0.05. Significant activity 
induced by PMA and FK alone in compared to control were shown (#p < 0.05).
 
On the other hand, chelerythrine chloride treated cells showed a significant increase 
(n = 5, ***p < 0.001) in TG2 catalysed biotin cadaverine incorporation activity (Fig. 
3.3.6D). H9c2 cells were pre-treated for 30 min with the PKA inhibitors KT 5720 (5 
μM) and Rp-8-Cl-cAMPs (50 μM; Dodge-Kafka et al., 2005; Kwak et al., 2008; 
Galliher-Beckley et al., 2011) prior to 5 min exposure to PMA or FK. PMA-and FK-
induced TG2 catalysed biotin-cadaverine incorporation (Fig. 3.3.6C). KT 5720 and 
Rp-8-Cl-cAMPs significantly (n = 5, ***p < 0.001) reduced and blocked FK-induced 
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TG2 activity, but had no effect on PMA responses, confirming the involvement of 
PKA in TG2 activation. 
3.3.5. The effects of protein kinase activators and inhibitors on purified guinea 
pig liver transglutaminase activity 
To study possible direct effect of protein kinase activators and inhibitors on TG2 
activity, transglutaminase activity purified guinea pig liver TG2 was assayed in the 
presence of both groups of protein kinase inhibitors using the biotin cadaverine 
incorporation assay and biotin-peptide crosslinking assay as described in materials 
and methods (section 2.2.9.1).  
3.3.5.1. The effects of protein kinase activators and inhibitors on purified 
guinea pig liver transglutaminase activity determined by cadaverine-
incorporation assay 
Initially the direct effect of PMA and FK on purified guinea pig liver 
transglutaminase activity was determined using the biotin cadaverine incorporation 
assay. As shown in figure 3.3.7A, PMA (1 µM) and FK (10 μM) had no significant 
effect on guinea pig liver transglutaminase activity. In marked contrast, purified 
transglutaminase activity was significantly inhibited by the protein kinase inhibitors 
Gö 6983 (5 µM; Gschwendt et al., 1996), chelerythrine (1 µM; Herbert et al., 1990; 
Chijiwa et al., 1990), and H-89 (1 µM; Chijiwa et al., 1990) but not by PKC inhibitor; 
Ro 31-8220 (10 μM; Davis et al., 1989) or by PKA inhibitors; KT 5720 (5 μM) and 
Rp-8-Cl-cAMPs (50 μM) (Dodge-Kafka et al., 2005; Kwak et al., 2008; Galliher-
Beckley et al., 2011) (see Fig. 3.3.7B).  
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Figure 3.3.7 The effects of protein kinase activators and inhibitors on purified 
guinea pig liver transglutaminase activity determined by cadaverine-
incorporation assay 
 
A) Effects of 1 µM PMA and 10 μM FK on guinea pig liver transglutaminase activity. 
B) Effects of protein kinase inhibitors on guinea pig liver transglutaminase activity. 
Data points represent the mean ± SEM TG2 activity from 4 independent experiments 
at basal level of purified guinea pig liver transglutaminase (TG2 Control = 100). Data 
analysis was performed using "Dunnett comparison test" to compare TG2 control vs. 
either TG2 + protein kinase activators or TG2 + protein kinase inhibitors. Statistical 
significance was accepted at ***p < 0.001, **p < 0.01, *p < 0.05.   
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3.3.5.2. The effects of protein kinase activators and inhibitors on purified 
guinea pig liver transglutaminase activity determined by TG2 protein 
crosslinking activity assay   
A) 
  
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 3.3.8 The effects of protein kinase activators and inhibitors on purified 
guinea pig liver transglutaminase activity determined by TG2 protein 
crosslinking activity 
A) Effects of 1 µM PMA and 10 μM FK on guinea pig liver transglutaminase activity. 
B) Effects of protein kinase inhibitors on guinea pig liver transglutaminase activity. 
Data points represent the mean ± SEM TG2 specific activity from 4 independent 
experiments at basal level of purified guinea pig liver TG2 (control = 100). Data 
analysis was performed using "Dunnett comparison test" to compare TG2 control vs. 
TG2 + either protein kinase activators or protein kinase inhibitors. Statistical 
significance was accepted at ***p <0.001, ** p < 0.01, *p < 0.05.
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The data suggest that there is a significant decrease (n = 4, ***p < 0.001) on purified 
guinea pig liver transglutaminase activity in presence of 1 µM PMA and 10 μM FK 
using the peptide crosslinking assay compared to untreated purified guinea pig liver 
transglutaminase (Fig. 3.3.8). Apart from chelerythrine, KT 5720 and Rp-8-Cl-
cAMPs, all other protein kinase inhibitors significantly attenuated guinea pig liver 
transglutaminase activity. As RO-31-8220 induces a significant decrease (n = 3, **p < 
0.001) in TG2 protein crosslinking activity assay (Fig. 3.3.8B). 
3.3.6. Effect of protein kinase activators on protein level of TG2 
3.3.6.1.  Screening cells for presence of transglutaminase family 
Cardiomyocyte H9c2 cells were probed for the presence of different members of the 
transglutaminase family (TG1, TG2 and TG3) using SDS page (section 2.2.10) and 
Western blot (section 2.2.12) techniques as described in material and methods. The 
following figure of Western blot reveals that H9c2 cells can express TG1 (Fig. 
3.3.9A) and TG2 (Fig. 3.3.9A and B). By contrast, TG3 was not detected in H9c2 
cells as shown in (Fig. 3.3.9A).   
A)                            B) 
 
 
 
 
Figure 3.3.9 Detection of transglutaminase family following in H9c2 cells  
The total protein extract (50 µg) from H9c2 cells was analysed by Western blotting 
for (A) TG1 by Anti-TG1 mAb (A), TG2 by Anti-TG2 (CUB 7402) mAb and TG3 by 
Anti-TG3 mAb (B) Anti-TG2 (ID10) mAb. Anti-GAPDH mAb was used as a loading 
control for the total amount of cellular protein. The results are typical of 4 
independent experiments 
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3.3.6.2. Levels of TG2 protein following PMA and FK exposure 
Western blotting analysis of H9c2 cell extracts indicated that the levels of TG2 might 
alter following exposure to PMA (Fig. 3.3.10A) or FK (Fig. 3.3.10C) using anti-TG2 
mAb (CUB 7402). Densitometry results for protein quantification of PMA treated 
H9c2 cells revealed strong significant increase (n=6, *p < 0.05) in TG2 protein level 
at 10 min incubation (Fig. 3.3.10B). However, cells that were treated with FK showed 
significant increases (n = 5, **p < 0.01) in TG2 protein level at both 5 and 10 min 
exposure time (Fig. 3.3.10D).  
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Figure 3.3.10 Levels of TG2 protein following PMA and FK exposure 
H9c2 cells were treated with A) 1 µM PMA or C) 10 μM FK for the times indicated. 
The total protein extract (50 µg) was analysed by Western blotting for TG2 by 
probing with primary antibody CUB 7402 and anti-GAPDH mAb was used as a 
control of the total amount of cellular protein and anti-pERK 1/2 as a control for 
protein kinase activators. (B-D) Densitometry was carried out in Adobe Photoshop 
CS4 and values plotted as relative intensity versus the treatment incubation time. 
Results represent mean ± SEM of the optical density ratio from 6 (B) or 5 (D) 
independent experiments. Data are expressed as the percentage of TG2 protein at 
basal level in the untreated cells (0 min) after GAPDH normalisation. Data analysis 
was performed using "Dunnett comparison test" to compare 0 min (control) vs. either 
PMA or FK incubation time. Statistical significance was accepted at *p < 0.05, **p < 
0.01.
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Transglutaminase 2 mRNA expression after PMA and FK treatment was also detected 
using reverse transcription polymerase chain reaction (RT-PCR). The PCR products 
along with the DNA ladder were resolved in 2.5 % (w/v) agarose gel electrophoresis 
(w/v) and visualized under UV light (see section 2.2.11). Transglutaminase 2 mRNA 
expression was also quantified by quantitative polymerase chain reaction (qRT-PCR) 
using Sybr Green (see section 2.2.25). The transcript abundance of TG2 relative to 
GAPDH transcript abundance was calculated and used to calculate changes in TG2 
mRNA expression. Both results are shown in figure 3.3.11. In gel, the expression of 
TG2 mRNA was shown to increase after 5 min exposure to PMA or FK followed by a 
decrease (Fig. 3.3.11A and B).  
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Figure 3.3.11 Expression of TG2 mRNA after PMA and FK exposure using RT-
PCR and qPCR 
A) H9c2 cells were treated with A) 1 µM PMA or B) 10 μM FK over time. Total 
RNA was extracted and the expression of TG2 mRNA was evaluated by RT-PCR. An 
equal load of PCR products were resolving in 2.5 % (w/v) agarose gel and visualised 
under UV light. The expression of GAPDH was used to normalize variable template 
loading. C-D) Quantification of TG2 mRNA expression by qPCR. Results represent 
mean ± SEM of TG2 mRNA expression from 3 independent experiment performed in 
triplicate. Data are expressed as the percentage of TG2 mRNA expression at basal 
level in the untreated cells (0 min) after GAPDH normalization. Data analysis was 
performed using "Dunnett comparison test" to compare 0 min (control) vs. either 
PMA (C) or FK (D) incubation time. Statistical significance was accepted at *p < 
0.05, ***p < 0.001.
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The TG2 mRNA expression results from qRT-PCR revealed increases in TG2 mRNA 
expression after 5 and 10 min exposure to FK, which was similar to the trends 
observed on probed western blots. However, the expression level of TG2 mRNA in 
samples treated with PMA showed a gradual, but not significant increase in 
expression. There was a significant increase (n = 3, ***p < 0.001) in TG2 mRNA 
expression detected after prolonged incubation with PMA at 40 min (Fig. 3.3.11C and 
D). 
3.3.7. Levels of TG2 protein following PMA and FK exposure in the absence 
and presence of protein kinase inhibitors 
Western blot analysis following PMA and FK exposure with pre-incubation of 
different protein kinase inhibitors showed a decrease in TG2 protein level compared 
to cells activated with either PMA (Fig. 3.3.12) or FK (Fig. 3.3.13) alone, GAPDH 
was used as intracellular control for cytoplasm protein, while pERK 1/2 was used as a 
control for protein kinase activators. A significant decrease (n = 5, **p < 0.01) in TG2 
expression was shown with FK /chelerythrine (CC) but not PMA and FK /RO-31-
8220 compare to FK treated cells (Fig. 3.3.13A and B). In PMA treated cells, pERK 
1/2 showed a significant increase compared to both control (n = 4, ***P < 0.001) and 
inhibitor treatments (n = 4, *p < 0.05) (Fig. 3.3.12A and B). In FK treated cells, 
pERK 1/2 also showed a significant increase compared to both control (n = 4, *p < 
0.05) and inhibitors (n = 4, **p < 0.01) (Fig. 3.3.13A and C).  
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Figure 3.3.12 Levels of TG2 protein following PMA exposure in the absence and 
presence of protein kinase inhibitors  
 
H9c2 cells were pre-incubated with different protein kinase inhibitors for 30 min 
followed by exposure for 5 min with 1 µM PMA. (A) The total protein extract (30 µg) 
was analysed by Western blotting for TG2 by anti-TG2 mAb (CUB 7402), anti-pERK 
1/2 as a control for protein kinase activators and anti-GAPDH mAb was used as a 
control of the total amount of cellular protein. (B & C) densitometry was carried out 
in Adobe Photoshop CS4 and values plotted as relative intensity versus the treatment 
incubation time. Results represent mean ± SEM of the optical density ratio from 5 
independent experiments. Data expressed as the percentage of TG2 protein at basal 
level of control after GAPDH normalisation. Data analysis was performed using 
"Bonferroni's multiple comparison test" to compare control vs. PMA or PMA vs. 
protein kinase inhibitors. Statistical significance was accepted at *p < 0.05, **p < 
0.01. Significant protein level induced by PMA alone in compared to control were 
shown (#p < 0.05 (B) and (#p < 0.001 (C)).Chelerythrine (CC). 
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Figure 3.3.13 Levels of TG2 protein following FK exposure in the absence and 
presence of protein kinase inhibitors  
H9c2 cells were pre-incubated with different protein kinase inhibitors for 30 min 
followed by exposure for 5 min with 10 μM FK. (A) The total protein extract (30 µg) 
was analysed by Western blotting for TG2 by anti-TG2 mAb (CUB 7402), anti-pERK 
1/2 as a control for protein kinase activators and anti-GAPDH mAb was used as a 
control of the total amount of cellular protein. (B & C) densitometry was carried out 
in Adobe Photoshop CS4 and values plotted as relative intensity versus the treatment 
incubation time. Results represent mean ± SEM of the optical density ratio from 6 
independent experiments. Data expressed as the percentage of TG2 protein at basal 
level of control after GAPDH normalisation. Data analysis was performed using 
"Bonferroni's multiple comparison test" to compare control vs. FK or FK vs. protein 
kinase inhibitors. Statistical significance was accepted at* p < 0.05, **p < 0.01, ***p 
< 0.001. Significant protein level induced by FK alone in compared to control were 
shown (#p < 0.05). Chelerythrine (CC). 
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3.4. Discussion 
Transglutaminases are regulated by PKA and PKC in non-cardiomyocyte cell types 
(Bollag et al., 2005; Mishra et al., 2007). However, the regulation of TG2 by PKA- 
and PKC-dependent signalling in cardiomyocytes had not been reported prior to the 
current study. Therefore, the modulation of TG2 activity by these protein kinase 
activators was measured using two different TG2 transamination assays.   
It is of essential to maintain and record the cell line growth and characteristics before 
setting any of experiment that require the use of cell line either in vitro or in situ 
investigation. Any abnormal alteration of cell growth can have significant effect on 
the experimental results (Wang, 2006). Therefore, initially, the growth of H92 cells 
was monitored and appropriate density of cells was defined. In this study, according 
to cell growth standard curve (Fig. 3.3.1B) the optimal day for sub-culturing and 
further experimental treatments of H9c2 cells was shown to be the third day of cell 
growth. A typical standard growth curve for different cultured cell lines has four 
different phases include, lag phase, log or growth phase, stationary phase and decline 
phase (Freshney, 2006; Wang, 2006). The third day was shown to be at the growth 
phase of H9c2 cardiomyocyte cells in which cells displayed rapid division and 
proliferation and form a monolayer of approximately 80-90 % confluent (Fig. 
3.3.1A). This stage has shown to be the recommended phase for cell lines to be 
maintained in and to be assessed for different cellular functions before they enter the 
stationary phase and monolayer becomes 100 % confluent (Freshney, 2006) as in days 
4-6 (Fig. 3.3.1). The sub-culturing and further experimental treatments of cells need to 
be setup in this phase to ensure cellular viability and enzymatic function, phenotypic 
and genetic stability (Budde et al., 1998). Accordingly, the third day of cells growth 
was adopted for subsequent experiments measuring the TG2 activity in H9c2 cells. 
Initially, the direct effect of PMA and FK on purified guinea pig liver 
transglutaminase activity was investigated for comparison. In the biotin cadaverine 
incorporation activity assay (Slaughter et al., 1992), no significant effect was 
observed on purified guinea pig liver transglutaminase (GPL) activity in the presence 
of protein kinase activators (PMA and  FK) (Fig. 3.3.7A). However, a significant 
decrease (n = 4, ***p < 0.001) was shown using the peptide crosslinking activity 
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assay (Trigwell et al., 2004) in comparison to purified guinea pig liver 
transglutaminase activity (Fig. 3.3.8). Conversely, the TG2 amine biotin cadaverine 
incorporation activity of H9c2 cells was shown to increase (n = 3, **p < 0.01) in the 
presence of protein kinase activators (PMA and FK) at the early treatment time points 
(Fig. 3.3.2). This response was subsequently shown to be concentration dependent 
(Fig. 3.3.3). This suggests a relatively wide range of PMA or FK concentrations is 
able to induce an increase in TG2 incorporation activity within H9c2 cells. 
Conversely, a significant reduction in TG2 protein crosslinking activity was noticed in 
early time point exposure of H9c2 cells to FK but not with PMA (Fig. 3.3.5A). It 
known that protein crosslinking requires high levels of Ca
2+ 
(Trigwell et al., 2004); 
therefore, the decrease could be due to either the concentration of calcium ions in 
cells not being at a high enough level to enhance TG2 crosslinking activity. 
Otherwise, the enzyme may have switched away from protein crosslinking to amine 
incorporation as a result of modification (phosphorylation). Moreover, since the 
substrate probe that was used in measurement of TG2 crosslinking activity is biotin-
TVQQEL, which can incorporate into lysine residue substrates (Ruoppolo et al., 
2003). It could be that H9c2 cells contain more many Glu-residue continuing 
substrates than Lys-residue continuing substrates. 
The fact that the protein kinase activators used in this study interacted differently with 
transglutaminase, could be due to involvement of these protein kinase activators in 
cell signalling alteration (Chemin et al., 2007) in a manner that changes the action of 
TG2 inside the cells. Furthermore, it could be possible that the protein kinase 
activators alter the conformation of potential TG2 substrates in cells, resulting in an 
increase in available substrate contributing to the higher TG2 activity observed. 
Indeed, it is already known that activation of protein kinases results in protein 
phosphorylation which in turn can directly affect the activity of target proteins by 
causing a conformational change in these target proteins (Cohen, 2000). Alternatively, 
the phosphorylated amino can bind to specific protein or other substrate and alter its 
activity and function (Pearce et al., 2010). Therefore, this study investigated the 
phosphorylation events induced by these two protein kinase activators in H9c2 cells. 
The activation of protein phosphorylation resulting from PMA induced-PKC 
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activation agrees with other studies that have reported phosphorylation effects of 
phorbol esters (Jacquier-Sarlin et al., 1995; Teixeira et al., 2003; Bollag et al., 2005).  
The present results have demonstrated that both PMA and FK induce protein 
phosphorylation in H9c2 cells. Following electrophoresis or polyacrylamide gels that 
were stained with Pro-Q Diamond fluorescent stain to evaluate protein 
phosphorylation and subsequently stained with SYPRO Ruby stain for total protein 
(see section 2.2.15). The ratio of total protein-to-protein phosphorylation was found to 
change significantly within 5 min after treatment with PMA and FK compared to the 
control cells (see appendix Fig. 8.1 and Fig. 8.2). The increase was most prominent 
after 5 and 10 min in cells that were pre-incubated with MA or FK. It had already 
been demonstrated that the exposure of cardiomyocytes to PMA for 5 min leads to 
increased protein phosphorylation mainly through activation of MAPK and mitogen-
activated extracellular signal-regulated kinase (MEK) 10 fold (Lazou et al., 1994; 
Lazou et al., 1998). The increased phosphorylation of proteins relative to the control 
in samples treated with PMA at the early time points was also confirmed in the 
current work. This may indicate a rapid increase (n = 4 ***P < 0.001) of 
phosphorylation events in cardiomyocyte-like H9c2 cells in response to PMA 
treatment (Fig. 8.1). This was also true when cells were treated with FK (Fig. 8.2). 
Increased protein phosphorylation has been reported in reperfused heart tissue in 
response to FK (England & Shahid, 1987). Additional reports have detailed the 
phosphorylation of the cAMP response element binding protein (CREB) in cardiac 
myocytes (Goldspink & Russell, 1994) and ser
16
 phosphorylation in swine artery 
HSP20 (Meeks et al., 2008). 
The level of protein phosphorylation in PMA or FK treated H9c2 cells at different 
time points was also monitored by western blot analysis using different anti-phospho-
amino acid antibodies (see appendix Fig. 8.3). The current study found increased 
phosphorylation of target proteins in serine, threonine and tyrosine residues.  Western 
blots of H9c2 cell extracts treated with either PMA or FK at different time points 
were probed with anti-phosphoserine (Fig. 8.3A) and anti-phosphothreonine 
antibodies (Fig. 8.2B). In general, the results demonstrate an increase in band 
intensity of proteins containing either phosphoserine or phosphothreonine in treated 
samples over time compared to the control cells (0 min). Interestingly, on the 
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nitrocellulose membrane filters that were probed with anti-phosphoserine (Fig. 8.3A). 
There was a slight increase in band intensity ~74 kDa, which corresponded to 
standard TG2, in comparison to control and one more band at 50 kDa. However, 
when membrane was stripped and re-probed with anti-phosphothreonine antibodies, 
the TG2 standard no longer appeared but a new band corresponding to ~70 kDa was 
detected. Another western blot of the sample was probed with anti-phosphotyrosine 
antibodies (Fig. 8.3C). This showed an increase in band intensity of proteins that 
corresponded to size of~100 kDa and ~77 kDa over the same incubation times.  
These observations demonstrated that a wide range of proteins can be phosphorylated 
in H9c2 cells following exposure to these kinase activators. Thus, it could be possible 
that this phosphorylation event results in conformational changes of these target 
proteins or in the affinity of specific proteins to recognise and bind to other proteins 
and thus affect the regulation of TG2 activity. Indeed, it has been suggested that PMA 
can alter polyamine levels in human promyelocytic leukemia cells, affecting 
transglutaminase activity (Huberman et al., 1981).  
Activity in both protein crosslinking and biotin cadaverine incorporation assay of 
purified guinea pig liver TG2 was shown to decrease in the presence of certain protein 
kinase inhibitors. The biotin cadaverine incorporation assay (Fig. 3.3.7B) shows a 
significant (n = 4, ***P <0.001) decrease in the presence of the protein kinase C 
inhibitors Gö 6983 (Peterman et al., 2004) and chelerythrine (Herbert et al., 1990), 
and the protein kinase A inhibitor H-89 (Makaula et al., 2005; Asai et al., 2009). By 
contrast, the protein crosslinking activity assay (Fig. 3.3.8B) shows a significant (n = 
3, ***p < 0.001) decrease in activity with RO-31-8220, a PKC or PKA inhibitor 
(Davies et al., 2000), whereas no significant decrease was observed with 
chelerythrine. The purified transglutaminase was shown to react to protein kinase 
inhibitors in the same manner to that of the TG2 assayed H9c2 cells before and after 
exposure to PMA or FK (Fig. 3.3.6). This indicates that protein kinase inhibitors may 
be able to interact directly with TG2, resulting in its inhibition. However, not all the 
protein kinase inhibitors induced changes in TG2 activity except chelerythrine, which 
showed a significant increase in TG2 catalysed biotin cadaverine incorporation 
activity of untreated cells with protein kinase activators (Fig. 3.3.6C). This suggests 
that chelerythrine reacts differently with TG2 following protein kinase activators pre-
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treatment in H9c2 cells, possibly interacting with TG2 kinase site. Indeed, the 
chelerythrine chloride is a selective-reversible inhibitor for protein kinase C that is 
able to inhibit the enzyme activity by two different ways, either competitively with 
phosphate acceptor or uncompetitively with ATP binding site of the enzyme (Herbert 
et al., 1990). These properties of the inhibitor can reduce its specificity toward PKC 
as it is appeared from this study that the inhibitor can block PKA activity as well. The 
inhibitor is also able to independently activate MAPK of PKC inhibition. This can 
explain the activation of TG2 incorporation activity of cells stimulated with 
chelerythrine chloride (CC) alone (Fig. 3.3.6C).  However, Kinetic analysis of the 
effects of the inhibitors may help to elucidate their mode of action.  
PKA inhibitors H-89 (1 μM), KT5720 (5 μM) and Rp-cAMPs (50 μM) have been 
already used in H9c2 and in HeLa cells to block cAMP and forskolin activated PKA 
(Dodge-Kafka et al., 2005; Kwak et al., 2008; Galliher-Beckley et al., 2011). In 
addition, both these protein kinase inhibitors H-89 and KT5720 have reversed the 
protective effects induced by either DBcAMP (a cAMP analogue) or forskolin in 
H9c2 cells (Chae et al., 2004).  Due to PKA heterotetramirc form, the inhibition of the 
enzyme can be achieved by two distinct ways either via inhibitors that have structure 
analogue to cAMP such as, Rp-8-Cl-cAMPS or via inhibitors structure analogues to 
ATP such as,  H-89 and KT 5720 (Christensen et al., 2003; Christensen et al., 2003; 
Lochner & Moolman, 2006). Since Rp-8-Cl-cAMPS are able to block the regulatory 
subunit of PKA preventing holoenzyme dissociation, thus it is work in very earlier 
step to block the enzyme (Davies et al., 2000). This unique difference in acting site by 
Rp-8-Cl-cAMPS to inhibit PKA makes it more specific than the other PKA inhibitors 
(Daugirdas et al., 1991; Hughes et al., 1997). Interestingly, PKA inhibitors KT 5720 
and Rp-8-Cl-cAMPS blocked FK induced TG2 activity (Fig. 3.3.6D), confirming the 
involvement of PKA in FK-mediated responses.   
These results are of particular interest, as the increase in TG2 activity at early time 
points occurs at a critical time in ischaemic preconditioning of heart tissue (Murry et 
al., 1986). A previous study by Tucholski & Johnson (2003) provided evidence that 
TG2 mediates adenylyl cyclase activity in human SH-SY5Y neuroblastoma cells. 
Another study in mouse embryonic fibroblasts showed that activation of PKA with 
dibutyryl-cAMP triggered phosphorylation of both TG2 at serine residue Ser
216
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(Mishra & Murphy, 2006) and retinoblastoma protein (Rb) at Ser
780
, but PKA kinase 
activity was inhibited by H-89 a PKA inhibitor (Mishra et al., 2007). In addition, 
phorbol esters have been implicated in the stimulation of transglutaminase activity in 
keratinocytes through activation of PKC (Chakravarty et al., 1990; Rice et al., 1996). 
In this study, PMA and FK modulated the levels of TG2 protein as verified by 
Western blotting (Fig. 3.3.10) and activity alterations that were impeded using 
different PKC and PKA inhibitors (Fig. 3.3.6). The altered expression of TG2 mRNA 
was also confirmed using semi- and qRT-PCR (Fig. 3.3.11). The discrepancy between 
PCR image results and quantification results is due to the limitation of traditional 
PCR that depends on size discrimination of agarose gel results, which is obtained 
from reaction end point (Heid et al., 1996; Schmittgen & Livak, 2008). The qPCR is 
unlike traditional PCR, its results are obtained from exponential phase, which is the 
optimal point for data analysis that representing the actual relation between the mount 
of starting sample and amplification of PCR product at different cycle number (Heid 
et al., 1996; Schmittgen & Livak, 2008). Although, the TG2 expression varies from 
sample to sample, detection of reaction end point in agarose gel is not able to resolve 
this variation. However, qPCR results confirmed these differences (Fig. 3.3.11B). 
Previous studies in a human endometrial adenocarcinoma cell line indicated that 
induction of TG2 expression was mediated by activation with calcitonin. This 
polypeptide hormone has been implicated in regulation of Ca
2+
 homeostasis through 
its cell surface receptor utilizing both cAMP and Ca
2+
 signalling pathways (Li et al., 
2002; Li et al., 2006). This expression was inhibited upon treatment with H-89, a 
PKA inhibitor but not with calphostin C a PKC inhibitor (Li et al., 2006). 
A phorbol ester (PMA) has also been used to investigate protein kinase C activation 
and ERK1/2 phosphorylation (Nanzer et al., 2004). Protein kinase C inhibitors impede 
PMA-induced phospholipase D (PLD) activation and ERK-1/2 phosphorylation in 
keratinocytes with a profile that associates with their ability to inhibit PMA-
stimulated TG1 activity (Bollag et al., 2005). In addition, FK-stimulated cAMP 
significantly increased ERK1/2 phosphorylation in ventricular myocytes (Wang et al., 
2009).  
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Extracellular signal-regulated kinases (ERK 1 and 2) are one of the major MAPK 
families that have already been shown to have a protective role in cardiomyocytes via 
activation of anti-apoptotic pro-survival pathways (Abe et al., 2000; Sugden & Clerk, 
2001). These kinases also reported to be involved in ischaemic and pharmacological 
preconditioning (Chesley et al., 2000; Punn et al., 2000). It has been reported that 
over-expression and activation of the G protein Gh (i.e. TG2) stimulates 
norepinephrine-induced ERK activation and is inhibited by an alpha-adreno-receptor 
blocker (prazosin) in neonatal rat cardiomyocytes (Lee et al., 2003). One study has 
shown that in H9c2 cells over expression of TG2 induced by retinoic acid (RA) 
induces phosphorylation of the MAPKs ERK1/2, and JNK; inhibition of TG2 by anti-
tTGase antibody resulted in an inverse effects on those kinases (Kim, 2009).  
Our study has shown that activation of TG2 via PKC and PKA activators leads to 
phosphorylation of ERK 1 and 2 in the response at PMA and FK (Fig. 3.3.10). 
Analysis of PKC and PKA downstream signalling pathways showed that constitutive 
activation or transient stimulation of TG2 activity were associated with increases in 
ERK1/2 activation in cardiomyocytes (Fig. 3.3.12 and Fig. 3.3.13). 
Modulation of TG2 by ERK signalling has been demonstrated in fibroblasts (Wang, 
2010). It has been reported that increased activation of the ERK pathway stimulates 
TG2 mRNA expression and biosynthesis, whereas inhibition of ERK results in the 
opposite effect (Akimov & Belkin, 2003). The effects of pharmacological inhibitors 
on different protein kinases in H9c2 cells resulted in inhibition of both ERK 
phosphorylation (Fig. 3.3.12 and Fig. 3.3.13) and transglutaminase activity. This 
suggests that the increase in TG2 activity following PMA or FK exposure could be a 
protective cellular response in H9c2 cardiomyocyte. 
In conclusion, these results suggest that a time course exposure of H9c2 cells to PMA 
or FK showed a significant increase in TG2 catalysed biotin cadaverine incorporation 
after 5 min exposure. This response was subsequently shown to be concentration 
dependent. Conversely, using different PKC and PKA inhibitors, this activation could 
be moderated. These data suggested modulation of TG2 in vitro by these protein 
kinase signalling pathways. 
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CHAPTER IV: 
IN SITU MODULATION OF TG2 ACTIVITY BY PKC / 
PKA AND THEIR RECEPTORS 
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4. Introduction 
Transglutaminase 2 activity is tightly regulated and controlled by posttranslational 
modification mechanisms. The extensively studied mechanism involves Ca
2+
 ions, 
guanine nucleotides and the redox state of the enzyme’s regulator environment. The 
activation of TG2 requires the binding of Ca
2+
 ions at multiple calcium binding sites 
(Bergamini, 1988; Király et al., 2009). The presence of the guanine nucleotide 
molecules GTP or GDP can inhibit Ca
2+
 ion binding to TG2 and thus inactivate it. 
However, high concentration of calcium and low GTP/GDP is needed for activation. 
The binding and release of these molecules with TG2 enzyme are associated with a 
large conformational changes in its structure (Fig. 4.1.1a). The active and inactive 
forms of TG2 have helped in understanding the reason why the enzyme remains 
inactive inside the cell under normal conditions (low free Ca
2+
 and high GTP/GDP; 
Siegel et al., 2008). The redox state of the enzyme environment has also helped in 
clarifying inactivation of TG2 in the extracellular environment (high calcium and low 
GTP/GDP; Siegel et al., 2008). This is due to the higher oxidative environment of the 
extracellular matrix, which maintains TG2 in its inactivate state by the formation of a 
disulphide bond between vicinal residues maintaining Ca
2+
 bound TG2 in an inactive 
state (Stamnaes et al., 2010; Jin et al., 2011). However, the protein cofactor 
thioredoxin-1 can transiently activate TG2 in a biological mechanism that could 
involve interferon-γ, a cytokine that helps immunity against infections and for tumour 
it is also key activator of macrophages (Abassi et al., 2001; Schroder et al., 2004; Jin 
et al., 2011).  
This mechanism was also shown to be responsible in activation of extracellular TG2, 
mediating the deamidation of gliadin in coeliac disease patients (Nadalutti et al., 
2013). Once activation of transglutaminase has occurred, the active site cysteine thiol 
residue is displayed and interacts with the glutamine protein bond carboxamide, 
resulting in ammonia release (Fig. 4.1.1b). Subsequently, the generated thioester 
intermediate can then be attacked by an ε-amino group from a lysine residue, 
converting glutamine to glutamate. This results in the formation of a stable ε(γ-
glutamyl)-lysine isopeptide bond that is resistant to proteolysis (Griffin et al., 2002).  
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A) 
 
B) 
 
 
 
 
 
 
Figure 4.1.1 Conformation state of transglutaminase and its activity  
A) Transglutaminase 2 states under different physiological conditions and their 
activity. B) the catalytic mechanism of TG2, the active site cysteine attacks the 
glutamine residue of acyl donor substrate 1,  generating an intermediate thioester that 
can be attacked by the amine contains a lysine of an acyl acceptor substrate 2, forming 
an isopeptide bond and ammonia released.
 
The transamidation activity of TG2 is of pharmacological importance, as it is believed 
that this activity contributes to a wide range of essential physiological processes and 
the pathogenesis of diseases. The enzymatic activity allows TG2 to crosslink proteins 
at diverse subcellular location and thus regulates cell adhesion, cell signalling, 
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apoptosis and differentiation (Spom & Roberts, 1983; Melino & Piacentini, 1998; 
Lorand & Graham, 2003; Zemskov et al., 2006). 
Many different methods have been developed to measure the enzymatic activity of 
TG2 ether in vitro or in situ. One of these is the using of a microplate in vitro TG 
assay which, usually utilizes N,N′-dimethylcasein as acyl donor and 5-
(biotinamido)pentylamine as the substrate (Slaughter et al., 1992) (section 2.2.3). The 
assay used to measure the incorporation of polyamines into proteins as signal 
absorbance (Piacentini et al., 1988; Fesus & Tarcsa, 1989; Esposito et al., 2003). The 
other approach is detection of in situ activity, which is unlike the in vitro assay as it 
depends on unknown substrates. The benefit of in situ experimentation is that it 
measures TG2 activity in its natural environments. In addition, this method is more 
visual than the in vitro assay and using it can help in the detection and localisation of 
TG substrates in different cell compartments. The in situ detection of transamidation 
activity of TG2 can be carried out by the incorporation of artificial substrates, e.g. 
monodansyl-cadaverine or 5-biotinamidopentylamine into protein in either 
permeabilised or intact cells. The incorporated substrates is then detected in SDS-
PAGE or in situ using antibodies (Jeon et al., 1989; Slaughter et al., 1992). Moreover, 
for the rapid and sensitive measurement of in situ activity, biotinylated or fluorescent 
amine incorporation into tissue (Lesort et al., 2000) or cells (Yamane et al., 2010; Itoh 
et al., 2011) has been used. 
The inhibition of enzymatic activity of TG2 is of therapeutic interest in the treatment 
of certain diseases (Yuan et al., 2005). Therefore many classes of TG2 irreversible 
inhibitors have been synthesised (Wodzinska, 2005; Siegel & Khosla, 2007). Some of 
these inhibitors are dihydroisoxazole small-molecule inhibitors, such as KCA075 and 
KCC009 that can highly specifically and irreversibly inhibit human TG2 (Choi et al., 
2005; Yuan et al., 2006). In addition, the membrane permeable irreversible inhibitors 
of transglutaminase R283 and ZDON (Fig. 4.1.2) were also used to confirm a 
reduction in in vitro and in situ TG2 activity in cells or tissue sections (Maiuri et al., 
2008; McConoughey et al., 2010).  
 
 
115 
 
A)                                                                           B) 
 
 
 
 
Figure 4.1.2 The chemical structure of membrane permeable irreversible 
transglutaminase inhibitors 
A) Z-DON; Benzyloxycarbonyl-(6-diazo-5-oxonorleucinyl)-L-Valinyl-L-Prolinyl-L-
Leucinmethylester a peptide-based irreversible, active site directed inhibitor. It 
contains a 6-diazo-5-oxonorleucinyl (DON) core mimics the gluten peptide and 
mediates the alkylation of active-site cysteine in TG2 that attack the carbonyl group, 
resulting in nitrogen release. B) R283; 1,3-dimethyl-2[(oxopropyl)thio]imidazolium) 
a potent irreversible, active site directed inhibitor. The reaction mediates the 
acetonylation of active-site cysteine in TG2 that attack the carbonyl group (functional 
group of the enzyme) mimic glutamine residue. Both inhibitors reaction resulting in a 
stable thioether adduct. Adapted from McConoughey et al., (2010).
 
Beta-adrenergic receptors (β-AR) belong to the G-protein coupled receptor (GPCR) 
superfamily. There are three subtypes of β-AR: β1, β2 and β3 all of which couple to Gs-
proteins and the β1-AR is the main subtype expressed in the mammalian heart. 
Accumulating evidence has shown that activation of β-AR is associated with the 
increasing of intracellular levels of cAMP in animal heart models (Xiang & Kobilka, 
2003; Dorn et al., 2008). Signalling by cardiac β-receptors has been extensively 
studied. The common pathway is initiated from stimulation of β-ARs coupled to Gs 
(an alpha subunit of the stimulatory G protein) which activate adenylyl cyclase (AC) 
and thus increases cAMP-production to activate PKA (Lefkowitz, 2007). The main 
target for cAMP is PKA, which represents a key signalling mechanism for neuro-
hormonal stimulation regulating diverse cardio-physiological processes from 
contraction and energy metabolism to heart performance. Upon activation of PKA in 
cardiac myocytes, two major changes are observed; a) improvement of cardiac 
contraction; and this involves phosphorylation of two essential ion channels on the 
plasma membrane and sarcoplasmic reticulum in addition to phosphorylation of 
myofibril contractile proteins (Xiang & Kobilka, 2003). b) The negative stimulation 
of ligand-bound β-ARs occurs by phosphorylation of activated receptors (Lefkowitz, 
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2007). Some of the protein targets phosphorylated following PKA activation are L-
type calcium channels (Zhao et al., 1994), troponin I, phospholamban (Sulakhe & Vo, 
1995) and MyBP-C a myosin binding protein-C (Kunst et al., 2000). It is of interest to 
notice that some of these essential proteins are also TG2 substrates, such as myosin 
(Orrù et al., 2003) and troponin I (McDonough et al., 1999).   
The A1-adenosine receptor is one of the G-protein coupled receptor superfamily and it 
is a member of four-adenosine receptor subtypes (A1, A2A, A2B and A3) that have been 
cloned and designated (Mubagwa & Flameng, 2001). Adenosine receptors have been 
shown to be expressed in ventricular cardiomyocytes and regulate different cellular 
functions (Auchampach & Bolli, 1999). Activation of the adenosine A1 receptor 
using different pharmacological agents on myocytes through binding to the (α) 
subunit of the heterotrimeric G protein (Gi) results in adenylyl cyclase inhibition and 
thus decreases concentration of cAMP, while the binding to (β or δ) subunits leads to 
PLC-β activation (Dickenson & Hill, 1997; Dickenson et al., 2012). This results in an 
increase of inositol triphosphate (IP3) and diacylglycerol (DAG) concentration (Wu et 
al., 1992; Terzic et al., 1993). Furthermore, the role of different adenosine subtype 
receptors in cardioprotection has been demonstrated in different species (Fredholm, et 
al., 2001). The adenosine receptor has been considered as a potential trigger for 
cardioprotection mechanism against ischaemic damage. However, the underlying 
mechanisms of adenosine-mediated cardioprotection remain unclear, but appear to 
involve PKC, since different protein kinase inhibitors e.g. (chelerythrine, polymyxin 
B and staurosporine) attenuate cardioprotection effects induced by adenosine receptor 
activation (De Jong et al., 2000).  
Agonists such as diazoxide will pharmacologically precondition the heart against the 
effects of ischaemia and thus reduce infarct size (area of ischaemic necrosis in issue), 
that is similar to the one induced by ischaemic preconditioning (Forbes et al., 2001). 
This diazoxide-induced activation of mitochondrial KATP channel is triggered by 
adenosine and nitric oxide (NO) (Lochner, et al., 2002). The adenosine allows 
mitochondrial KATP channel opening via diazoxide, while nitric oxide improves 
mitochondrial KATP channel activation by diazoxide (Sato et al., 2000). The opening 
of mitochondrial KATP results in elevated levels of ROS and reactive nitrogen species 
(RNS) that are required for the signalling cascade. This in turn activates a wide range 
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of kinases, such as PKC, JAK/STAT, and p38 MAPK that are also involved in cardiac 
protection (Nakano et al., 2000). Moreover, the translocation of heat shock proteins 
was also shown to be a downstream target for adenosine receptor or PKC activation in 
the cardioprotection process (Sakamoto et al., 2000). However, receptor-mediated 
cardiomyocyte signalling pathways involved in TG2 activation have not been 
investigated before.   
Taken together, the above considerations coupled with the importance of both of these 
G protein-coupled receptors in cardioprotection mechanism and the fact that they are 
both downstream targets for PKA (β-adrenergic receptor) and PKC (A1-adenosine 
receptor) activation suggest that further investigation would be worthwhile. 
Therefore, the possible link between the stimulation of these receptors to induce PKC 
or PKA and TG2 activation mediated by this pathway was investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
4.1. Aims  
The main aims of the work presented in this chapter were to determine the effects of 
receptors activation and PMA/FK on TG2 activity in situ in present and absence of 
TG2 inhibitors. 
4.2. Methods  
As described in chapter 2 of this study (section 2.2). 
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4.3. Results 
In the previous chapter, the data presented showed that time dependent exposure of 
H9c2 cells to PMA or FK showed a significant transient increase in TG2 catalysed 
biotin cadaverine incorporation after 5 min. This response was subsequently shown to 
be concentration-dependent. Conversely, using different PKC and PKA inhibitors, 
this activation could be moderated. However, western blotting analyses of H9c2 cell 
extracts and qRT-PCR indicated that the protein and mRNA levels of TG2 might alter 
following exposure to PMA or FK and protein kinase inhibitors. In this chapter, TG2 
activity was investigated in intact cells. 
4.3.1. Activation of endogenous TG2 in response to PMA and FK in a calcium-
dependent manner 
To determine whether PMA or FK-induced TG2 activation in H9c2 cells was related 
to activation of endogenous TG2 in a calcium-dependent manner, equal amounts of 
cell proteins were incubated in the presence of 1 mM biotin cadaverine (BTC) which 
represents the acyl-acceptor probe in the presence of either 5 mM Ca
2+
 or EDTA 
(background control). Reaction mixtures were subjected to immuno-blotting and the 
membranes were probed with ExtrAvidin
®
peroxidase as described in materials and 
methods (section 2.2.19). The acyl-acceptor probe biotin cadaverine was incorporated 
into endogenous protein substrates of TG2 in H9c2 cells. The results showed calcium 
dependent incorporation of biotin cadaverine into numerous proteins in H9c2 cells 
(Fig. 4.3.1). More importantly, treatment of H9c2 cells with PMA and FK in the 
presence of 5 mM CaCl2 resulted in significant labelling of cellular proteins while 
control cells that were not treated with PMA or FK were shown to have less biotin 
cadaverine labelling in the presence or absence of calcium (Fig. 4.3.1).  
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Figure 4.3.1 Activation of endogenous TG2 in response to PMA and FK in a 
calcium-dependent manner 
Labbling of endogenous protein substrates in (A) PMA-treated H9c2 and (C) FK-
treated H9c2, control (lanes 1 and 4), 5 min treated cells  (lanes 2 and 5), and 20 min 
treated cell (lanes 3 and 6) and ladder (L). Activity was analysed by incubating total 
cell lysate proteins in the presence of 1 mM BTC (biotin cadaverine) and 5 mM CaCl2 
(lanes 1–3) or EDTA (lanes 4–6). At the indicated times, 4x sample buffer was added 
to stop the reaction, and the reaction mixtures (50 μg per lane) were subjected to SDS-
PAGE followed by Western blotting and then analysed for TG2-catalyzed conjugation 
of BTC into proteins using ExtrAvidin®-peroxidase as a probe. (B &D) Densitometry 
results represent mean ± SEM of the relative intensity versus the incubation time at 
37°C from 3 independent experiments. (B) Two-way ANOVA showed significant 
effect of Ca 
+2
 incubation (F= 8.92, dF =3, 16, **p<0.01) and PMA treatment (F= 
22.59, dF =2, 16, ***p < 0.001), and statistical significant of the interaction of PMA/ 
Ca
+2 
(F = 3.38, dF =6, 16,*p < 0.05).  ***P < 0.001, control vs 5 min PMA, ***P < 
0.001 and **P < 0.01 control vs 20 min PMA as determined by "Bonferroni post-
tests". (D) Two-way ANOVA showed significant effect of Ca
+2
 incubation (F = 
10.60, dF =3, 24, ***p < 0.001) and FK treatment (F=6.21, dF =2, 24, **p < 0.01), 
and no statistical significant of the interaction of FK/ Ca
+2
. *P < 0.05 compered of FK 
at 5 min with control as determined by "Bonferroni post-tests". Arrow indicated to 
biotin conjugated proteins (non-specific bands).
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4.3.2. Visualisation of endogenous in situ TG2 activity following PMA and FK 
exposure  
An assay was developed using a biotinylated probe to assess in situ TG2 activity in 
H9c2 cells in response to PMA and FK. A biotinylated primary amine such as a 
biotin-X-cadaverine (BTC) acts as the acyl-acceptor in the transamidating reaction 
catalysed by TG2 and becomes incorporated into the endogenous intracellular protein 
substrates of TG2 (Lee et al., 1993). H9c2 cells were pre-incubated with 1 mM biotin-
X-cadaverine for 4h at 37°C prior to treatment with 1 µM PMA or 10 μM FK for 5, 
10, or 20 min. After fixation and permeabilisation, intracellular proteins with 
covalently attached biotin-X-cadaverine, as a result of PMA/FK-induced TG2 
activity, were visualized using ExtrAvidin
®
-FITC (section 2.2.9.2). As shown in 
Figure 4.3.2, PMA and FK-induced time dependent increases were observed in biotin-
X-cadaverine incorporation into endogenous protein substrates of TG2 in H9c2 cells. 
The incorporation was most evident after 5 and 10 min incubation. This biotinylation 
in living cells were reduced after 20 min incubation with PMA or FK (Fig. 4.3.2). 
These data are comparable to TG2 transamidation activity observed in vitro (see Fig. 
3.3.1). Surprisingly, given the covalent nature of biotin-X-cadaverine incorporation, 
fluorescence staining returned to control levels after 20 min incubation with PMA and 
FK. 
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Figure 4.3.2 Visualisation of endogenous in situ TG2 activity in H9c2 cells 
following PMA and FK exposure 
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine 
(BTC) for 4 hours. Cells were then treated with 1 µM PMA or 10 μM FK for 5, 10, 20 
min. Untreated cells used as control either in presence of BTC (+) or in absence of 
BTC (-), The TG2 mediated biotin-X-cadaverine incorporation into intracellular 
proteins was visualised with ExtrAvidin
®
-FITC (green). Nuclei were stained with 
DAPI (blue). The original magnification of the images was 400x. The results are 
typical of 4 independent experiments. 
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4.3.3. Identification and fractionation of acyl-donor TG2 proteins in extra- and 
intracellular proteins 
In order to investigate the reduction in TG2 incorporation activity (biotinylated 
products) in living cells after 20 min incubation with PMA or FK, the presence of 
biotinylated (biotin-cadaverine labelled) proteins in the culture medium (M) and  
lysates (L) of treatment sample at different time point was investigated by immuno-
dotblotting.  
A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
125 
 
C) 
 
 
 
 
 
 
D) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3 Identification and fractionation of acyl-donor TG2 proteins in extra- 
and intra-cellular proteins  
H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine (BTC) for 4 h in 
culture hood. Cells were then treated (A & B) with 1 µM PMA or (C & D) with 10 
μM FK at the indicated time points, while untreated cells (0 min) used as control. The 
culture medium (M) and extracted protein lysate (L) from H9c2 cells following a 
biotinylating experiment were then collected at different time points. An equal 
amount (500 µg) of biotinylated (biotin-cadaverine labelled) proteins were extracted 
using Captavidin
®
agarose beads. The captured biotinylated proteins were either (15 
µl) dot-blotted onto nitrocellulose filters (A & C) or (30 µl) resolved by SDS-PAGE 
followed by Western blotting (B & D). TG2 transamidating activity and protein 
substrates were detected using ExtrAvidin
®
-peroxidase. The results are typical of 3 
independent experiments. (-) without BTC while, (+) with BTC.
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The cell culture medium from the incubated cells at different time’s incubation with 
PMA or FK was collected and passed through Captavidin
®
agarose beads (section 
2.2.17). The eluted biotin-cadaverine labelled proteins were subjected to dot blotting 
assay (section 2.2.18) or SDS-PAGE followed by Western blotting and probing with 
ExtrAvidin
®
-peroxidase. Biotin-cadaverine labelled proteins were visualised in the 
culture medium after 5 min incubation, suggesting that they were rapidly externalised 
by the H9c2 cells (Fig. 4.3.3).  
4.3.4. The effect of TG2 inhibitors on PMA and FK-induced TG2 activity 
To confirm that TG2 is responsible for PMA and FK-stimulated TG2 activity in H9c2 
cardiomyocytes, two structurally different specific TG2 inhibitors were tested. R283 
(1,3-dimethyl-2 [(oxopropyl)thio]imidazolium) derivative is a cell permeable and 
irreversible TG2 inhibitor (Freund et al., 1994; Balklava et al., 2002), whereas Z-
DON (Z-DON-Val-Pro-Leu-OMe) is a peptide-based cell permeable inhibitor, which 
irreversibly alkylates the active site of TG2 (Schaertl et al., 2010). 
4.3.4.1. The effect of different concentrations of TG2 inhibitors on TG2 biotin  
cadaverine incorporation activity stimulated with FK in H9c2 cells 
To identify the effective TG2 inhibitor concentrations that were able to block TG2 
activity induced by protein kinase activators, H9c2 cardiomyocyte cells were pre-
treated for 1h with  a wide concentration range (1-150 μM) of the TG2 inhibitors Z-
DON or R283 (1-200 μM) prior to 5 min exposure to 10 μM FK. The cells were then 
lysed and subjected to the biotin cadaverine incorporation assay.  
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Figure 4.3.4 The effect of TG2 inhibitors on TG2 biotin cadaverine incorporation 
activity stimulated with FK in H9c2 cells 
H9c2 cells were pre-treated with A) 1-150 μM (Z-DON) or B) 1-200 μM (R283) TG2 
inhibitors for 1h and then stimulated with 10 μM FK for 5 min. Cell lysates were 
subjected to biotin cadaverine incorporation assay. Graph plotted using Nonliner 
regression curve fit, "log(inhibitor) vs. response". Data points represent the mean ± 
SEM TG2 specific activity from 3 independent experiments. Data analysis was 
performed using "Bonferroni's multiple comparison test" to compare control 
(untreated cells) vs. FK and FK vs. Z-DON or R283. Statistical significance was 
accepted at ***p < 0.001, **p < 0.01, *p < 0.05. 
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As shown in Figure 4.3.4, Z-DON completely blocks FK-induced TG2 biotin 
cadaverine incorporation activity, which returned to basal level at concentration of 
100-150 μM and 150-200 μM with R283. The data show that both treatments induced 
a significant decrease (n = 3, ***p < 0.001 versus FK+ 150 μM Z-DON (Fig. 4.3.4A) 
and n = 3, **p < 0.01 versus FK+ 200 μM R283 (Fig. 4.3.4B) in TG2 catalysed biotin 
cadaverine incorporation activity. These data further suggest that Z-DON at a 
concentration less than 100 μM and R283 at 150 μM have no significant effect on the 
FK-induced transglutaminase amine incorporation activity of H9c2 cells, compared to 
untreated cells (control), suggesting that 150 μM/Z-DON and 200 μM /R283 were 
appropriate concentrations to use to block TG2 activity in this cell line. Accordingly, 
these two concentrations (150 μM/Z-DON and 200 μM /R283) were adopted for 
subsequent experiments measuring the TG2 activity in H9c2 cells. 
4.3.4.2. The effect of TG2 inhibitors on TG2 biotin cadaverine incorporation 
activity stimulated with PMA and FK in H9c2 cells  
To confirm that TG2 was responsible for PMA and FK-stimulated TG2 activity in 
H9c2 cardiomyocytes, two structurally different specific, cell permeable and 
irreversible TG2 inhibitors R283 and Z-DON were tested. Cardiomyocyte H9c2 cells 
were pre-treated for 1h with the TG2 inhibitors Z-DON (150 μM) or R283 (200 μM) 
prior to 5 min exposure to 1 µM PMA or 10 μM FK as described in methods section 
(Fig. 2.1A). The cells were then lysed and subjected to the biotin cadaverine 
incorporation assay. As shown in Figure 4.3.5, Z-DON and R283 completely block 
PMA and FK-induced TG2 incorporation activity confirming the involvement of 
TG2. The data suggest that both treatments showed a significant decrease (n = 5, **p 
< 0.01 versus PMA+ Z-DON *p < 0.05 versus FK+ Z-DON (Fig. 4.3.5A) and n = 3, 
***p < 0.001 versus PMA+ R283, and **p < 0.01 versus FK+ R283 (Fig. 4.3.5B) in 
TG2 catalysed biotin cadaverine incorporation in the presence of TG2 inhibitors.  
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Figure 4.3.5 The effect of TG2 inhibitors on TG2 biotin cadaverine incorporation 
activity stimulated with PMA and FK in H9c2 cells 
H9c2 cells were pre-treated with A) 150 μM (Z-DON) or B) 200 μM (R283) TG2 
inhibitors for 1h and then stimulated with 1 µM PMA or 10 μM FK for 5 min. Cell 
lysates were subjected to biotin cadaverine incorporation assay. Data points represent 
the mean ± SEM TG2 specific activity from 5 (a) or 3 (b) independent experiments. 
Data analysis was performed using "Bonferroni's multiple comparison test" to 
compare control (untreated cells) vs. either PMA or FK and these later vs. Z-DON or 
R283. Statistical significance was accepted at ***p < 0.001, **p < 0.01, *p < 0.05. 
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4.3.4.3. The effect of TG2 inhibitor on in situ TG2 activity stimulated with 
PMA and FK in H9c2 cells  
To confirm the involvement of TG2 activation, cells were also treated with 150 μM 
site specific inhibitor of TG2 (Z-DON) prior to incubation with either 1 µM PMA or 
10 μM FK for 5 min. The presence of this inhibitor in treated cells resulted in 
complete inhibition of TG2 activity and prevented BTC being incorporated into 
endogenous protein substrates (green) of cytoplasmic compartment and cytoskeletal 
elements (Fig. 4.3.6). 
 
Figure 4.3.6 The effect of TG2 inhibitor on in situ TG2 activity stimulated with 
PMA and FK in H9c2 cells 
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine 
(BTC) for 4 hours. Cells were then incubated either with (+) or without (-) 150 μM 
(Z-DON) TG2 inhibitor for 1h prior to PMA/FK treatments for 5 min, while untreated 
cells used as control. The TG2 mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualised with ExtrAvidin
®
-FITC (green). Nuclei were 
stained with DAPI (blue). The original magnification of the images was 400x. The 
results are typical of 4 independent experiments.
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4.3.5. The effect of the selective adenosine A1 receptor agonist N
6
-
cyclopentyadenosine and the non-selective β-adrenergic receptor agonist 
isoprenaline on in situ TG2 activity 
Since TG2 activity was shown to be elevated in the presence of activators of protein 
kinase A and C, it could be activated in presence of their receptor activators. 
Receptors mediated by these protein kinases were also investigated by in situ TG2 
amine incorporation activity. A selective adenosine A1 receptor agonist N
6
-
cyclopentyadenosine (CPA) and the non-selective β-adrenergic receptor agonist 
isoprenaline (ISO) were used. Transglutaminase 2 transamidation activity was found 
to be elevated in the presence of 1 µM CPA or ISO for 5 min and BTC was 
incorporated into endogenous protein substrates of TG2 in response to both treatments 
(Fig. 4.3.7). Expectedly, the presence of TG2 inhibitor (Z-DON) blocked this 
activation and prevented BTC being incorporated into TG2 substrate proteins in H9c2 
cells. 
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Figure 4.3.7 Endogenous in situ TG2 activity following CPA and ISO exposure 
visualised by biotin cadaverine incorporation activity  
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine 
(BTC) for 4h. Cells were then incubated either with (+) or without (-) 150 μM (Z-
DON) TG2 inhibitor for 1h prior to 1 µM of either N
6
-cyclopentyadenosine (CPA) or 
isoproterenol (ISO) for 5 min. Untreated cells (control) in absence of BTC (-) or in 
presence of BTC (+). The TG2 mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualised with ExtrAvidin
®
-FITC (green). Nuclei were 
stained with DAPI (blue). The original magnification of the images was 400x. 
Untreated cells (control) in absence of BTC (-) or in presence of BTC (+).The results 
are typical of 3 independent experiments.
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4.3.6. The effect of adenosine A1 receptor antagonist in situ TG2 activity 
following CPA exposure  
In order to confirm whether a selective adenosine A1 receptor agonist N
6
-
cyclopentyadenosine (CPA) modulated TG activity in H9c2 cardiomyocytes, 
antagonists for this receptor was also tested. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.8 The effect of adenosine A1 receptor antagonist in situ TG2 activity 
following CPA exposure visualised by biotin cadaverine incorporation activity 
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine 
(BTC) for 4h. Cells were then incubated either with (+) or without (-) 10 μM 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX) adenosine A1 receptor antagonist prior of 
1 µM & 0.1 µM N
6
-cyclopentyadenosine (CPA) for 5 min. Untreated cells used as a 
control in absence of BTC (–ve) or in presence of BTC (+ve). The TG2 mediated 
biotin-X-cadaverine incorporation into intracellular proteins was visualised with 
Extravidin
®
-FITC (green). Nuclei were stained with DAPI (blue). The original 
magnification of the images was 400x.The results are typical of 3 independent 
experiments.
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Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine 
(BTC) for 4h in cell culture incubator. H9c2 cells were then treated with 10 μM 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX) adenosine A1 receptor antagonist prior to 
the addition of 1 µM and 0.1 µM CPA for 5 min. The TG2 mediated biotin-X-
cadaverine incorporation into intracellular proteins was visualised with Extravidin
®
-
FITC (green). As shown in Figure 4.3.8, the adenosine A1 receptor antagonist DPCPX 
was able to partially block in situ TG2 transamidation activity that was elevated in the 
presence of both concentrations of CPA and prevent BTC incorporated into 
endogenous protein substrates of TG2. 
4.3.7. The detection of TG2 activity in mitochondria and endoplasmic reticulum  
To detect some of cell compartments that could be co-localised with TG2 
incorporation activity, anti-monoamine oxidase B (MAO-B) mAb was used as a 
mitochondrial marker, while calnexin (AF18) was used as an endoplasmic reticulum 
(ER) marker. 
The monoamine oxidases are considered to be enzyme located on the outer membrane 
of mitochondria (Berry et al., 1994; Abell & Kwan, 2000). Merging of the images 
demonstrates the co-localization of amine incorporation activity in the mitochondria 
of PMA/FK-treated cells (red + green = yellow/orange; Fig. 4.3.9). Transglutaminase 
2 activity co-localised in ER (Fig. 4.3.10) was also shown to be enhanced by PMA 
and FK treatment. 
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Figure 4.3.9  Assessment of TG2 activity in mitochondria 
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine for 
4h. Cells were then treated with either 1 µM PMA or 10 μM FK, while untreated cells 
used as a control. The TG2-mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualised with Extravidin
®
-FITC (green). Nuclei were 
stained with DAPI (blue). Mitochondria (Mito) were detected by rabbit anti-
monoamine oxidases B (MAO-B) mAb and visualised by red (anti-rabbit-Alexa 568 
secondary antibody). The original magnification of the images was 400x. The results 
are typical of 3 independent experiments.
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Figure 4.3.10 The co-localisation of TG2 activity in endoplasmic/sarcoplasmic 
reticulum  
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine for 
4h. Cells were then treated with either 1 µM PMA or 10 μM FK while, untreated cells 
used as a control in absence of BTC (–ve) or in presence of BTC (+ve). The TG2 
mediated biotin-X-cadaverine incorporation into intracellular proteins was visualised 
with Extravidin
®
-FITC (green). Endoplasmic/sarcoplasmic reticulum (ER/SR) was 
detected by mouse anti-Calnexin (AF18) antibody mAb and visualised by red (anti-
mouse-Alexa568 secondary antibody). Nuclei were stained with DAPI (blue). The 
original magnification of the images was 400x. Co-localisation of endoplasmic 
reticulum (red) and TG2 activity (green) stained yellow shown in the merged 
photograph. The results are typical of 3 independent experiments.
 
137 
 
4.3.8. The detection of TG2 in mitochondria and sarcoplasmic/endoplasmic 
reticulum fraction 
Since TG2 activity was also shown to target mitochondria and 
sarcoplasmic/endoplasmic reticulum proteins, the presence of TG2 in these two 
cellular organelles was also investigated for comparison. For this, extracts from H9c2 
cells before and after PMA/FK treatments were sub-fractionated by differential 
centrifugation as described in material and methods (section 2.2.8). The results show 
the presence of TG2 in endoplasmic reticulum and mitochondria as well as cytosol 
(Fig. 4.3.11). Anti-tubulin antibodies were used as a marker for cytosol, anti-lamin 
antibodies were used as marker for nucleus while calnexin antibodies were used as a 
marker for ER/SR. 
 
 
 
 
 
 
 
Figure 4.3.11 Detection of TG2 in subcellular fractions of H9c2 cells after PMA 
/FK treatment 
H9c2 cells were treated with either 1 µM PMA or 10 μM FK, after which they were 
lysed with 500 μl of subcellular fractionation buffer, homogenized and subjected to 
subcellular fractionation by centrifugation. Untreated cells used as a control (Con). 
An equal amount of subcellular fraction protein (30 µg) were analysed by Western 
blotting using monoclonal antibodies to TG2 (CUB 7402) calnexin, lamin, and α-
tubulin (B512). The results are typical of 3 independent experiments. Cytosol (Cyto.), 
mitochondria (Mito.) sarcoplasmic/endoplasmic reticulum (ER/SR) and purified 
guinea pig liver transglutaminase used as stander (TG2 St).
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4.4. Discussion 
The data presented in this and other studies clearly indicate that TG2 activity can be 
regulated by PKA and PKC-dependent signalling pathways (Mishra & Murphy, 2006; 
Mishra et al., 2007). However, since TG2 is a calcium-activated enzyme (Griffin et 
al., 2002), it is not clear if modulation of TG2 activity by protein kinases occurs 
independently of its regulation by calcium. To address this, this study monitored TG2 
activity, following PMA and FK treatment, in the presence and absence of calcium. 
From the data presented, it appears that PMA and FK-induced TG2 activity depends 
on the continued presence of calcium (Fig. 4.3.1).  
In this study, the acyl-acceptor probe biotin cadaverine (Smethurst et al., 1993) was 
incorporated into endogenous protein substrates of TG2 in H9c2 cell lysates in the 
presence of calcium and EDTA. Since TG2 is a calcium-activated enzyme (Hand et 
al., 1985), TG2 biotin cadaverine incorporation activity was elevated in the presence 
of calcium after 30 min incubation at 37C° of both PMA and FK treated and untreated 
cells (Fig. 4.3.1). Importantly, this increase was statistically significant for both PMA 
and FK treatments. The results showed calcium dependent incorporation of biotin 
cadaverine into numerous proteins in H9c2 cells because none or less proteins were 
labelled in the presence of EDTA. Control cells that were not treated with either PMA 
or FK showed less biotin cadaverine labelling in the presence or absence of calcium. 
In addition, it was shown that there was significant (***p< 0.001) labelling of cellular 
proteins after an hour incubation at 37C°. This confirms the previous in vitro results 
of TG2 biotin cadaverine incorporation assay (see Fig. 3.3.1) indicating that PMA or 
FK-induced TG2 activation in H9c2 cells was related to activation of endogenous 
TG2 in a calcium dependent manner. 
In chapter three, the study showed that a time-dependent exposure of H9c2 cells to 
PMA or FK caused a significant increase in TG2 catalysed biotin cadaverine 
incorporation after 5 min exposure in vitro (see Fig. 3.3.1). Conversely, using 
different PKC and PKA inhibitors, this activation was moderated (see Fig. 3.3.6). In 
this chapter, the study confirmed this activation in intact cells in the presence of TG2 
inhibitor. An immunocytochemistry-based assay was developed that enabled the 
visualisation of in situ TG2 activity. 
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Initially, the effective TG2 inhibitor concentrations that were able to block TG2 
activity induced by protein kinase activators was determined. The data show that Z-
DON at a concentration lower than 100 μM and R283 at 150 μM had no significant 
effect on the FK-induced transglutaminase amine incorporation activity of H9c2 cells, 
compared to untreated cells (control) (Fig. 4.3.4). This suggests that a concentration 
of 150 μM/Z-DON and 200 μM/R283 were appropriate concentrations to be used to 
block TG2 activity in these cells. A higher concentration of R283 (250 μM) has been 
used to block TG2 activity in other cell lines such as in human SH-SY5Y 
neuroblastoma cells with no apparent toxicity (Beck et al., 2006). Thus, this suggests 
that 200 μM R283 is also able to inhibit TG2 activity of H9c2 cells and may not affect 
cell viability either. On the other hand, a lower concentration for Z-DON (50 μM) has 
been used to attenuate TG2 activity in some cells, including YAC128 primary 
neurons (McConoughey et al., 2010) and rat vena cava smooth muscle cells (Johnson 
et al., 2012). However, it is possible that this concentration of Z-DON could block 
TG2 activity if used for long period of incubation as shown in YAC128 primary 
neurons after 12h and for 24h in wild type (Q7) and mutant HD (Q111) striatal cells 
(McConoughey et al., 2010). Furthermore, this concentration can partially attenuate 
TG2 activity as shown in rat vena cava smooth muscle cells (Johnson et al., 2012). 
The results from these previous studies and this study suggest that the concentration 
of Z-DON needed can vary between different cell types and could be affected by the 
incubation period. 
The TG2 biotin cadaverine incorporation activity stimulated by protein kinase A and 
C activators showed a significant decrease (n = 5, ** P < 0.01 versus PMA+ Z-DON, 
*P < 0.05 versus FK+ Z-DON) in the presence of TG2 inhibitor (Z-DON; Fig. 
4.3.5A). There was a 50 % decrease relative to the protein kinase activator treated 
cells, but no significant difference from the control (untreated cells) level. The 
inhibitor Z-DON is an irreversible TG2 inhibitor that attaches covalently to the TG2 
active site cysteine (Choi et al., 2005; Schaertl et al., 2010; Verhaar et al., 2011). 
Similarly, R283, a cell permeable and irreversible TG2 inhibitor (Freund et al., 1994; 
Balklava et al., 2002), completely blocks PMA and FK-induced transglutaminase 
amine incorporation activity confirming the involvement of TG2 (Fig. 4.3.5B). 
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Most cells take up polyamines (Seiler et al., 1996) and biotin-X-cadaverine has been 
used to label cells in situ and to visualise proteins that are targeted by 
transglutaminase (Perry et al., 1995). In situ TG2′s transamidation activity (Fig. 4.3.2) 
appeared variable between different treatments. However, biotin-X-cadaverine was 
found to be predominantly incorporated into endogenous protein substrates of TG2 in 
PMA or FK treated H9c2 cells. It was seen prominently as a punctate pattern in the 
cytoplasm and cytoskeletal elements with a bright nucleus after 5 and 10 min 
incubation. This biotinylation in living cells showed a reduction after 20 min 
incubation with PMA or FK (Fig. 4.3.2), in agreement with measurements of TG2 
transamidating activity in the in vitro assay (see chapter 3) and TG2 substrates 
detection (Fig. 4.3.1). 
However, given the covalent nature of biotin-X-cadaverine incorporation into protein 
substrates, it was surprising to observe in situ TG2 activity returning to basal levels 
after 20 min (Fig. 4.3.2). The question where now raised here is; How do the 
biotinylated proteins at 5 and 10 min disappear within 20 min showing a reduction in 
labelling? This suggested that some proteins could be expelled from the cell (e.g. via 
exosomes) or that they could be rapidly degraded by the proteasome or another 
proteolytic network. Therefore, the substrate proteins (biotin-cadaverine labelled 
proteins) in the cell culture medium and cell lysate from the treated cells were 
collected and biotin-cadaverine labelled proteins captured with Captavidin
®
agarose 
beads. Biotin cadaverine labelled proteins were visualised in the culture medium after 
5 min incubation suggesting that the biotinylated proteins were rapidly externalized 
by the H9c2 cells. The presence of biotinylated proteins in the culture medium 
decreased after 10 and 20 min incubation (Fig. 4.3.3) suggesting that it may be they 
are degraded outside the cells. 
The presence of TG2 inhibitor in intact cells resulted in complete inhibition of TG2 
activity and prevented BTC incorporation into protein substrates (Fig. 4.3.6). This 
suggests a relationship between protein kinase activation and TG2 which may be 
mediated by their G protein coupled receptors (GPCRs). The activation of PKA has 
shown to be mediated by a non-selective β-adrenergic receptor (β-AR) agonist 
(isoproterenol) that elevates cAMP (Lohse et al., 2003). It has been suggested that 
adenosine A1 receptor-mediated activation of PKC induces cardioprotection (Dana et 
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al., 2000; Kudo et al., 2002). Although these receptors have important roles in cardiac 
physiological function and protection, as has TG2, the link between them and TG2 
has not been investigated to this date. This study has shown that the selective 
adenosine A1 agonist N
6
-cyclopentyladenosine (CPA; Elzein & Zablocki, 2008), and 
β-adrenergic receptor (β-AR) agonist (isoproterenol) can both stimulate TG2 
incorporation activity in situ (Fig. 4.3.7) and these were reversed by the TG2 inhibitor 
(Z-DON). However, an antagonist for selective adenosine A1 (8-cyclopentyl-1,3-
dipropylxanthine (DPCPX)) was tested and showed its ability to block this activation, 
suggesting modulation of TG2 activity by this receptor (Fig. 4.3.8). These results 
presented suggest a novel role for TG2 in mediating adenosine and β-adrenergic 
receptor. However, a further study for in vitro TG2 activity and target substrates via 
these receptors agonists is still needed. 
Transglutaminase 2 incorporation activity as induced by either PMA or FK was 
shown to be co-localised in mitochondria of H9c2, confirmed by co-localisation with 
anti-monoamine oxidases B (MAO-B; Fig. 4.3.9). This enzyme has been detected in 
cardiomyocytes of spontaneously hypertensive rat (Pino et al., 1997) and in different 
human tissues (Rodríguez et al., 2001). Interestingly, the present results have shown 
that MAO-B was elevated in the presence of protein kinase activators compared to 
untreated H9c2 cells. This agrees with other studies that have reported that PMA 
treatment can elevate both MAO-B gene and protein levels in human hepatocytoma 
cells (Wong et al., 2002; Shih & Chen, 2004). In addition, MAO-B's activity has been 
shown to be increased in aging tissues (Diez & Maderdrut, 1977; Shih et al., 1999). 
This suggests that the role of TG2 is mediated by protein kinase activators in cell 
proliferation and differentiation. It is possible that MAO-B could be one of TG2 
substrate proteins. Thus, further work is needed to detect this protein among the 
biotinylated target proteins in PMA/FK treated H9c2 cells identified by western 
blotting.  
It is already known that the endoplasmic/sarcoplasmic reticulum (ER/SR) acts as an 
intracellular calcium store that helps to maintain a steady state low concentration of 
intracellular free Ca
2+
 and this in turn participates in the rapid of release of Ca
2+
 in 
response to signalling (Brown & Loew, 2012; Lukyanets & Lukyanetz, 2013). 
Transglutaminase 2 has not been detected either in the ER or Golgi compartment in 
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previous studies (Lorand & Graham, 2003; Iismaa et al., 2009). However, the ER may 
possibly contribute in the activation of TG2 through release of calcium in the 
cytoplasm (Jeitner et al., 2009). In this study, calnexin was used as an endoplasmic 
reticulum marker (Volpe et al., 1992; Kleizen & Braakman, 2004) and TG2 activity 
was co-localised to the endoplasmic reticulum (Fig. 4.3.10).Moreover, calnexin 
detection was also shown to be enhanced in the presence of PMA and FK. Calnexin is 
also often found on the mitochondria-associated ER membrane, suggesting its role in 
regulation of ER Ca
2+
 signalling (Myhill et al., 2008). The presence of calnexin in the 
mitochondrial fraction could be due to palmitoylation, which is covalent attachment 
of fatty acids to cysteine or serine and threonine residues of membrane proteins 
(Lynes et al., 2011). Although there was a lamine-contamination in mitochondria 
fractions, TG2 was shown in the enrichment compared to the nucleus fractions. 
Subcellular fractionation also confirmed the presence of TG2 in ER/SR of H9c2 cells, 
which was more abundant in PMA and FK treated cells (Fig. 4.3.11). This is in 
agreement with more recent observation showing that the activation of TG2 was 
associated with the ER in differentiated SH-SY5Y cells. In addition, the accumulation 
of TG2 on the surface of ER membranes following exposure to MPP+ (1-methyl-4-
phenylpyridinium a toxic molecule can cause ATP depletion and cell death), 
suggesting its possible role in Parkinson's disease (Verhaar et al., 2012). Since 
mitochondria and sarcoplasmic reticulum have shown to have an important role in 
cardiomyocytes signaling (Maechler & Wollheim, 2001; Lukyanets & Lukyanetz, 
2013), it would be worth in future work to investigate TG2 activity in each fractions. 
The identification of the TG2 substrates in different organelles would help to establish 
the role of TG2 in cardiomyocyte. 
In conclusion, the results presented in this chapter of study have shown that TG2 
activity is also mediated by PKC/PKA and their G-protein coupled receptors in intact 
cells. In addition, they provided a strong evidence for a so far undetected, localisation 
of TG2 in the ER/SR, at least in cardiomyocyte cells. This suggests that activation of 
TG2 may have a direct influence on posttranslational modification of ER/SR proteins. 
However, the ER/SR and mitochondrial membranes have not been extensively 
characterised for cross contamination by other cellular structures and remains a 
limitation of this study.  
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CHAPTER V:  
PROTECTIVE ROLE OF TG2 IN THE 
CARDIOMYOCYTE RESPONSE TO OXIDATIVE 
STRESS 
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5. Introduction 
Oxidative stress is a term that can be used to describe an imbalance between the 
systematic production of reactive oxygen species (ROS) and the capability of a 
biological system to repair the resultant damage (Maritim et al., 2003). In cells or 
tissues, oxidative stress can either increase oxidizing species generation or 
significantly decrease antioxidant defences (Schafer & Buettner, 2001). Generally, the 
disruption of cellular homeostasis of redox state by pathogens or stress stimuli can 
cause toxic effects through the triggering of elevated ROS production (Giordano, 
2005). These are short-lived oxygen derived species and include peroxides and free 
radicals. These latter reactive species are responsible for damage to all of the cells 
components including DNA, proteins and lipids (Evans & Cooke, 2004).  
Superoxide is one of the less reactive species that can be also converted to more 
violent reactive oxidants by redox (reduction-oxidation) cycling compounds results in 
massive cellular damage (Valko et al., 2005). However, low concentrations of ROS 
can act as cell signalling molecules involved in protein synthesis. In contrast, at high 
levels, they can cause cell injury via inducing oxidation and lipid peroxidation of 
cardiac proteins, stimulating apoptosis (Kwon et al., 2003). Therefore, oxidative stress 
is able to interact with cellular signalling as well (Giordano, 2005). In addition, its 
effects on cells are dependent upon the level of toxic stress generated and the ability 
of the cells to overcome this perturbation. Under normal conditions, cells produce a 
low level of oxygen-derived species through normal aerobic metabolism and these are 
usually destroyed by normal cellular defence mechanisms. This may involve 
regeneration of antioxidant molecules either enzymatically by thioredoxin and 
thioredoxin reductase, or non-enzymatically by intracellular antioxidants such as the 
vitamins E, C, and β-carotene (Conrad et al., 2004). However, more severe oxidative 
stress can drive cells to death. For example, a modest oxidative stress can induce 
apoptosis, while strong stresses can result in necrosis by causing a significant 
reduction in ATP production that prevents the normal control of apoptotic cell death 
(Lennon et al., 1991; Lelli et al., 1998).  
Oxidative stress is suspected to contribute to the pathogenesis of numerous diseases.  
For example, production of ROS and reactive nitrogen in association with a reduction 
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of antioxidant activity and energy metabolism have been detected in 
neurodegeneration (Guidi et al., 2006). The accumulation of oxidative stress and 
mitochondrial dysfunction were reported as biomarkers for Alzheimer's disease and 
Parkinson's disease (Ramalingam & Kim, 2012). Oxidative stress is believed to be 
linked to certain cancers, in which it acts as a mutagen resulting in DNA damage and 
it can also suppress apoptosis, thus enhancing tumour cell proliferation and 
invasiveness (Halliwell, 2007).  
It is widely accepted that oxidative stress is linked to cardiovascular diseases through 
oxidation of small particles of lipoproteins, which are also used as a marker for 
coronary artery disease (Holvoet et al., 2001). These small particles of lipoproteins 
can be transported to the artery wall resulting in plaque formation, stopping blood 
flow and thus increasing the risk for atherosclerosis, heart attack , stroke, myocardial 
infarction and subsequently cardiac death (Carmena et al., 2004). Oxidative stress is a 
major component of ischaemia/reperfusion injury, as cells under the ischaemia-
reperfusion state prefer to convert the less reactive oxidants, such as hydrogen 
peroxide or nitric oxide, to more reactive species such as hydroxyl radicals or 
peroxynitrite (Wang & Zweier, 1996). This is due to the acidic and reducing 
environment associated with the ischaemia-reperfusion state that can result in the 
release of ferric and ferrous ions from metallo-proteins, which in turn can catalyse the 
less reactive oxidants to from more reactive species (Goswami et al., 2007). For the 
period of ischaemia-reperfusion, the increase in ROS level and extended intracellular 
free-radical system can lead to cellular damage. It has also been reported that ROSs 
are involved in alteration of cation homeostasis via membrane proteins that regulate 
lipid peroxidation and cation transport resulting in membrane permeability changes 
(Buja, 2005). Moreover, oxidative stress has been shown to be involved in eliciting 
the inflammatory response against ischaemia reperfusion through leukocyte activation 
(Granger et al., 1989; Kurose et al., 1999). An accumulation of evidence has 
implicated oxidative stress in many other cardiac diseases, including myocardial 
infarction (heart attack) (Jones et al., 2001), myocardial stunning (contractile 
dysfunction) (Lefer & Granger, 2000), and heart failure (Byrne et al., 2003). 
There is a strong relationship between TG2 overexpression and oxidative stress, 
which can result in either cell death or cell survival. This depends upon the cell type, 
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stress levels, the length of stress, as well as the TG2 location and its state of activation 
(Ientile et al., 2007; Iismaa et al., 2009). Both activation and up-regulation of TG2 has 
been detected in almost all of the neurodegenerative disorders in which oxidative 
stress is considered as a key factor. These include ischaemia, Huntington’s, 
Alzheimer’s and Parkinson’s diseases (Caccamo et al., 2004; Ruan & Johnson, 2007; 
Caccamo et al., 2010). In situ increased TG2 activity has been reported in response to 
H2O2 induced ROS activation in Swiss 3T3 fibroblasts (Lee et al., 2003). This 
activation was blocked in the presence of ROS scavengers such as N-acetyl-L-
cysteine (NAC) and cystamine (also a TG2 inhibitor). Since oxidative stress-induced 
ROS accumulation can cause either direct or indirect cell signalling cascades 
involving programmed cell death, researchers have focused on oxidative stress-
induced TG2 activation resulting in cell injury (Fesus & Szondy, 2005). It has been 
reported that during under stress stimuli, TG2 can differentially affect the cell’s 
response, driving it to either apoptosis or survival (Fesus & Szondy, 2005; Song et al., 
2011). The H2O2-induced oxidative stress in cardiomyocytes was shown to result in 
TG2 up-regulation, in correlation with an increase in the expression of apoptotic 
markers such as caspase-3, Bax and cytochrome C (Song et al., 2011). This suggested 
a role for TG2 in cardiomyocyte apoptosis in response to oxidative stress induced by 
ischaemic injury. However, the protective role of TG2 in cardiomyocyte apoptosis 
remains unclear.  
The protective role of PKA activation induced by FK against oxidative stress has been 
reported in neurones and the rat PC12 adrenal pheochromocytoma cell line (Kamata 
et al., 1996; Jin et al., 2010; Park et al., 2012). Similarly, the activation of PKC using 
PMA has a neuroprotective effect against H2O2-induced toxicity on rat hippocampal 
and cortical neuronal cells (Doré et al., 1999). Moreover, the activation of both PKC 
and the MAPK pathway with PMA seem to inhibit cell death induced by H2O2 in 
mutant (ST111/111Q) huntingtin striatal cells (Ginés et al., 2010). Thus, it is possible 
that both these protein kinase activators can induce cardioprotective effects against 
oxidative stress. Previous studies have shown that TG2 protects cardiomyocytes from 
ischaemia/reperfusion-induced injury (Szondy et al., 2006). Since PKC and PKA are 
two key mediators of ischaemic preconditioning and pharmacological preconditioning 
in cardiomyocytes (Yellon & Downey, 2003; Sanada et al., 2011). This study 
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investigated the role of TG2 in PMA and FK-induced cytoprotection against oxidative 
stress in H9c2 cells. 
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5.1. Aims 
The aim of the work in this chapter of the study was to determine whether TG2 played 
a role in PKC/PKA-mediated cardioprotection in H9c2 cells. The work focused on the 
effects of PMA/ FK induced cytoprotection against oxidative stress induced by H2O2 
and the activity of TG2. Furthermore, for comparison the effects of its inhibitors in 
these protective effects was were assessed.  
5.2. Methods  
As described in chapter 2 of this study (section 2.2). 
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5.3. Results 
The role of TG2 in PMA and FK-induced cytoprotection 
In order to study the involvement of TG2 in cardioprotection of H9c2 
cardiomyocytes, H2O2 was used to mimic schaemia-like stress, after pre-treatment 
with PMA and FK.  
5.3.1. The effect of the TG2 inhibitors on oxidative stress-induced cell death: 
PMA and FK-induced cytoprotection 
The H9c2 cells were pre-treated with or without PMA or FK for 5 min alone or in the 
presence or absence of 150 μM TG2 site specific inhibitor (Z-DON-Val-Pro-Leu-
OMe) for 1h followed by incubation with 600 μM H2O2 (Chanoit et al., 2011; 
Daubney et al.,  2014; Mao et al., 2014) for 2h as described in methods (section 
2.2.3.3 and fig. 2.1B). The lysed cells were subjected to biotin cadaverine 
incorporation assay as method described by Slaughter et al. (1992). The exposure of 
H9c2 cells to H2O2 caused an increase in TG2 catalysed biotin cadaverine 
incorporation activity but this was not a statistically significant increase (Fig. 5.3.1A). 
However, a significant increase was shown in samples pretreated with PMA but not 
with FK (n = 5, *P < 0.05). In contrast, the use of TG2 inhibitor (Z-DON) resulted in 
a significant reduction (n = 5, *P < 0.05 versus H2O2 and ** P < 0.01 versus 
PMA+H2O2) of the activation. However, using the protein crosslinking TG2 assay 
(Trigwell et al., 2004), H2O2 treatment in the presence of TG2 inhibitor caused an 
increase in TG2 cross linking activity compared to H2O2 treated cells (Fig. 5.3.1B). 
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Figure 5.3.1 The effect of the TG2 inhibitor on oxidative stress-induced cell 
death and PMA and FK-induced cytoprotection 
H9c2 cells were pre-treated with or without 150 μM TG2 inhibitor (Z-DON) for 1h 
and stimulated with either 1 µM PMA or 10 μM FK for 5 min alone or followed by 
induction of 600 μM H2O2 for 2h while, unstimulated cells was used as control. Cell 
lysates were subjected to A) biotin cadaverine incorporation assay and B) protein 
crosslinking assay. Data points represent the mean ± SEM TG2 specific activity from 
5 (a) or 6 (b) independent experiments. Data analysis was performed using 
"Bonferroni's multiple comparison test". Statistical significance was accepted at ** P 
< 0.01, *P < 0.05. 
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5.3.2. Endogenous in situ amine incorporation into intracellular H9c2 cell 
proteins following PMA/FK treatment and H2O2 exposure  
This activity was also measured in situ and visualised by TG2-meditated biotin-X-
cadaverine incorporation into protein in the presence of the TG2 inhibitor Z-DON. 
The results are shown below in Fig. 5.3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.2 Endogenous in situ labelling of intracellular H9c2 cell proteins by 
TG2 following PMA/FK treatment and H2O2 exposure  
Cells cultured in chamber slides were incubated with 1 mM biotin-X-cadaverine for 
4h. Cells were then treated either with 1 µM PMA or 10 μM FK alone or followed by 
exposure to 600 μM H2O2 for 2h in the presence or absence of 150 μM Z-DON while, 
unstimulated cells was used as control. The TG2 mediated biotin-X-cadaverine 
incorporation into intracellular proteins was visualised with Extravidin
®
-FITC 
(green). Nuclei were stained with DAPI (blue). The original magnification of the 
images was 400x.  The results are typical of 3 independent experiments.
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Cells in the chamber were incubated with 1 mM biotin-X-cadaverine for 4h. They 
were then treated with either 1 µM PMA or 10 μM FK alone or followed by the 
addition of H2O2 for 2h in presence or absence of 150 μM TG2 inhibitor. After 
fixation and permeabilisation, intracellular H9c2 proteins with covalently attached 
biotin-X-cadaverine as a result of PMA/FK-induced TG2 activity were visualised 
following incubation with ExtrAvidin–FITC using a florescence microscope (section 
2.2.9.2). TG2-mediated biotin-X-cadaverine incorporation was found to be 
predominantly associated with endogenous protein substrates in response to oxidative 
stress and PMA or FK/ pretreatment against this stress (Fig. 5.3.2). Pre-treatment with 
the TG2 inhibitor Z-DON prevented biotin-X-cadaverine incorporation (green) into 
the endogenous protein substrates of the cytoplasmic compartment and cytoskeletal 
elements. Thus, the presence of the TG2 inhibitor Z-DON in treated cells resulted in 
reduction of TG2 incorporation activity. As a result of this series of experiments, it 
was important to consider whether the TG2 inhibitors blocked PMA/FK induced 
cardioprotection. 
5.3.3. Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection of H9c2 against H2O2 determined by MTT and LDH assay 
To investigate the possible role of TG2 in cardioprotection of H9c2 cardiomyocytes, 
the effect of TG2 inhibitors in H9c2 cardiomyocyte cell death were tested. Cellular 
viability was determined by MTT reduction assay (section 2.2.21.1) and cytotoxicity 
was measured with LDH activity assay (section 2.2.21.2). H9c2 were pre-incubated 
either with or without 150 μM TG2 inhibitor (Z-DON) for 1h prior to 5 min treatment 
either with 1 µM PMA or 10 μM FK followed by 600 μM H2O2 for 2h.  
The results show that H2O2 can induce a significant reduction in cell viability (***P < 
0.001 versus untreated cells; Fig. 5.3.3A). Pretreatment of cells with either PMA or 
FK significantly reversed the H2O2-induced cell death (** P < 0.01 and *P < 0.05 
versus H2O2, respectively), TG2 inhibitor blocks this protection (*** P < 0.001 versus 
PMA+ H2O2, **P < 0.01 versus FK+ H2O2; Fig. 5.3.3A). Cytotoxicity was measured 
using the release of lactate dehydrogenase. H2O2 induced a significant release of LDH 
in the H9c2 medium (*** P < 0.0001 versus untreated cells). Pretreatment of cells 
with PMA and FK significantly reversed the H2O2-induced cell death (**P < 0.01 
153 
 
versus H2O2). TG2 inhibitor (Z-DON) blocked this protection (*P < 0.05 versus 
PMA+H2O2; Fig. 5.3.3B). However, Z-DON alone had no significant effect on H9c2 
cell viability either in the presence or absence of PMA and FK (Fig. 5.3.3C and D). 
 
A)  
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 H
2O
2
PM
A
 +
 H
2O
2
FK
+H
2O
2
H
2O
2+
Z-
D
O
N
PM
A
/H
2O
2+
Z-
D
O
N
FK
/H
2O
2+
Z-
D
O
N
0
20
40
60
80
M
T
T
 r
ed
u
ct
io
n
(%
C
on
tr
ol
 )
**
*
***
**
2O
2H
2O
2
PM
A
 +
 H
2O
2
FK
+H
+Z
-D
O
N
2O
2H
+Z
-D
O
N
2O
2
PM
A
/H
+Z
-D
O
N
2O
2
FK
/H
100
120
140
160
***
***
**
**
L
D
H
 (
%
C
on
tr
ol
)
154 
 
C
on
tr
ol
PM
A FK
C
on
+Z
-D
O
N
PM
A
+Z
-D
O
N
FK
+Z
-D
O
N
0
50
100
150
M
T
T
 r
ed
u
ct
io
n
(%
 C
on
tr
ol
)
C
on
tr
ol
PM
A Fk
C
on
tr
ol
+Z
-D
O
N
 P
M
A
+Z
-D
O
N
 F
K
+Z
-D
O
N
0
50
100
150
L
D
H
 (
%
 C
on
tr
ol
)
 
C) 
 
 
 
 
 
 
 
 
D) 
 
 
 
 
 
 
Figure 5.3.3 Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection of H9c2 against H2O2 determined by MTT and LDH assay 
H9c2 cells were pre-incubated with or without 150 μM TG2 inhibitor (Z-DON) for 1h 
prior to 5 min with either 1 µM PMA or 10 μM FK followed by 600 μM H2O2 for 2h 
while, unstimulated cells was used as control. A) Cell viability was determined by 
MTT assay. B) The release of lactate dehydrogenase was determined by LDH assay. 
H9c2 were pre-incubated with or without 150 μM TG2 inhibitor (Z-DON) for 1h 
prior of 5 min 1 µM PMA or 10 μM FK and cell viability was determined by either 
MTT assay (C) or LDH (D). Data points represent the mean ± SEM from 5 (A & B), 
4 (C) or 3 (D) independent experiments. Data analysis was performed using 
"Bonferroni's multiple comparison test" where the statistical significance was 
accepted at ***P < 0.001, ** P < 0.01 and *P < 0.05. 
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5.3.4. Effect of the TG2 inhibitor R283 on PMA and FK-induced cytoprotection 
of H9c2 cells against H2O2 determined by MTT assay 
For confirmation of the results in Figure 5.3.3, an irreversible, site specific TG2 
inhibitor 1,3,dimethyl-2-[(2-oxopropyl) thio] imidazolium chloride (R283; Freund et 
al., 1994) was used and cell viability was measured by MTT reduction assay and 
cytotoxicity was measured with LDH activity assay. The results are shown in Figure 
5.3.4 and they show that H2O2 induced a significant reduction in the cell viability 
(***P < 0.001 versus untreated control).  
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Figure 5.3.4 Effect of the TG2 inhibitor R283 on PMA and FK-induced 
cytoprotection of H9c2 against H2O2 determined by MTT assay and LDH assay 
H9c2 cells were pre-incubated with or without 200 μM R283 for 1h prior to 5 min 
with either 1 µM PMA or 10 μM FK followed by 600 μM H2O2 for 2 h while, 
unstimulated cells was used as control. A) Cell viability was determined by MTT 
reduction assay. B) The release of lactate dehydrogenase was determined by LDH 
assay. H9c2 cells were pre-incubated with or without 200 μM R283 for 1h prior to 5 
min of either 1 µM PMA or 10 μM FK and cell viability was measured by either MTT 
assay (C) or LDH (D). Data points represent the mean ± SEM from 4 (A & C), or 3 
(B & D) independent experiments. Data analysis was performed using "Bonferroni's 
multiple comparison test" where the statistical significance was accepted at ***P < 
0.001, ** P < 0.01 and *P < 0.05. 
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Pre-treatment of cells with PMA and FK significantly reversed the H2O2 can induce 
cell death (***P < 0.001,*P < 0.05 versus H2O2). The cell-permeable TG2 inhibitor 
(R283; Griffin et al., 2008) blocks this protection (***P < 0.001 versus PMA+H2O2, 
*P < 0.05 versus FK+ H2O2).  H2O2 induced a significant release of LDH in the H9c2 
medium (***P < 0.001 versus untreated (control) =100 %). Pre-treatment of cells 
with PMA and FK significantly reversed the H2O2-induced cell death (***P < 0.001 
versus H2O2). TG2 inhibitor (R283) blocks this protection (**P < 0.01 versus PMA+ 
H2O2 and FK+ H2O2; Fig. 5.3.4B). However, R283 alone had no significant effect on 
H9c2 cell viability ether in presence or absence of PMA and FK (Fig. 5.3.4C and D). 
5.3.5. Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection against H2O2 determined by cell morphological change 
To observe any  morphological change in the cells after oxidative stress induced by 
H2O2 and the effect of TG2 inhibitors (Z-DON) on cytoprotection by PMA and FK, 
Coomassie blue staining of living cell (Mochizuki & Furukawa, 1987) was 
performed. The H9c2 cells were exposed to different treatments stained Coomassie 
brilliant blue and morphological change were observed using an inverted light 
microscope at x 100 magnification as described previously (section 2.2.4). The 
morphological change was also monitored in cell culture as well (Fig.5.3.5B). 
As shown in Figure 5.3.5, typical cardiomyocytes presented stretched pseudopodia, 
connected to each other with cell junction and a confluent monolayer. When the cells 
were treated with 600 μM H2O2, the cardiomyocytes exhibited retracted pseudopodia 
and some vacuoles. Many of the cells could not attach to the surface, with granular 
material in the remaining cardiomyocytes. The extent of these morphological change 
was more evident in the cells treated with TG2 inhibitors. Cardiomyocytes pretreated 
with either PMA or FK showed slightly retracted pseudopodia and had less vacuoles 
compared with cells treated with 600 μM H2O2, which indicated that the oxidative 
damage of cardiomyocytes was reduced by PMA and FK, confirming a protective 
effect of this reagents (Fig. 5.3.5). 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.5  Morphological change of H9c2 cardiomyocytes  
A) H9c2 cells were pre-incubated with or without 150 μM Z-DON for 1h prior to 5 
min stimulation with either 1 µM PMA or 10 μM FK alone or followed by 600 μM 
H2O2 for 2h while, unstimulated cells was used as control. Cells were visualised either 
B) in culture or A) after staining with Coomassie blue. Morphological changes of 
cells were observed using an inverted light microscope at x 100 magnification and 
digital images were captured on a Canon PC 1200 camera. The results are typical of 3 
independent experiments.
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5.3.6. The effects of Z-DON and R283 on PMA and FK-induced ERK1/2 
activation 
The reversal of PMA and FK-induced cytoprotection by R283 and Z-DON may be a 
consequence of these TG2 inhibitors possessing PKC/PKA inhibitor activity. To 
address this important consideration, this study determined the effect of R283 and Z-
DON on PMA and FK-induced ERK1/2 activation. As shown in Figure 5.3.6, pre-
treatment of H9c2 cells with R283 (200 μM; 1h) had no significant effect on PMA or 
forskolin-induced ERK1/2 activation (Fig. 5.3.6C & D). Similarly, Z-DON (150 μM; 
1h) did not reverse PMA or FK-induced ERK1/2 activation. These data suggest that 
R283 and Z-DON do not function as inhibitors of PKC or PKA (Fig. 5.3.6A & B).  
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Figure 5.3.6 Effect of the TG2 inhibitors on PMA and FK-induced ERK1/2 
activation 
H9c2 cells were pretreated for 1h with (+) or without (-)TG2 inhibitors A) R283 (200 
μM) or C) Z-DON (150 μM) prior to 5 min stimulation with either PMA (1 µM) or 
FK (10 μM). Following PMA and FK exposure, cell lysates (50 μg per lane) were 
analysed by Western blotting for activation of ERK1/2 using a phospho-specific 
antibody. Samples were also analysed on separate blots using antibodies that 
recognise TG2 and GAPDH (to confirm equal protein loading). B and D) Quantified 
data are expressed as the percentage of control cell values and represent the mean  
SEM of 3 independent experiments. Data analysis was performed using "Bonferroni's 
multiple comparison test" where the statistical significance was accepted at ***P  
0.001, **P  0.01 and,*P  0.05.
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5.3.7. Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection against H2O2 determined by caspase-3 activity 
Since both TG2 inhibitors were shown to block the protective role of PMA and FK 
against H2O2-treated cells resulting in increased cell death, the activity of caspase-3 
which is an enzyme responsible for the induction of programmed cell death (Cohen, 
1997; Nicholson, 1999) was measured.  
The H9c2 cells were pre-treated either with or without PMA or FK for 5 min in either 
the presence or absence of 150 μM TG2 site-specific inhibitor Z-DON for 1h, 
followed by incubation with 600 μM H2O2 for 2h. The lysed cells were subjected to 
colorimetric caspase-3 assay (section 2.2.22) as described by Sordet et al. (2002). The 
exposure of H9c2 cells to H2O2 resulted in an increase in caspase-3 activity that was 
not statistically significant. However, Z-DON significantly decreased this activation 
(n = 5, *P < 0.05). Interestingly, a significant increase was shown in samples 
pretreated via PMA, but not FK (n = 5, *P < 0.05). In contrast, the use of Z-DON 
resulted in a reduction that was significant with FK+H2O2 (n = 5, *P < 0.05 versus 
H2O2), but not with PMA+H2O2 (Fig. 5.3.7A). Western blotting analysis of H9c2 cell 
extracts indicated that the levels of active caspase-3 were significantly increased in 
cells treated with H2O2 and pretreated with PMA but not FK (n = 3 *P < 0.05 versus 
untreated control); Fig. 5.3.7B & C). 
A) 
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Figure 5.3.7 Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection against H2O2 determined by caspase-3 activity 
H9c2 cells were treated with 1 µM PMA or 10 μM FK for 5 min followed by 600 μM 
H2O2 for 2h in presence or absence of 150 μM Z-DON. A 1 µM staurosporine-treated 
cells was used as positive control. A) pNA release correlated to caspase-3 activity was 
determined by colorimetric assay. B) The total protein extract (50 μg per lane) was 
resolved by SDS-PAGE and transferred on to nitrocellulose filters. Western blotting 
for caspase-3 was detected by rabbit anti-caspase-3 mAb and anti-GAPDH mAb was 
used as a control of the total amount of the collected protein. Data are expressed as 
the percentage of caspase-3 at basal level in the untreated cells (control). Values are 
means ± SEM of 5 (A) or 3 (C) independent experiments. Data analysis was 
performed using "Bonferroni's multiple comparison test" where the statistical 
significance was accepted at *P < 0.05, **P < 0.01.
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5.3.8. In situ analysis for caspase-3 activation in response to the TG2 inhibitor 
Z-DON on PMA and FK-induced cytoprotection against H2O2   
This activity was also measured in situ and visualised by active caspase-3 antibody 
probing of western blots from cells treated in the presence of the TG2 inhibitor Z-
DON.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.8 The detection of active caspase-3 in H9c2 treated cells 
Cells in chamber slides were treated either with 1 µM PMA or 10 μM FK alone or 
followed by addition of 600 μM H2O2 for 2h in the presence or absence of 150 μM Z-
DON for 1h. Cells treated with 1 µM staurosporine (STS) for 2h, were used as a 
positive control, while, unstimulated cells was used as control. Caspase-3 activity was 
detected by rabbit anti-active caspase-3 antibody mAb and visualised by red (anti-
rabbit-Alexa 568 secondary antibody). Nuclei were stained with DAPI (blue). The 
original magnification of the images was 400x. The results are typical of 3 
independent experiments.
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The results are shown in Fig. 5.3.8. Cells incubated in chamber slides were treated 
with either 1 µM PMA or 10 μM FK followed by induction of 600 μM H2O2 for 2h in 
presence or absence of 150 μM TG2 inhibitor. Cells treated with 1 µM staurosporine 
for 2 h were used as positive control. After fixation, permeabilisation and blocking, 
cell slides were incubated overnight at 4 °C with anti-active caspase-3 antibodies as 
shown in Fig. 5.3.8. The active caspase-3 was shown to be dominant in response to 
oxidative stress and less so in PMA or FK-pretreated cells (Fig. 5.3.8). The presence 
of TG2 inhibitor in treated cells resulted in a reduction of active caspase-3 staining.  
5.3.9. Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection against H2O2  determined by DNA fragmentation 
In order to confirm the possible role of TG2 in H9c2 cardiomyocytes protection, DNA 
fragmentation (section 2.2.23) was also investigated. DNA fragmentation (smeared 
bands) was observed in extracts from cells treated with H2O2 alone or in cells pre-
incubated with Z-DON (Fig. 5.3.9). 
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Figure 5.3.9 Effect of the TG2 inhibitor Z-DON on PMA and FK-induced 
cytoprotection against H2O2  determined by DNA fragmentation assay 
H9c2 cells were treated with 1 µM PMA or 10 μM FK for 5 min either alone or 
followed by 600 μM H2O2 for 2h in the presence or absence of 150 μM Z-DON for 
1h. A 1 µM staurosporine (STS)-treated culture was used as positive control while, 
unstimulated cells was used as control. DNA was then extracted and a mass of 30 μg 
extracted DNA was separated by electrophoresis in a 1.5 % (w/v) agarose gel and 
then visualized under UV light. The results are typical of 3 independent experiments.
 
5.3.10. The detection of TG2 protein level in H9c2 cells pre-treated with PMA 
and FK following H2O2 exposure  
In order to find out if there was a correlation between TG2 activity and TG2 protein 
level in H9c2 cells pre-treated with either PMA or FK following H2O2 exposure, TG2 
protein was detected after Western blotting. Western blotting analysis of H9c2 cell 
extracts indicated that the level of TG2 protein increased in the presence of PMA or 
FK, but this level did not show significant in change response to H2O2 alone or in 
cells pretreated with PMA but not FK (Fig. 5.3.10A & B) using the anti-TG2 mAb 
(CUB 7402). Densitometry results for protein quantification of FK treated H9c2 cells 
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following H2O2 exposure revealed strong significant increase (n = 3, P < 0.01) in TG2 
protein level that showed a significant decrease in presence of Z-DON. 
A)  
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
Figure 5.3.10 The detection of the TG2 protein level in H9c2 cells pretreated with 
PMA and FK following H2O2 exposure  
H9c2 cells were treated with or without 150 μM Z-DON for 1h. Cells were then given 
5 min with 1 µM PMA or 10 μM FK treatment either alone or prior to the addition of 
600 μM H2O2 for 2h. The total protein extract (50 μg per lane) was resolved by SDS-
PAGE and transferred onto nitrocellulose filters. A) Western blotting for TG2 by anti-
TG2 mAb (CUB 7402); anti-GAPDH mAb was used as a control of the total amount 
of the collected protein. B) Densitometry was carried using Adobe Photoshop CS4 
and the values were plotted as relative intensity versus different treatments. Data are 
expressed as the percentage of TG2 proteins at basal level in the untreated cells 
(control). Values are means ± SEM of 3 independent experiments. Data analysis was 
performed using "Bonferroni's multiple comparison test" where the statistical 
significance was accepted at *P < 0.05.
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5.3.11. The effect of Z-DON on survival proteins (pERK1/2 and pAKT) in H9c2 
cells pre-treated with PMA and FK before H2O2 exposure 
The effects of H2O2 and Z-DON on the activity of cell survival proteins such as 
pERK1/2 and pAKT were also investigated. Data presented in Figure 5.3.11 indicated 
that cells pre-treated with PMA and FK followed by H2O2 showed a significant 
increase in pERK (n = 3, P < 0.0001for PMA and P < 0.001 for FK) compared to 
control and H2O2 treated cells. In the presence of Z-DON these activation did not 
show any significant attenuation (Fig. 5.3.11A & B). However, pAKT showed a 
significant increase in cell pre-treated with PMA and FK prior to H2O2, which was 
also significantly decreased in presence of Z-DON (Fig. 5.3.11C & D). 
A) 
 
 
 
B) 
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Figure 5.3.11 The effect of Z-DON on survival proteins (pERK1/2 and pAKT) in 
H9c2 cells pre-treated with PMA and FK followed by H2O2 exposure 
H9c2 cells were treated either with or without 150 μM Z-DON for 1h. They were then 
incubated for 5 min with either 1 µM PMA or 10 μM FK alone or prior to the addition 
of 600 μM H2O2 for 2h. The total protein extract was resolved by SDS-PAGE and 
transferred onto nitrocellulose filters. A) Western blotting for anti-phospho-specific 
ERK1/2 mAb, C) anti-phospho-specific Akt where,  anti-GAPDH mAb was used as a 
control of the total amount of the collected protein. B) and D) Densitometry was 
carried using Adobe Photoshop CS4 and values plotted as relative intensity versus the 
different treatments. Data are expressed as the percentage of proteins at basal level in 
the untreated cells (control). Values are means ± SEM of 3 independent experiments, 
Data analysis was performed using "Bonferroni's multiple comparison test" where the 
statistical significance was accepted at *P < 0.05, **P < 0.01, ***P < 0.001. 
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5.4. Discussion 
The data presented in this study provides provide evidence that the activity of TG2 is 
modulated in H9c2 cells by PMA and FK and in turn, this seems to have an 
involvement in the protection of H9c2 cells against oxidative stress.   
Transglutaminase 2 (TG2) has been suggested to be involved in many pathologlogical 
condition including neurodegenerative disorders, cardiac-vesicular diseases some 
cancers and coeliac disease (Verma et al., 2008). It has also been shown to protect 
mouse cardiomyocytes against ischaemia and reperfusion-induced cell death by 
regulating ATP synthesis (Szondy et al., 2006). Protein kinase C (PKC) and PKA 
have been shown to be modulators of ischaemic preconditioning (IPC) and 
pharmacological preconditioning (PPC) in cardiomyocytes of different animals 
(Yellon & Downey, 2003). In the previous chapters, the results of this study have 
shown that the activity of TG2 is modulated in H9c2 cells treated with either PMA or 
FK. Moreover, this was confirmed by an in situ assay in the presence of TG2 
inhibitors. In this chapter, the possible role of TG2 in cytoprotection against oxidative 
stress was also investigated for comparison.  
Hydrogen peroxide (H2O2) has been widely used to induce oxidative stress in order to 
mimic the condition of ischaemia-reperfusion injury in cardiac cells (Kurose et al., 
1999). Oxidative stress has been shown to contribute to the pathogenesis of numerous 
cardiovascular diseases, including ischaemic heart disease (Wang & Zweier, 1996), 
atherosclerosis heart attack, stroke (Carmena et al., 2004), heart failure and sudden 
cardiac death (Byrne et al., 2003). In this study, a concentration of H2O2 has been 
optimised by our lab group and significant death has been observed in H9c2 cells at 
this concentration (600 µM) (Daubney et al., 2014). Similarly, another study by Mao 
et al. (2014) has shown that the ranges of H2O2 concentration 200-1000 µM are able 
to induce-oxidative stress in H9c2 cells result in mitochondrial dysfunction and 
apoptosis (Mao et al., 2014). In addition, the pre-treatment of cells by Levocarnitine 
has shown to reverse this effect and protect H9c2 cells (Mao et al., 2014).  In addition, 
600 µM of H2O2 has shown to induce mitochondrial permeability transition pore 
(mPTP) opening in H9c2 cells (Chanoit et al., 2011). Therefore, this concentration has 
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been adapted to induce oxidative stress in H9c2 to study effect of the TG2 inhibitor 
on oxidative stress-induced cell death and PMA and FK-induced cytoprotection. 
The activation of in situ TG2 activity following oxidative stress induced either by 
H2O2 or UV irradiation has been reported in human lens epithelial cells (HLE-B3; 
Shin et al., 2004). The present data show that oxidative stress is induced in H9c2 cells 
by 600 µM H2O2. In turn, this results in stimulation of TG2 biotin cadaverine 
incorporation activity in the in situ (Fig. 5.3.2) and in vitro assays but not significantly 
as in the later (Fig. 5.3.1A). However, it did not stimulate protein crosslinking activity 
(Fig. 5.3.1B). Indeed, it has been reported that oxidative stress via H2O2 could not 
elevate in vitro TG activity as this depends on the cell type and the existence of 
specific cellular factors (Shin et al., 2004; Park et al., 2010). However, when the 
oxidative stress was induced followed by pre-treatment with PMA, but not FK, there 
was a statistically significant increase in TG2 catalysed biotin cadaverine 
incorporation both in vitro (Fig. 5.3.1A) and in situ with both treatments (Fig. 5.3.2). 
In contrast, treatment with the TG2 inhibitor (Z-DON) resulted in a reduction of this 
activation in vitro (Fig. 5.3.1) and in intact H9c2 cells (Fig. 5.3.2). This suggested that 
this the activity was due to activation of endogenous TG2 in H9c2 cells.  
The level of TG2 protein increased in the presence of with PMA or FK, but this level 
did not show a significant increase in response to H2O2 alone or in pretreatment by 
PMA, but not FK (Fig. 5.3.10A & B). This confirms the previous suggestion by Shin 
et al., (2004) that there is no correlation between TG2 protein level and its activity 
(Jeon et al., 2004). Although in this study, no correlation has been observed between 
TG2 protein level and its in vitro activity in the presence of H2O2, there was a 
correlation between TG2 protein level and its in situ activity (Fig. 5.3.2). This is in 
disagreement with a previous observation in SH-SY5Y neuroblastoma cells treated 
with retinoic acid that showing correlation between TG2 protein level and in vitro but 
not in situ activity (Zhang et al., 1998). However, these opposing views could be due 
to the fact that the level of TG2 activation depends upon cell and stress types (Shin et 
al., 2004). Until now, the molecular mechanism (s) by which intracellular TG2 is 
regulated is not clear. While some TG family members have been reported to have a 
proteolysis site that activates the intracellular enzymes (Lorand & Graham, 2003), no 
proteolytic activation has been reported in TG2 regulation (Jeon & Kim, 2006). 
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However, phosphorylation of TG2 by PKA has been reported (Mishra et al., 2007) 
TG2-SUMOylation (SUMO is small ubiquitin-like modifier that covalently attaches 
to and detaches from cellular proteins altering their functions) in response to oxidative 
stress increases its proteins level and enhances its activity in CF airway epithelial cells 
(Luciani et al., 2009). In this study, therefore, it is possible that TG2 is regulated by 
posttranslational modification by these kinase activators. This may explained the 
reduction of TG2 protein level by Z-DON, when the oxidative stress was induced in 
cells pre-treatment with FK (Fig. 5.3.10A & B). This reduction could be either due to 
reduction in its protein levels itself or due to phosphorylation by PKA that alter the 
binding of anti-TG2 mAb to its target results in reduction in band intensity. Further 
study is needed it to investigate if the anti-TG2 mAb showed differential binding in 
the presence or absence of a posttranslational modification of TG2. 
To investigate the possible role of TG2 in the cytoprotection of H9c2 cardiomyocytes 
to oxidative stress, the effect of TG2 inhibitors in H9c2 cardiomyocyte cell viability 
were tested. Lactate dehydrogenase is an enzyme widely expressed in mammalian 
cells and commonly used as marker for cell damage (Cho et al., 2008). This enzyme is 
not released from the cytoplasm under normal physiological conditions. Thus, it is an 
ideal enzyme for measurement of cellular cytotoxicity as a consequence of membrane 
insult (Cho et al., 2008; Kim et al., 2009). Thus, the release of LDH into H9c2 cell 
culture medium can reflect the amount of damage occurring in the presence of H2O2. 
The present results here indicated that H2O2 can induce a significant decrease on in 
H9c2 cell viability as shown by inhibition of MTT reduction (Fig. 5.3.3A) and a large 
release of LDH into the culture medium (***P < 0.001 versus untreated control) (Fig. 
5.3.3B). This in agreement with many studies that used a similar concentrate of H2O2 
in this cell lines (Chanoit et al., 2011; Daubney et al.,  2014; Mao et al., 2014), 
Pretreatment of cells with PMA and FK reversed the H2O2-induced cell death. This 
may be due to the ability of PMA to directly activate PKC and mimic ischaemic 
preconditioning in reperfusion heart (Kuno et al., 2007; Liu et al., 2008). Thus, it may 
be generating a signalling cascade that reverses the cell injury induced by oxidative 
stress. Treatment with the TG2 inhibitors Z-DON or R283 (Griffin et al., 2008), 
significantly blocked this protection against LDH release (Fig. 5.3.4). These results 
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indicate a significant role for TG2 in modulating both PKC and PKA signalling and 
its protective effect through this signalling pathway.  
The recommended IC50 for Z-DON to be cell permeable is 50 μM. However, in the 
current study used a higher concentration (150 μM) of Z-DON because lower 
concentrations were not able to block TG2 activity (Fig. 4.3.4A). Therefore, this study 
considered that this dose might result in cell death, as had been reported in a 
Huntington’s disease (HD) transgenic model where high concentrations of Z-DON 
mainly above 80 μM were shown to be associated with toxicity in some cells 
(Schaertl et al., 2010). Another study, on the other hand, has used 125 µM Z-DON in 
food given to fruit flies (Drosophila model of HD) which, showed a ~80 % decrease 
in TG activity with no obvious toxic effects (McConoughey et al., 2010). Cell 
viability was also measured with Z-DON and R283 alone or in presence of PMA and 
FK. The result indicated that 150 μM of Z-DON had no significant effect on H9c2 
cell viability either in presence or absence of PMA and FK (Fig. 5.3.3C). This 
observation could be due to the cell type and the cytotoxicity assay that has been used. 
Similar observations were made with 200 μM R283 (Fig. 5.3.4C) and this is 
consistent with evidence that R283 ranging from 50-250 μM has no effect on viability 
of human SH-SY5Y neuroblastoma cells (Beck et al., 2006).  
The cell morphology changes after oxidative stress induced by H2O2 and the effect of 
TG2 inhibitors (Z-DON) on cytoprotection by PMA and FK was observed. The 
stretched pseudopodia and connected cells that are usually observed in normal H9c2 
cells were retracted, disconnected and many granular materials and vacuoles were 
formed when the cells were exposed to 600 μM H2O2 (Fig. 5.3.5). However, these 
effects were attenuated by PMA and FK and were more pronounced in the presence of 
the TG2 inhibitor Z-DON. This observation has indicated an important role of TG2 in 
modulating PMA and FK inducing cytoprotection against oxidative stress. 
DNA fragmentation is a characteristic phenomenon of cell undergoing apoptosis. 
Moreover, it can be generated by activation of caspase activated DNase (CAD) by 
caspase-3 (Enari et al., 1998). DNA fragmentation and caspase activation induced by 
oxidative stress have been already detected in H9c2 cells under oxidative stress 
(Turner et al., 1998). The using of agarose gel electrophoresis for DNA fragmentation 
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detection is a common method in apoptotic cells due to simplicity and feasibility 
(August & Kaufmann, 1997). However, the method is limited by DNA recovering and 
thus it requires a high amount of cells to allow DNA to be detectible, these makes the 
method less sensitive and only qualitative (Collins et al., 1992; Gavrieli et al., 1992). 
In the current study, the DNA fragmentation was shown as a smear band but not as a 
laddering in cells when exposed with H2O2 alone and in cells pre-incubated with Z-
DON (Fig. 5.3.9). Indeed, this could be either due to unsufficient DNA recovery or 
due to DNA fragmentation at an earlier time point and appeared as DNA smearing 
associated with necrosis (Portera-Cailliau et al., 1995).   
Since caspases are enzymes responsible for the induction of cell death by apoptosis 
(Cohen, 1997; Nicholson, 1999), caspase-3 activity and its proteins level were 
investigated. The exposure of H9c2 cells to H2O2 resulted in an increase in caspase-3 
activity, although this was not statistically significant. However, the TG2 inhibitor Z-
DON significantly decreased this activation. Interestingly, a significant increase was 
shown in pretreatment via PMA, but not FK. In contrast, the use of Z-DON resulted in 
a reduction in caspase activation that was significant compared with FK+H2O2, but 
not PMA+H2O2 (Fig. 5.3.7A). Both immunoblotting and immunohistochemistry 
analyses of H9c2 cells indicated the presence of active caspase-3 when treated with 
H2O2 and pretreated with either PMA or FK. Active caspase-3 was shown to be 
predominant in response to oxidative stress and less in PMA or FK/ pretreated cells 
(Fig. 5.3.8). The presence of TG2 inhibitor in treated cells resulted in reduction of 
caspase-3 activation. Indeed, a recent study in rat neural cells has revealed that 
caspase-3 activation acts as downstream event of ischaemic preconditioning in 
parallel with CAD, in which preconditioning intervenes to prevent apoptotic cell 
death (Tanaka et al., 2004). Another study referred that activation of caspase-3 and 
some elements that are normally associated with cell death, such as ROS, are essential 
in neuroprotection for up-regulation of the protective protein HSC70 (McLaughlin et 
al., 2003). Furthermore, they suggested that the activation of caspase-3 in 
preconditioning was prevented from eliciting cell death. Therefore, the blocking of 
this activation might prevent protective proteins from being synthesised. Moreover, it 
could be possible that the complete inhibition of caspase-3 in cells treated with Z-
DON (TG2 inhibitor) results in a shift of cells death from apoptosis to necrosis, as 
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previously reported in ATP depletion stimulated B lymphocyte apoptotic cell death 
(Lemaire et al., 1998). 
The effect of H2O2 and Z-DON on survival proteins such as pERK1/2 and pAKT 
were also investigated. The activation and phosphorylation of ERK1/2 and AKT are 
crucial for survival signalling associated with cardioprotective mechanism (Kilter et 
al., 2009; Kim et al., 2012). The present results indicated that cells pretreated with 
either PMA or FK alone or in the presence of H2O2 showed significant increase in 
pERK compare to control and H2O2 treated cells (Fig. 5.3.11A & B). In the presence 
of Z-DON this activation did not show significant attenuation. However, pAKT 
showed a significant increase in cells pretreated with PMA and FK in presence of 
H2O2 that was also significantly decreased in the presence of Z-DON (Fig. 5.3.11C & 
D). These results suggest that PMA and FK can activate AKT signalling under H2O2 
induced oxidative stress and that TG2 plays a role in this protective effect, as 
confirmed by the reversal of this effect in the presence of Z-DON. 
Although the data failed to shows apoptosis and conventional DNA fragmentation 
ladder, the cell death was evident by MTT, LDH and by morphological change data. 
Thus, the results of this chapter clearly suggest that TG2 activity can be regulated via 
PKC and PKA-dependent signaling. Nonetheless, TG2 activity modulates PMA /FK- 
has cytoprotection effect against oxidative stress induced by H2O2 suggesting a cell 
survival (protective) role for TG2 in H9c2 cells through these signalling. 
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CHAPTER VI:  
IDENTIFICATION OF TG2 SUBSTRATES IN H9c2 
CELLS 
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6. Introduction 
Transglutaminase 2 (TG2) is widely expressed in certain mammalian tissues and has 
been shown to possess many enzymatic function. For example, it is able to catalyse a 
transamidating, a deamidating, GTP-binding/hydrolyzing activity, an intrinsic kinase 
and isopeptidase activities (Griffin et al., 2002; Mishra & Murphy, 2004). Therefore, 
it has been assigned in many fundamental biological processes including proliferation, 
differentiation and apoptosis (Aeschlimann & Paulsson, 1994; Griffin et al., 2002). 
The first suggestion of the involvement of TG2 activity in cellular apoptosis was 
observed in rat liver with hyperplasia inducing cell death (Fesus et al., 1987). The 
crosslinking activity of TG2 is thought to be responsible in stabilising dying cells 
through the formation of intracellular crosslinked protein structures, which prevent 
leakage of apoptotic cell components (Fesus & Szondy, 2005), thus inhibiting the 
inflammatory response. In addition, the presence of TG2 outside the cell has 
implicated it in the formation and repair of extracellular matrix (Aeschlimann & 
Thomazy, 2000). Transglutaminase 2 has also been reported to be involved in cell 
adhesion and the migration of monocytic cells through fibronectin matrices during 
inflammation (Akimov & Belkin, 2001a). The involvement of TG2 in signal 
transduction through α1-adrenergic receptors has also been reported (Nakaoka et al., 
1994) where it has been implicated in the protection of mouse hepatocytes against 
Fas-mediated cell death (Sarang et al., 2005). In addition, TG2 can also modify 
specific proteins through its catalytic action that incorporates polyamines into acyl-
donor substrates. This catalytic action can alter the structure and function of specific 
proteins or kinases thus, triggering cascades. An example includes, TG2 catalysed 
polyamine incorporation of spermine and spermidine into the neurotransmitter peptide 
substance P, providing enriched resistance to proteases action in vitro (Esposito et al., 
1999). A similar polyamination reaction has also shown to be responsible for inducing 
cell death in human vascular and melanoma cells (Facchiano et al., 2001). Moreover, 
TG2 has been reported to mediate the polyamination of human and rat vasoactive 
intestinal peptide (VIP), enhancing its ability to bind to and activate pituitary adenylyl 
cyclase activating peptide receptor (VPAC1), which is an important hypophysiotropic 
hormone acting as a neuromodulator (De Maria et al., 2002). 
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Recently, TG2 was found to be implicated in a wide variety of pathological states 
such as coeliac disease, inflammation, cancer, fibrosis, neurodegenerative disorders 
e.g. Alzheimer’s and Huntington’s diseases (Cooper et al., 2002; Kim et al., 2002). In 
human cardiovascular pathology, the induction of TG2 activity enhanced cell matrix 
crosslinking causing vascular stiffening in aging (Santhanam et al., 2010). In 
cardiomyocytes, TG2 knockout mice display sensitivity to ischaemia/reperfusion 
injury compare to wild type mice in correlation with a significant decrease in ATP 
(Mastroberardino et al., 2006; Szondy et al., 2006). Furthermore, this research group 
has found that adenine nucleotide translocator 1 (ANT1) can act as a TG2 substrate 
for its protein crosslinking activity, thus modulating mitochondrial ADP/ATP 
exchange in apoptosis (Malorni et al., 2009). Elafin also known as trappin is a TG2 
extracellular substrate (Schalkwijk et al., 1999) and the TG2 crosslinking activity 
results in aggregation of this substrate and the formation of plaques in atherosclerotic 
human coronary artery (Sumi et al., 2002).  
Another TG2 substrate and possibly related to cell fate is RhoA, which is a member of 
the Ras superfamily of G-proteins, plays a significant role in cell growth and actin 
cytoskeleton regulation. In vivo TG2 can modulate the transamidation of RhoA 
induced by retinoic acid, stimulating stress fibre and focal adhesion complex 
formation in HeLa cells (Singh et al., 2001). RhoA has also been shown to promote 
cytoskeleton rearrangement and activation of the MAP kinase pathway in SH-SY5Y 
neuroblastoma cells induced to differentiate by retinoic acid (Singh et al., 2003).  
Recently, TG2 activity was shown to be associated with the inward remodelling of 
smooth muscle cells therefore the extracellular protein that may act as TG2 substrates 
were investigated (van den Akker et al., 2011). Transglutaminase 2 activity was 
stimulated by DTT in smooth muscle cells, while TG2 substrates were labelled with 
the amine donor biotin cadaverine. This was analysed by mass spectrometry for 
identification of labelled proteins. Collagen, fibulin-2 and nidogen-1 were identified 
as glutamine donors for transamidation activity of TG2 in these smooth muscle cells 
(van den Akker et al., 2011).   
TG2 is capable of catalysing the incorporation of polyamines into a wide range of 
substrates including proteins, peptides, mono- and polyamines and nucleotides. Thus, 
identification of these substrates is of critical importance in understanding the role of 
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TG2 in cell physiological function and in disease states (Esposito & Caputo, 2005). In 
addition, the identification of theses substrates may have a significant impact on 
resolving the complexity of this multifunctional enzyme in cardiomyocytes and 
provide a guide for new diagnostic markers and drug targets in heart disease. 
Many approaches have been developed for the detection and identification of TG 
substrates. An indirect method for recognizing substrates is the detection of protein 
crosslinking using SDS-PAGE and Western blotting, and inhibition of protein 
crosslinking with amines or incorporation of glutamine-rich peptides (Butler & 
Landon, 1981; Groenen et al., 1992; Lajemi et al., 1997). The labelling of TG 
substrates with radioactive amines, FITC-cadaverine and biotinylated glutamine-
containing peptides have been used to identify TG substrates both in vitro and in vivo 
(Nemes et al., 1997; Csosz et al., 2002). These detection methods can be also 
validated by utilising the in situ assay in which biotinylated amines or glutamine-
containing peptides are used to localise different substrates within the organelles of 
cells. This strategy can be used in conjunction with affinity chromatography for the 
isolation of substrates followed by identification of the labelled TG-reactive protein 
using mass spectrophotometry. This approach has been applied in placenta and has 
yielded information on TG2-catalyzed posttranslational modification of specific 
proteins or peptides e.g. actin, annexin, integrins alpha V/alpha IIb and monoamine 
oxidase type A (Robinson et al., 2007). 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is one of the most 
commonly used proteomics techniques to separate proteins according to their 
variation in isoelectric point (pI) and their molecular weights. This separation method 
is carried out in two dimensions, the first of which separates proteins by isoelectric-
focussing, whereas the second dimension uses SDS-PAGE to separate polypeptides 
according to their relative molecular mass. Using these methods, a thousand different 
proteins in a lysate sample can be characterized, separated, resolved, and detected 
(Issaq & Veenstra, 2008). Various staining method can then be applied to visualise 
the separated proteins by probing the protein itself using different dyes such as, 
Coomasse blue and silver stain. This approach has also been applied to verify TG 
substrates in bone (Kaartinen et al., 2002). 
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Together, with developments in mass spectrometry techniques and software tools, the 
identification of proteins from complex mixtures of biological origins becomes more 
stringent and accurate. There are two approaches for characterizing the proteins either 
by ionization of whole proteins via matrix-assisted laser desorption/ionization 
(MALDI) or electrospray ionization (ESI) and then analysed by mass spectrometry 
(Preisler et al., 2000). This approach is known as a “top-down” protein analysis 
strategy. The other approach is a “bottom-up” proteomic strategy, in which proteins 
are digested by protease enzyme such as, trypsin to generate smaller peptides then 
they are also introduced to a mass spectrometry and thus identification can be done 
using peptide mass fingerprinting or tandem mass spectrometer through database 
comparison (Henzel et al., 1993). The MALDI time-of-flight (MALDI-TOF) 
instrument is commonly used in peptide mass analysis. 
Since TG has been shown to be having pathological and protective roles in different 
diseases, it is essential to have a better insight in TG2 substrates, target sites and 
interacting proteins, which may act as novel drug targets or new diagnostic markers. 
Thus, this chapter is focused on detection of TG2 substrates in response to PMA and 
FK and their protective effect against H2O2-induced stress. The fractionation of acyl-
donor TG2 substrate proteins was analysed in H9c2 cells, using a pull down assay 
followed by protein separation in 1D/2D PAGE, and subsequent analysis by Western 
blotting and immunoprobing techniques. Subsequently, identification of target 
substrates by MS-MALDI was performed. In some cases, TG2 activity was also 
confirmed by immunofluorescence staining techniques.  
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6.1. Aims 
The main aim of the work in this chapter was to identify and fractionate acyl-donor 
TG2 substrates in H9c2 cardiomyocytes. The work focused on detection of TG2 
substrates in response to PMA and FK and their protective effect against H2O2-
induced cytotoxicity.  
 
6.2. Methods  
As described in chapter 2 of this study (section 2.2). 
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6.3. Results 
6.3.1. Identification of proteins that serve as substrates for TG2 
6.3.1.1. Detection of TG2 activity and protein substrates following PMA and 
FK exposure in the presence and absence of TG2 inhibitor 
To detect TG2 protein substrates and activity in PMA and FK treated cells, equal 
amounts of whole cell extract proteins from control and stimulated cells were resolved 
by SDS-PAGE and transferred onto nitrocellulose membrane filters. Proteins 
conjugated with biotin-X-cadaverine by in situ TG2 activity were visualized by 
probing with ExtrAvidin
®
-peroxidase. The acyl-acceptor probe biotin cadaverine was 
incorporated into endogenous protein substrates of TG2 in H9c2 cells as described in 
Material and Methods (section 2.2.17). 
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Figure 6.3.1 Detection of TG2 activity and protein substrates following PMA and 
FK exposure in the presence and absence of Z-DON  
H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine for 4h. They were then 
treated with 150 μM Z-DON for 1h prior to either 1 µM PMA or 10 μM FK 
treatments for 5 min. The total protein extract (50 µg) was resolved by SDS-PAGE 
and transferred on to nitrocellulose membrane filters. A) TG2 transamidating activity 
and protein substrates were detected with ExtrAvidin
®
-peroxidase. Anti-GAPDH 
mAb was used as a control of the total amount of cellular protein. The arrows point to 
the changed proteins. B) Densitometry was carried out in Adobe Photoshop CS4 and 
the values were plotted as relative intensity versus the treatments. Data are expressed 
as a percentage of TG2 substrate proteins at basal level in the untreated cells (control) 
after GAPDH normalisation. Values are means ± SEM of 3 independent experiments. 
Data analysis was performed using "Bonferroni's multiple comparison test" where the 
statistical significance was accepted at * p<0.05 and **p < 0.01. 
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The results in fig. 6.3.1 show elevated biotin-X-cadaverine incorporation into 
numerous proteins in PMA and FK-stimulated compared to untreated control H9c2 
cells, with molecular weights ranging from ~25 to 200 kDa and higher molecular-
masses sometimes observed. (n = 3, *p < 0.05; Fig. 6.3.1B & A, lane 3 & 4). The 
biotin cadaverine labelled proteins also showed reduced biotinylation in the presence 
of the TG2 inhibitor Z-DON (n = 3, **p < 0.01; Fig. 6.3.1B & A, lane 6 and 7).  
6.3.1.2. Detection of TG2 protein substrates following PMA/FK treatment and 
H2O2 exposure 
To detect biotinylated TG2 substrate proteins following PMA/FK treatment and H2O2 
exposure, an equal amounts of protein extracted from whole cells were resolved by 
SDS-PAGE and transferred onto nitrocellulose membrane filters. Proteins conjugated 
with biotin-X-cadaverine by in situ TG2 activity were visualized by probing with 
ExtrAvidin
®
-peroxidase. The acyl-acceptor probe biotin cadaverine was incorporated 
into endogenous protein substrates of TG2 in H9c2 cells.  
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Figure 6.3.2 Detection of TG2 protein substrates following PMA/FK treatment 
and H2O2 exposure 
H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine for 4h then treated 
with or without 150 μM Z-DON for 1h. They were then treated for 5 min either with 1 
µM PMA or 10 μM FK prior to the addition of 600 μM H2O2 for 2h. The total protein 
extract (50 µg) was resolved by SDS-PAGE and transferred onto nitrocellulose filters. 
A) TG2 transamidating activity and protein substrates were detected with 
ExtrAvidin
®
-peroxidase. Anti-GAPDH mAb was used as a control of the total amount 
of cellular protein. The arrows point to the changed proteins. B) Densitometry was 
carried out in Adobe Photoshop CS4 and values were plotted as relative intensity 
versus the treatments. Data are expressed as a percentage of TG2 substrate proteins at 
basal level in the untreated cells (control). Values are means ± SEM of 3 independent 
experiments. Data analysis was performed using "Bonferroni's multiple comparison 
test" where the statistical significance was accepted at *p < 0.05, **p <0.01 and ***P 
< 0.001.
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The results in fig. 6.3.2 show biotin cadaverine incorporation into numerous proteins 
in H9c2 cells, which was elevated in response to either PMA or FK-induced 
cytoprotection against H2O2 stress compared to untreated cells (control)  (n = 3, *P < 
0.05; Fig. 6.3.2B & A, lanes 4 & 5). The labelling of proteins was reduced in the 
presence of the TG2 inhibitor Z-DON (n = 3, *P < 0.05 versus H2O2, **P < 0.01 
versus PMA+ H2O2, ***P < 0.001 versus FK+ H2O2; Fig. 6.3.2B & A, lane 6-8). A 
similar banding pattern of biotin-cadaverine labelled proteins to that observed in 
response to PMA or FK alone (Fig. 6.3.1) was found in cells treated with either PMA 
and FK followed by H2O2 insult. 
6.3.2. Fractionation and identification of acyl-donor (Gln-donor) TG2 substrate 
proteins 
To isolate TG2 substrate proteins after treatment by either PMA or FK, the biotin-
cadaverine labelled target proteins in treated H9c2 cells were captured with 
CaptAvidin beads as described in Materials and Methods (section 3.9 and figure 
2.2.2) and subjected to SDS-PAGE on a 4-15 % polyacrylamide gradient gel and 
visualised by Coomassie Blue-stain.  
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Figure 6.3.3 TG2-mediated labelling after PMA and FK treatments in H9c2 cells 
with the acyl-acceptor probe (biotin-X-cadaverine) 
The treated H9c2 proteins were fractionated on CaptAvidin beads, equal amounts of 
bound (right panel) and unbound materials (left panel) were loaded onto 4-15 % 
gradient gels stained with Coomassie Blue-stain. The arrows indicate excised bands 
that were selected for protein identification. The lanes in right panel represented, 
ladder (lane 1), total cell lysate (lane 2), control untreated cells (lane 3), PMA treated 
cells (lane 4) and FK treated cells (lane5). The lanes in left panel represented, ladder 
(lane 1), CaptAvidin captured cell lysate (lane 2), control untreated cells (lane 3), 
PMA treated cells (lane 4) and FK treated cells (lane5). The results are typical of 4 
independent experiments.
 
Figure 6.3.3 shows a biotinylated and non-biotinylated fraction of TG substrates 
detected in PMA/ FK H9c2 treated cells. Many proteins were detected and differences 
were shown compared to control. It was clear that CaptAvidin beads selectively 
isolated and captured biotin-X-cadaverine labelled proteins since the large number of 
bands that appeared in whole cell lysate seemed to disappear from the non-
biotinylated (supernatant) fractions (Fig. 6.3.3). These missing bands were recovered 
in the eluted fraction and represent biotin cadaverine labelled substrates (Fig. 6.3.3). 
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There were less biotin-cadaverine labelled products remaining in the supernatant and 
wash fractions when they were analysed by Western blotting and probed with 
ExtrAvidin
®
-peroxidase (see appendix Fig. 8.4).  
6.3.3. Detection of TG2 substrate protein in PMA treated H9c2 cells using 2D-
PAGE 
In order to gain a better resolution of TG2 substrate proteins in response to PMA 
treatments, biotin-X-cadaverine labelled proteins in PMA treated cells were 
fractionated on CaptAvidin beads, then subjected to 2D-PAGE (section 2.2.14) and 
visualised by either silver stain (section 2.2.16)  or by Western blotting.  
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Figure 6.3.4 Detection of TG2 substrate proteins in PMA treated H9c2 cells by 
2D-PAGE 
For the first-dimension of isoelectric focusing protein was loaded onto immobilized 
pH gradient (IPG) strips with a pH range of 3 to 10. After subsequent SDS-PAGE in 
the second dimension, the proteins were fixed and visualized using silver staining kit. 
A) 2D-PAGE of total proteins (50 µg) after biotin-X-cadaverine labelling in untreated 
H9c2 cells (left panel) and PMA-treated H9c2 cells (right panel). B) Biotinylated 
control and PMA treated H9c2 proteins isolated with CaptAvidin beads. The results 
are typical of 5 independent experiments.
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In the current study, the 2D-PAGE technique was used to investigate the activity of 
TG2 in response to PMA in H9c2. On silver stained gels, many protein spots were 
detected and differences were shown compared to control (Fig. 6.3.4). However, it 
was clear that CaptAvidin beads were selectively isolating and capturing biotin-X-
cadaverine labelled protein since the amount and profile of protein spots that were 
present before CaptAvidin fractionation (Fig. 6.3.4A) changed dramatically after 
CaptAvidin fractionation (Fig. 6.3.4B).  
These captured proteins that resolved by 2D-PAGE were also analysed by Western 
blotting and detected with ExtrAvidin
®
-peroxidase (Fig. 6.3.5). The results of 
Western blotting revealed that many protein spots showed increased intensity in 
response to PMA (circled in Fig. 6.3.5A) which reflected increasing TG2 
incorporation activity. Changes in TG2 incorporation activity were quantified by 
Progenesis same spots software.  
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Figure 6.3.5 Biotin cadaverine labelled PMA treated H9c2 proteins detected with 
HRP-ExtrAvidin-peroxidase 
H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine for 4h. They were then 
treated A) without (left panel) or with 1 µM PMA (right panel) for 5 min. The 
biotinylated (biotin-cadaverine labelled) proteins (500 µg) were isolated with 
CaptAvidin beads and 50 µg subjected to PAGE, transferred onto nitrocellulose 
membrane filters and the captured TG2 substrates were detected with ExtrAvidin
®
-
peroxidase. Red circle represent the changed TG2 substrates. B) Western blot analysis 
image of the biotin cadaverine labelled proteins. Control (untreated sample) was used 
as reference for 2D-PAGE analysis image in Progenesis same spots software. The 
results are typical of 5 independent experiments. 
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Table 6.3.1 The 2D-PAGE analysis data of TG2 substrate proteins in PMA 
treated H9c2 cells 
  
 
 
Data table represent activated and decreased protein spots reflecting altered TG2 
activity.  Data values of 3 accumulated 2D-PAGE, *P < 0.05 was viewed as 
significant. Fold change is shown. 
 
 
 
TG2 activity Protein spots Anova (P) Fold change 
Increased Proteins 1 0.016 9.1 
5 0.009 5.9 
10 0.001 4.3 
11 9.457e-004 4.2 
13 8.850e-004 3.4 
14 2.410e-004 3.2 
16 0.009 3.0 
18 0.002 2.9 
19 0.003 2.8 
23 2.828e-004 2.7 
25 0.001 2.6 
31 0.005 2.1 
32 0.008 2.0 
34 0.003 1.9 
38 0.002 1.6 
41 0.021 1.4 
48 0.054 1.8 
Decreased Proteins 4 0.001 6.4 
6 1.657e-004 5.4 
7 0.004 4.8 
8 3.306e-004 4.6 
9 3.600e-005 4.6 
12 2.605e-005 3.6 
15 0.002 3.1 
17 2.552e-004 3.0 
20 2.830e-004 2.8 
21 0.003 2.7 
27 0.002 2.6 
29 1.981e-004 2.2 
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Approximately 60 protein spots were detected from the isolated biotinylated TG2 
substrates in PMA treated H9c2 cells when sufficient protein was applied on 2D-
PAGE. Fourteen protein spots represented in Figure 6.3.5 and listed in Table 6.3.1 
were shown to exhibit significant increases in compared to control sample by ≥ 2.00 
fold (Fig. 6.3.5B) and eight more protein spots showed increases that were not 
significantly different from the control. However, twelve protein spots showed a 
significant decrease by ≥ 2.00 fold in compered to control (see fig. 6.3.5B and Table 
6.3.1). 
6.3.4. Identification of TG2 substrates 
The protein bands that showed activation and inhibition were excised from gels 
according to their molecular weight, judging from molecular weight ladder (Fig. 
6.3.1). The proteins were then extracted from gel by dehydration and hydration, 
followed with trypsin digestion as described in Material and Methods (section 2.2.26 
and figure.2.2.2). Samples were then directly analyzed by LC-MS/MS in which 
multiple proteins were identified within a single protein band. Proteins with a high 
score and sequence coverage (see appendices section fig. 8.6) following peptide 
mapping are listed in Table 6.3.2. More than 25 proteins that can serve as acyl-donor 
for transglutaminase were identified, which ranged in molecular weight from 25 to 
100 kDa. These targets include cytoskeletal organizing proteins, chaperone proteins, 
Ca
2+
 and phospholipid binding proteins and proteins involved in vesicle transport 
processes. Some of these proteins were also identified from silver stained 2D-PAGE 
(see appendix Fig. 8.5). 
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Table 6.3.2 Functional classification of identified acyl-donor TG2 protein 
substrates in H9c2 treated cells 
 
 
The biotin cadaverine labelled proteins were analysed by mass spectrometry. Data of 
identified proteins are reported according to high score and sequence coverage 
percentage (SC%). Molecular weight (MW) is also indicated in kDa. (*) According to 
the TRANSDAB database (http://genomics.dote.hu/wiki/index.php/). 
 
Functional group Proteins MW 
 [kDa] 
SC [%] Known 
substrate* 
Cytoskeleton 
network 
 
 
 
 
 
α-actinin-1  
Actin; cytoplasmic 1, 
Alpha cardiac muscle 1&  
Aortic smooth muscle. 
Tubulin  
Myosin-9 
Elongation factor 1-alpha 1 
Tropomyosin  
Vimentin,  
Prelamin  
102 
41 
41 
41 
50 
226 
50 
32 
54 
74 
26 
31  
29 
29 
31 
31 
23 
29 
21 
22 
No 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Ca
2+
and 
phospholipid 
binding protein 
Annexin; A2 
& A3    
38 
36 
31 
33 
No 
No 
Protein folding Heat shock protein HSP 90-
alpha, beta 
Heat shock cognate 71 kDa 
protein, 78 kDa glucose-
regulated protein 
Malectin 
 Serpin H1 
84 
83  
70 
72 
 
32 
46 
26 
 22 
25 
24 
 
28 
31 
Yes 
Yes 
Yes 
No 
 
No 
No 
Energy 
metabolism 
Prohibitin-2  
Voltage-dependent anion-
selective channel protein 1 
33 
 
31 
39 
 
44 
No 
 
No 
Miscellaneous 
 
 
 
Endomembrane 
vesicle trafficking 
 
mRNA 
metabolism and 
transport 
 
Guanine nucleotide-binding 
protein subunit beta-2-like 1 
 
Arf-GAP -containing protein 
1 (ASAP1) 
Ras-related protein Rab-35  
 
Heterogeneous nuclear 
ribonucleoprotein A1 
60S ribosomal protein L5 
 
35 
 
 
127 
 
25 
 
34 
 
34 
 
18 
 
 
23 
 
30 
 
39 
 
35 
 
No 
 
 
No 
 
No 
 
Yes 
No 
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6.3.5. Co-localisation of α-actinin and tubulin with TG2 activity 
Work to this point has established the modulation of TG2 activity following PKA and 
PKC activation in H9c2 and their protective role against oxidative stress mediated by 
TG2 and identified target substrate proteins. However, it was important to confirm 
whether selected target proteins could be localised in intact cells. One of the main 
functional classifications of TG2 substrates in the H9c2 PMA/FK treated cells were 
cytoskeleton organising proteins, suggesting a role for TG2 in the organization and 
turnover of cardiomyocytes plasma membranes and its associated cytoskeleton. 
Alpha actinin and tubulin are among the most abundant TG2 target protein substrates 
observed in PMA/FK treated H9c2 cells (Table 6.3.1). Evidence of direct α-actinin 
biotin cadaverine labelling in stimulated cells was obtained by immunological 
techniques using anti-α-actinin 1 antibody. 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B)                                                                 C) 
 
 
 
 
 
Figure 6.3.6 The co-localisation of α-actinin with TG2 activity as TG2 
cytoskeleton substrate 
A) Cells in chamber slides were incubated with 1 mM biotin-X-cadaverine for 4h and 
then treated with either 1 µM PMA or 10 μM FK while, unstimulated cells used as 
control in absence of BTC (–ve) or in presence of BTC (+ve). The TG2 mediated 
biotin-X-cadaverine incorporation into intracellular proteins was visulaised with 
Extravidin
®
-FITC (green). Actinin was detected by mouse anti-α-actinin mAb and 
visualised by anti-mouse-Alexa 568 secondary antibody (red). Nuclei were stained 
with DAPI (blue). The original magnification of the images was 400x. Co-localisation 
of α-actinin (red) and TG2 activity (green) stained yellow is shown in the merged 
photograph. B) The biotin-cadaverine labelled proteins were isolated with CaptAvidin 
beads subjected to SDS-PAGE and transferred onto nitrocellulose membrane filters 
the captured α-actinin substrates were detected with anti-α-actinin mAb. C) 
immunoprecipitation of biotin-cadaverine labelled proteins using α-actinin mAb and 
detected with HRP-conjugated
®
ExtrAvidin-peroxidase. The results are typical of 3 
independent experiments.
 
196 
 
A) 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
B) 
 
 
Figure 6.3.7 The co-localisation of α-tubulin with TG2 activity as TG2 
cytoskeleton substrate 
Cells in chamber slides were incubated with 1 mM biotin-X-cadaverine for 4h. They 
were then treated with either 1 µM PMA or 10 μM FK, while unstimulated cells used 
as control in absence of BTC/ α-tubulin (–ve) or in presence of BTC/α-tubulin (+ve). 
The TG2 mediated biotin-X-cadaverine incorporation into intracellular proteins was 
visualised with Extravidin
®
-FITC (green). The Microtubules were detected by mouse 
anti-tubulin mAb and visualised by anti-mouse-Alexa 568 secondary antibody (red). 
Nuclei were stained with DAPI (blue). The original magnification of the images was 
400x. Co-localisation of tubulin (red) and TG2 activity (green) stained yellow is 
shown in the merged image. B) an equal amount (500 µg) of the biotin-cadaverine 
labelled proteins were isolated with CaptAvidin beads subjected to SDS-PAGE and 
transferred onto nitrocellulose membrane filters, and the captured α-tubulin substrates 
were detected with anti-α-tubulin mAb. The results are typical of 3 independent 
experiments.
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Immunoblotting detection of α-actinin 1 was carried out from PMA/FK treated H9c2 
cells, and the presence of elevated levels of a biotin cadaverine labelled 
immunoreactive band was verified in stimulated cell extracts by probing blots with 
anti-α-actinin antibody (Fig. 6.3.6B). No other bands appeared on the probed 
nitrocellulose membrane, suggesting that the CaptAvidin beads were selective and the 
antibodies were specific. The immunoprecipitate of α-actinin from biotin cadaverine 
labelled samples (section 2.2.20) was subjected to SDS-PAGE, transferred to 
nitrocellulose membrane and detected using HRP-conjugated
®
ExtrAvidin-peroxidase 
(Fig. 6.3.6C). The result showed a similar band and enrichment in PMA and FK 
stimulated cell extracts that was detected with anti α-actinin mAb, further confirming 
the previous data. 
To confirm that α-actinin serves as TG a substrates, immunolocalisation of selected α-
actinin to TG2 activity in the presence or absence of PMA and FK was carried out 
using a double staining immunohistochemistry technique. Merging of the images 
demonstrates the co-localisation of alpha actinin to TG2 incorporation activity in 
PMA/FK-treated cells (red + green = yellow/orange; Fig. 6.3.6A).  
Tubulin was also confirmed as a TG2 substrate by in vitro and in situ activity (Fig. 
6.3.7A). Immunoblotting of α-tubulin was carried out from H9c2 PMA/FK treated 
cells, and a biotin cadaverine labelled immunoreactive band was verified by the 
binding to the anti-α-tubulin antibody (Fig. 6.3.7B). Again, the elevated levels of 
antibody reactivity were suggestive of increased amine incorporation into tubulin in 
PMA and FK-stimulated cells. 
6.3.6. The effect of TG2 inhibitor on α-actinin distribution in response to 
PMA/FK and H2O2 exposure 
To investigate the effects of TG2 inhibitors on α-actinin expression following PKA 
and PKC activation in H9c2 and their protection against oxidative stress, an equal 
amount of protein extracted from whole cells was resolved by SDS-PAGE and 
transferred onto nitrocellulose membrane filters. The level of α-actinin protein was 
detected by anti-α-actinin antibody. As shown in Figure 6.3.8 both PMA and FK 
treatments of H9c2 cells resulted in increased band intensity of α-actinin protein while 
TG2 inhibitors either Z-DON (Fig. 6.3.8B) or R283 (Fig. 6.3.8C) treatments result in 
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reduced levels of α-actinin. However, the increase of α-actinin protein was more 
evident in cells treated with PMA than in FK treated cells. Similar observations were 
recorded in PMA/FK treated samples followed by H2O2 insult (Fig. 6.3.8A). 
A)  
 
 
 
 
B) 
 
 
 
 
C) 
 
 
 
 
 
Figure 6.3.8 Detection of α-actinin in H9c2 cells in response to PMA, FK and 
H2O2 stress in the presence and absence of TG2 inhibitors  
H9c2 cells were treated with or without A) 150 μM Z-DON or B) 200 μM R 283 for 
1h. Cell were stimulated for 5 min with either 1 µM PMA or 10 μM FK treatment 
alone or C) prior to 600 μM H2O2 exposure for 2h while, unstimulated cells used as 
control. The total protein extract (50 µg) was resolved by SDS-PAGE and transferred 
onto nitrocellulose filters. Western blots were probed with anti-α-actinin and anti-
GAPDH mAb was used as a loading control. The results are typical of 3 independent 
experiments.
 
199 
 
6.4. Discussion 
The results in the previous chapters show the modulating of TG2 in both PKC and 
PKA signalling and its cytoprotective role through these signalling molecules. 
Transglutaminase 2 protein substrates and activity were detected in H9c2 treated cells. 
Biotin cadaverine was incorporated into endogenous protein substrates of TG2 in 
H9c2 cells. The results show biotin cadaverine incorporated into numerous proteins in 
H9c2 cells which exhibit increased amine incorporation following PMA or FK 
treatments (Fig. 6.3.1) or during PMA or FK mediated cytoprotection against H2O2 
stress in comparison to untreated cells (Fig. 6.3.1). Biotin cadaverine labelling of 
proteins decreased in the presence of the TG2 inhibitor Z-DON. Comparing the 
labelled proteins detected in the in situ assay (Fig. 6.3.1) to the labelled proteins found 
in vitro in the presence of Ca
2+
 (see chapter 4, Figure 4.3.1), a similarity in 
distribution and the number of bands was observed. This observation suggests that the 
substrates that were labelled in vitro assay might be obtainable also by in situ assay. 
In the current study for first time this activity was also detected by 2D-PAGE and 
Western blotting analysis. This 2D-PAGE technique was used to investigate the 
activity of TG2 in response to PMA in H9c2 cells using a pull-down assay. The 
quantification of proteins spots from 2D-PAGE results revealed that up to 30 protein 
spots were shown to increase or decrease in response to PMA treatment (Fig. 6.3.5B 
and Table 6.3.1).  
Many intra-and extra cellular proteins can interact with TG2 acting as substrates that 
are modulated by amine incorporation (Esposito & Caputo, 2005). This interaction 
may be essential for those cellular proteins to perform their biological functions. The 
TG2-catalyzed posttranslational modification of the substrates through incorporation 
of polyamines can modify the physical-chemical properties of proteins. For example, 
this modification would alter their isoelectric point by changing the surface charge 
through the addition of extra positively by charged amine groups, which may control 
their biological activity (Aeschlimann & Thomazy, 2000; Fesus & Piacentini, 2002; 
Griffin et al., 2002; Lorand & Graham, 2003). The recognition of proteins that act as 
TG2 substrates is important in the study of biological roles of TG2. For example, 
fibronectin, fibulin-2, nidogen-1 and alpha-1 chain of collagen type I were identified 
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as extracellular TG2 substrates that may play a role in remodeling of smooth muscle 
cells (van den Akker et al., 2011). 
Since TG2 has been shown to have pathological and a protective role against different 
diseases, it is therefore essential to have a better knowledge and understanding of its 
substrates, target sites and interacting proteins, which may act as novel drug targets or 
new diagnostic markers. Although protein kinases have been shown to provide 
cardioprotection signalling in response to ischaemic preconditioning (Helen et al., 
2012; Kloner & Jennings, 2001) and TG2 has also shown to protect heart from 
ischaemic reperfusion injured (Szondy et al., 2006), no one has investigated the TG2 
substrates that may involved in this protective mechanism. In addition, the substrates 
of TG2 in H9c2 cardiomyocytes have not been previously studied. 
Therefore, the detection some of TG2 substrate proteins which were exhibited 
increased amine incorporation in response to PMA and FK treatment in either the 
presence or absence of H2O2 and those which were inhibited via a TG2 inhibitor 
blocked protective action is of interest. The biotin-X-cadaverine labelled target 
proteins in treated H9c2 cells were captured with CaptAvidin beads and analyzed by 
LC-MS/MS. This enabled multiple proteins to be identified within a single protein 
band. Proteins with a high score and high sequence coverage of peptide mapping 
report are listed in Table 6.3.2. More than 25 proteins were identified which serve as 
acyl-donor substrates for transglutaminase.  
Using SDS-PAGE various targets were identified, this approach was used in the past 
to determine TG2 protein substrates (Orrù et al., 2003; Robinson et al., 2007). 
However, the advantage of the current approach was to use the cell penetrating 
synthetic TG substrate biotin-X-cadaverine as a probe to identify TG2 protein 
substrates. This amine substrate does not interfere with normal cell processes and 
does not require the addition of calcium activation buffer (Esposito & Caputo, 2005). 
In addition, using this approach for labelling of TG2 substrates does not require 
extensive proteolysis and HPLC analysis that is needed with [
14
C]putrescine labelling 
(Folk et al., 1980).  
According to the TRANSDAB database (http://genomics.dote.hu/wiki/index.php/), 
some of the identified proteins were already reported as TG2 substrates, but not in 
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H9c2 cells; these included heat shock proteins 70 and 90, actin, tubulin, myosin-9, 
elongation factor 1-alpha 1, tropomyosin, vimentin, heterogeneous nuclear 
ribonucleoprotein A1. However, some of the proteins have not been previously 
identified as TG substrates either in H9c2 or in other cell lines.  
Relative to their biological functions, the identified target proteins were classified into 
seven groups. These include cytoskeletal organizing proteins, chaperone proteins, 
Ca
2+
 and phospholipid binding proteins, proteins involved in energy metabolism, 
miscellaneous proteins, and proteins involved in vesicle transport processes. 
The first classification group of identified TG2 substrates is cytoskeleton organising 
proteins (Table 6.3.2). The cardiomyocyte cytoskeleton is an important biological 
structure because of its complexity and the numerous roles it plays (Sarantitis et al., 
2012). The cytoskeleton contributes to the maintenance of myocardial cell structural 
and functional integrity. It can also participate in cell division, cell migration, vesicle 
transport, receptors localisation, the cell function and communication, and signalling 
transduction (Schweitzer et al., 2001; Pyle & Solaro, 2004).  
The thin filaments in sarcomeric cytoskeleton of cardiomyocyte consist of actin and 
tropomyosin proteins while myosin protein is present in the thick filaments (Modica-
Napolitano & Singh, 2002; Camelliti et al., 2006). In this study, the actin (cytoplasmic 
1, alpha cardiac muscle 1 and aortic smooth muscle), tropomyosin and myosin 9 all 
were shown to act as TG2 substrates in H9c2 cells (Table 6.3.2). These proteins have 
been shown to play an important role in cardiac contraction performance (Noguchi et 
al., 2004). Moreover, the connection of tropomyosin with cardiac tropomodulin 
complex has been shown to thin filament and thus stopping actin depolymerisation of 
cardiomyocyte (Goodwin & Muntoni, 2005; Camelliti et al., 2006). Interestingly, 
proteomic analyses of H9c2 cells has shown that the level of cytoplasmic actin 
decreased in response to oxidative stress induced by H2O2 treatment (Chan, 2013).  
This study identified α-actinin as a glutamine donor TG2 substrate. Alpha actinin is 
an actin microfilament binding protein, which regulates microfilament function and 
organisation (Gregorio & Antin, 2000; Calaghan et al., 2004). Immunofluorescence 
images showed co-localisation of α-actinin with TG2 activity induced by PMA or FK, 
confirming it as TG2 substrate (Fig. 6.3.6A). The α-actinin was also confirmed as 
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TG2 substrate on a Western blot following a pull down assay (Fig. 6.3.6B) and 
immunoprecipitation of α-actinin (Fig. 6.3.6C). It has been reported that the activation 
of PKC by phorbol esters results in enrichment of the actin-associated protein α-
actinin and PKC isoform translocation in the human neutrophil cytoskeleton (Niggli 
et al., 1999). Alpha actinin has been shown to play an essential role in the contractile 
function of smooth muscle cells, modulating cytoskeleton restructuring (Fultz et al., 
2000). However, the accumulation of α-actinin protein was observed in the 
sarcoplasmic reticulum of myocytes from patients with failing hearts, but not as a 
toxic effect (Fultz et al., 2000, Hein et al., 2009). Alpha actinin is located at the Z-line 
of the sarcomere, where PKCɛ can be translocated and exert its cardioprotection 
effects through maintenance of the contractile apparatus (Robia et al., 2001). 
Therefore, the depletion of α-actinin by TG2 inhibitors (Fig. 6.3.8) could possibly 
affect PKCɛ translocation and activation, thus removing its protective effects.  
The interaction between α-actinin and annexin A6 has been detected in  
cardiomyocytes suggesting an important role for annexin A6 in excitation and 
contraction process (Mishra et al., 2011). Therefore, altered levels of α-actinin might 
disrupt the cardiac excitation and contraction cycle. 
Tubulin was also among the identified TG2 substrates and was confirmed as a TG2 
substrate for in vitro and in situ TG2 activity (Fig. 6.3.7). Tubulins are the main 
structural protein of cardiac-microtubules in which α- and β-tubulin heterodimers are 
polymerized (Gregorio & Antin, 2000). Because of their dynamic features of rapid de- 
polymerisation and re-polymerisation, they have the ability to alter the cytoskeleton’s 
flexibility, thus contributing to myocardial cell contractile activity (Severs et al., 
2006). Together with cardiac-microtubule associated proteins, the α- and β-tubulin 
can stabilise cardiomyocytes by connecting the subcellular structure and thus play an 
important role in the transmission of chemical and mechanical signalling within- and 
between cells (Gregorio & Antin, 2000; Schweitzer et al., 2001; Severs et al., 2006). 
Furthermore, this study was identified the protein vimentin as a TG2 substrate (Table 
6.3.2); this is known to form intermediate filaments that contribute to structural 
organisation in the cytoplasm (Schaper et al., 1991). An increase in tubulin and 
vimentin protein levels has been observed in patients with dilated cardiomyopathy (a 
condition in which the heart becomes enlarged; Schaper et al., 1991; Di Somma et al., 
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2000). However, it was suggested that the increase in these cytoskeleton elements 
could be an action taken by myocardium cells when contractile material is impaired to 
compensate for the lack of cellular stability (Heling et al., 2000). Interestingly, PKCɛ 
activation has been shown to mediate the phosphorylation of vimentin and regulation 
of β1-integrin (a cell surface receptor) compartment, recycling and motility in 
fibroblast cell lines (Ivaska et al., 2005) or human kidney (HEK-293) cells (Kim et al., 
2010). This observation is of interest, as it supports the present data showing that TG2 
mediated the incorporation of biotin into vimentin in response to PMA activated PKC. 
In addition, it could be possible that phosphorylation of TG2 substrates by PKC 
facilitates TG2 biotin cadaverine incorporation activity. 
In the current study, prelamin A was also detected and identified as a TG2 substrate. 
Prelamin A is an immature form of lamin A that requires serial posttranslational 
modifications in its carboxyl-terminal to become a mature lamin (Davies et al., 2009). 
Type A lamin is a nuclear cytoskeleton proteins belonging to the intermediate 
filament family and is commonly observed in differentiated cardiomyocytes (Mudry 
et al., 2003; Kong & Kedes, 2004). Nuclear lamin has been shown to have multiple 
functions; it is involved in DNA replication and repair, transcription, chromatin 
organisation, apoptosis, nuclear growth and cell differentiation (Dechat et al., 2010). 
Elongation factor 1α, a multifunctional protein that acts as actin-binding protein, 
peptide synthesis promoter and substrate for Rho-associated kinase (Izawa et al., 
2000) was identified as a TG2 substrate in H9c2 cells. Moreover, a significant 
reduction in elongation factor 1α expression has been shown to be associated with cell 
death that can eliminate abnormal tetraploid cells (which have mis-segregated 
chromosomes due to a fault in the compact of chromatids during mitosis) and inhibit 
tumorigenesis (Kobayashi & Yonehara, 2008). Oxidative stress can result in down 
regulation of elongation factor 1α while pre-treatment with quercetin (a natural 
polyphenolic compound that has anti-inflammatory and anti-oxidant effects; Boots et 
al., 2008) can reverse this effect (Chan, 2013).  
The second classification of TG2 substrates included Ca
2+ 
and phospholipid binding 
proteins. Annexin is a calcium-dependent cytoskeleton and phospholipid-binding 
protein involved in several biological events (Gerke et al., 2005). It can interact with 
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various cell-membrane components regulate cellular structural organisation, control 
cell growth mediate intracellular signalling and it also can act as a typical calcium 
channels (Moss & Morgan, 2004). Different types of annexin have been identified in 
myocardium these include annexin A1, A2, A4, A5, A6 and A7 but not annexin A3 
(Camors et al., 2005). In this study, two annexins type A2 and a novel annexin type 
A3 were identified as TG2 substrates in H9c2 cells. 
Interestingly, the actin, elongation factor 1-alpha 1, annexin, lamin-A and myosin-9 
have all been shown to be a target for quercetin’s protective effect against oxidative 
stress in H9c2 cells (Chan, 2013).  
The third group of TG2 substrates (Table 6.3.2) represents proteins involved in 
protein folding machinery (chaperones) including heat shock protein HSP 90-α and β, 
heat shock cognate 71 kDa protein, 78 kDa glucose-regulated protein, malectin, and 
serpin H1. The heat shock protein HSP 90-α and β, both belong to the heat shock 
family of stress proteins and are mainly found in the cytoplasmic (Benjamin & 
McMillan, 1998). One more function known for chaperones in vivo is to prevent 
aggregation of proteins under stress conditions and to stimulate reparation of the 
enzymatic activity of the denatured substrates such as citrate synthase, β-
galactosidase, or luciferase on removal of stress (Benjamin & McMillan, 1998). Heat 
shock protein 90 is one of the chaperone proteins that facilitate the folding, gathering, 
and segregating of other proteins (Benjamin & McMillan, 1998). The HSP 90 
chaperone protein is considered to be a key regulator in cell physiology and can 
mediate various processes including signal transduction and differentiation beside its 
role in protein folding. This could be due to the fact that the majority of cellular 
proteins require HSP 90s to reach their final conformation such as growth factor 
receptors (Sawai et al., 2008), kinases (Yun & Matts, 2005), and many carcinogenic 
proteins (da Silva & Ramos, 2012). Recently, HSP 90 has been reported to mediate 
the cardioprotection effects stimulated by hydrogen sulphide (H2S) against chemical 
hypoxia-induced injury in H9c2 cardiomyocytes through the attenuation of oxidative 
stress and enhancement of mitochondrial function (Yang et al., 2011). This chaperone 
has been shown to be involved in regulation of oestrogen receptor function by 
modulating its binding to its cognate DNA (Sabbah et al., 1996).  
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Heat shock protein 71 is a constitutive chaperone, which shares ~90 % identical 
sequence homology with rat HSP70 (Morshauser et al., 1999). This heat shock protein 
also functions inside the cell as a chaperone involved in protein folding and transport, 
beside its function in tissue protection against stress and injury (Srivastava, 2002). 
Moreover, it has an extracellular function in cell signalling mediated stress 
(Calderwood et al., 2007). The HSC 70 released in response to ischaemia-reperfusion 
suggested that it might have a crucial role in the myocardial inflammatory response 
and cardiac dysfunction (Zou et al., 2008). 
The 78 kDa glucose-regulated proteins are sarcoplasmic/endoplasmic reticulum 
chaperones and they are of particular clinical interest, because of the important 
functions of sarcoplasmic/endoplasmic reticulum in repair or degradation of 
misfolded proteins as a result of cell injury after myocardial ischaemia or mutations 
(Glembotski, 2008). The induction of 78 kDa glucose-regulated proteins has been 
reported in response to ischaemic pre-conditioning in brain tissue to protect from 
further ischaemic damage by reducing sarcoplasmic/endoplasmic reticulum stress and 
preventing delayed neuronal cell death (Hayashi et al., 2003). 
Proteomic analysis of H9c2 cells revealed that the heat shock protein 71 kDa was up-
regulated while 78 kDa glucose-regulated protein was down regulated in response to 
doxorubicin-induced damage in cardiomyocytes (Bao et al., 2012). Both HSPs and 
PKC have been well documented to be cardioprotective against ischaemia-reperfusion 
injury (Dorn et al., 1999; Fryer et al., 2001; Coaxum et al., 2007). The PMA induced 
activation of PKC results in increased HSP 70 and HSP 90 expression either due to 
mRNA stabilisation in human blood monocytes (Jacquier-Sarlin et al., 1995) or to 
transcriptional activation in H9c2 cardiomyocytes cells (Coaxum et al., 2007). Since 
all of these HSPs have been identified as TG2 substrates in the current study, this may 
suggest that the increase in TG2 activity following PMA and FK exposure is in fact, a 
cardioprotective cellular response. However, this cannot rule out the possibility that 
the presence of HSPs may be due to the biotin-X-cadaverine itself. 
The fourth group of identified TG2 substrates (Table 6.3.2) contains proteins involved 
with metabolism and energy involved production proteins such as prohibitin and 
voltage-dependent anion-selective channel protein 1. The latter is of particular interest 
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as it acts as Ca
2+
 regulator for transportation in-and out of the mitochondrial 
membrane and extensively communicates with metabolic enzymes (e.g. pyruvate 
dehydrogenase) that use Ca
2+
 as a cofactor in metabolic processes (Zaid et al., 2005). 
However, it also plays a role in apoptosis by facilitating the release of cytochrome C 
(Lemasters & Holmuhamedov, 2006). Proteomic analysis of H9c2 cells has revealed 
that down regulation of prohibitin and voltage-dependent anion-selective channel 
protein 1 was associated with doxorubicin-induced damage in cardiomyocytes (Bao et 
al., 2012). The role of mitochondria in triggering necrosis and apoptosis pathway has 
been extensively studied in cardiomyocytes under oxidative stress (Borutaite & 
Brown, 2003). Prohibitin has been known as a mitochondrial chaperone protein 
involved in its structure and function (Nijtmans et al., 2002; Kasashima et al., 2008) 
and the Ras-raf signal transduction pathway (Rajalingam & Rudel, 2005). The 
protective role of this protein has been reported in H9c2 cardiomyocytes in response 
to oxidative stress-induced cell injury (Liu et al., 2009). Prohibitin transfected H9c2 
cells showing overexpression of this protein suppressed the mitochondria-mediated 
apoptosis pathway through inhibition of cytochrome C release from mitochondria to 
cytoplasm and by alteration of the mitochondrial membrane permeability transition 
pore (Liu et al., 2009). Similarly, it has also been reported to protect cardiomyocytes 
against hypoxia induced cell death (Muraguchi et al., 2010). 
The fifth group of identified TG2 substrates (Table 6.3.2) contains endomembrane 
vesicle trafficking proteins including the Arf-GAP-containing protein 1 and Ras-
related protein Rab-35. The Arf-GAP-containing protein 1 is a members of the ADP-
ribosylation factor (ARF) family of G proteins that regulates membrane traffic and 
organelle structure by engaging vesicle coat proteins, mediating membrane lipid 
conformation and interacting with G proteins regulators (Donaldson & Jackson, 
2011). The Arf-GAP-containing protein 1 is a prototype of the peripheral ARF GAPs, 
serving to organise the cell signalling effects of platelet-derived growth factor, the 
actin cytoskeleton and membrane trafficking during cell movement (Randazzo et al., 
2000).  
Ras-related protein Rab-35 is one of Rab proteins from the branch of the small G 
protein superfamily proteins that are known to regulate intracellular vesicle trafficking 
(Takai et al., 2001). The functional role of Rab35 has been reported to be the 
207 
 
regulation of actin filament assembly during bristle progression in Drosophila by 
recruiting the actin-bundling protein fascin as an effector protein (Zhang et al., 2009). 
The proteomic analysis of purified exosomes from oligodendroglial cells has revealed 
that the majority of identified proteins are Rab GTPases and Rab-35 is the most 
abundant protein suggesting, a role in exosome secretion (Hsu et al., 2010). 
The final group (Table 6.3.2) represents the proteins involve in mRNA metabolism 
and transport, which consist of heterogeneous nuclear ribonucleoprotein A1 and 60S 
ribosomal protein L5. The heterogeneous nuclear ribonucleoprotein A1 belongs to the 
RNA-binding protein family and has key roles in gene expression regulation at the 
transcriptional level (He & Smith, 2009). The role of heterogeneous nuclear 
ribonucleoprotein A1 in differentiation of smooth muscle cell from the stem cells and 
in cardiovascular regenerative medicine has been identified (Wang et al., 2012; 
Huang et al., 2013). The 60S ribosomal protein L5 is one of the ribosomal proteins 
important in coordinating cell growth and cell division (Donati et al., 2013). It plays 
an important role in activation of tumor suppressor protein (p53) under stress 
conditions through binding to and inhibition of the ubiquitin E3 ligase to induce cell 
cycle arrest and apoptosis (Sun et al., 2010). Interestingly, some of these identified 
proteins were also identified in 2D-PAGE (see appendix, Fig.8.5), including (1)78 
kDa glucose-regulated protein, (2) tubulin, (3) annexin; A2, (4) actin, (5) voltage-
dependent anion-selective channel protein 1, (6) α-actinin, (7) vimentin and (8-9) 60S 
ribosomal protein L5.  
The main functional classifications of TG2 substrates in the H9c2 PMA/FK treated 
cells were cytoskeletal organising proteins (Table 6.3.2), suggesting a role for TG2 in 
the organization and turnover of the cardiomyocyte cytoskeleton. Alpha actinin and 
tubulin are among the most abundant target protein families observed in the H9c2 
cells. In conclusion, the present results have shown that TG2-catalyses 
posttranslational modification of the target substrates that are predominately involved 
in cytoskeletal organisation, protein folding or endomembrane vesicle trafficking, 
through polyamine incorporation activity. 
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7. General discussion and future work 
The history of transglutaminase can be traced back to the mid-1950s when a new 
enzyme (called transglutaminase) extracted from liver was discovered with the 
establishment of its reaction catalysis (Sarkar et al., 1957). The transamidation 
activity remained the only function known for transglutaminase until the discovery of 
the ability of TG2 to bind and hydrolyse GTP, which then defined its GTPase function 
(Achyuthan & Greenberg, 1987). Since that time, several more enzymatic functions 
for TG2 have been reported and different isoenzymes have been discovered. However, 
the impact of TG2 and its activities in cellular responses until now are still under 
investigation. 
Transglutaminases (TGs) are a family of Ca
2+
 dependent enzymes that catalyse the 
posttranslational modification of proteins. Several classes of this enzyme have been 
identified (TGs 1-7) (Lorand & Graham, 2003). Transglutaminase 2, which is 
ubiquitously expressed, possesses multiple enzymatic activities, including 
transamidation, deamidation, protein disulphide isomerase, esterase, nucleosidase and 
protein kinase, acting as a G-protein in trans-membrane signalling (Gundemir et al., 
2012). The cytoplasmic form of TG2 has been ascribed a role in apoptosis and cell 
signalling whereas the extracellular TG2 has roles in ECM stabilisation, cell adhesion 
and migration (Iismaa et al., 2009; Nadalutti, et al., 2011). TG2 has been shown to 
mediate cardioprotection against ischaemia and reperfusion-induced cell death 
(Szondy et al., 2006). Similarly, increased TG2 expression protects neuronal cells 
from oxygen and glucose deprivation-induced cell death (Filiano et al., 2008) and 
protects cells from DNA degradation (Tucholski, 2010).  
Protein kinase C and PKA are two major mediators of signal transduction pathways 
associated with ischaemic preconditioning and pharmacological preconditioning 
induced cardioprotection (Yellon & Downey, 2003; Hassouna et al., 2004; Sanada et 
al., 2011). Transglutaminase 2 and TG1 can be regulated by PKA and PKC in some 
cell lines (Bollag et al., 2005; Akar et al., 2007b; Mishra et al., 2007). However, the 
modulation of by TG2 activity in cardiomyocytes by these protein kinases has been 
never investigated. The impact of this modulation on cell survival as key role in 
cardioprotection has never been reported. Thus, the purpose of this study in H9c2 
cells was to investigate the activation of TG2 in response to phorbol-12-myristate-13-
acetate (PMA) acts as a PKC activator and forskolin (FK) acts a PKA activator and to 
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determine whether TG2 played a role in PKC/PKA-mediated cytoprotection. The 
H9c2 cells are derived from embryonic rat heart tissue (Kimes & Brandt, 1976) and 
are extensively used as an in vitro model for investigating and studying 
cardioprotection events since they display similar morphological, biochemical and 
electrophysiological properties to primary cardiac myocytes (Hescheler et al., 1991). 
The data presented here provide evidence that TG2 activity is modulated in H9c2 
cells by signalling pathways induced by PMA and FK. Moreover, the inhibition of 
TG2 activity decreased PMA and FK-mediated cytoprotection against H2O2-induced 
oxidative stress suggesting a cardioprotection role for TG2.  
 
Modulation of TG2 by PKC and PKA-dependent signalling in H9c2 cells in vitro 
and in situ activity 
As detailed in the introduction, the activity of TG2 and other TG family members can 
be regulated by PKA and PKC (Bollag et al., 2005; Mishra et al., 2007). However, at 
present the regulation of TG2 by both PKA and PKC-dependent signalling in 
cardiomyocytes has not been reported. Hence, in this study, the potential regulation of 
TG2 by PKC and PKA-dependent signalling was investigated in H9c2 cells treated 
with PMA and FK. PMA and FK treatments triggered significant time and 
concentration-dependent increases in TG2-mediated biotin cadaverine incorporation 
activity in H9c2 cells. Forskolin but not PMA also induced a time-dependent increase 
in TG2-mediated protein crosslinking activity. Transglutaminase crosslinking activity 
involves the formation of a covalent bond between glutamine and lysine residues in 
adjacent proteins, whereas TG amine activity refers to incorporation of primary 
amines into protein substrates. The regulation of TG2 activity in H9c2 cells by FK is 
in agreement with previous studies in mouse embryonic fibroblasts (MEF), which 
have shown TG2 becomes phosphorylated at Ser
216
 in response to PKA activation 
(Mishra & Murphy, 2006; Mishra & Murphy, 2006). The phosphorylation of TG2 by 
PKA appears to have several consequences, including the enhancement of protein-
protein interactions, promotion of its kinase activity and inhibition of protein 
crosslinking activity. However, it is notable that in this study FK-treatment enhanced 
TG2-mediated crosslinking activity in mouse embryonic fibroblasts (Mishra & 
Murphy, 2006; Mishra et al., 2007). It should be noted that the inhibition of TG2 
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protein crosslinking activity reported by Mishra et al. (2007) was detected with 
histidine-tagged TG2 immobilised on nickel-agarose and incubated with the PKA 
catalytic subunit, whereas in the current H9c2 cells were treated with FK prior to 
measurement of TG2 protein crosslinking activity. Hence, the effects of FK on TG2 
observed in the current may by PKA-independent (e.g., FK triggers a robust increase 
in ERK1/2 phosphorylation).  
Importantly, PMA and FK-stimulated transglutaminase activity in H9c2 
cardiomyocytes was inhibited by Z-DON and R283, two structurally different (see 
section 4) TG2 inhibitors (Freund et al., 1994; Schaertl et al., 2010) confirming the 
modulation of TG2. Although the expression TG2 is regulated by PKC in pancreatic 
cancer cells (Akar et al., 2007) there does not appear to be any published data 
regarding the regulation of TG2 activity by PKC-dependent pathways. Hence, the 
data presented in the current study have shown for the first time that TG2 activity 
(amine incorporation but not crosslinking) can be stimulated following treatment of 
H9c2 cells with the PKC activator PMA. However, previous studies have shown that 
the crosslinking activity of TG1 is enhanced by PMA-induced PKC activation (Bollag 
et al., 2005). It is interesting to note that TG1 activation by PMA is sensitive to the 
MEK1 inhibitor PD98059, suggesting the involvement of ERK1/2 in PMA-induced 
TG1 activation (Bollag et al., 2005). Interestingly, TG1 but not TG3 for the first time 
was also detected in H9c2 cells; however, its level of protein expression was not 
altered by these kinase activators. This observation could eliminate the possibility that 
TG1 has a role in contributing this activity. Future experiments could explore the 
potential involvement of ERK1/2 (and possibly other potential downstream protein 
kinases) in PMA-induced TG2 activation in H9c2 cells.  
To confirm the involvement of PKA in FK and PKC in PMA-mediated TG2 
activation, inhibitors for these kinases were tested for their ability to inhibit PMA or 
FK-induced TG2 activity. The PKC inhibitors Gö 6983 (5 µM) (Gschwendt et al., 
1996), Ro 31-8220 (10 μM) (Davis et al., 1989), chelerythrine (1 µM) (Herbert et al., 
1990; Chijiwa et al., 1990) and the PKA inhibitor H-89 (1 µM) (Chijiwa et al., 1990) 
significantly blocked both PMA and FK-induced TG2 catalysed biotin cadaverine 
incorporation. These observations suggest either a lack of protein kinase inhibitor 
selectivity or a possibly a direct effect of the inhibitors on TG2 activity. Interestingly, 
Gö 6983, H-89 and chelerythrine significantly inhibited the activity of purified 
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guinea-pig liver TG2, revealing of a direct interaction of these inhibitors with TG2. 
Although Ro-318220 did not attenuate purified TG2 activity, it is still unclear as to 
why this PKC inhibitor blocked FK-induced TG2 activity since it does not 
significantly attenuate PKA activity (Davies et al., 2000). However, PKA inhibitors 
KT 5720 and Rp-8-Cl-cAMPS blocked FK induced TG2 activity, confirming the 
involvement of PKA in FK-mediated responses. Further studies will investigate a 
wider range of PKA and PKC inhibitors not only on the activity of purified guinea-pig 
liver TG2 and also on their ability to inhibit PMA and FK-induced TG2 activity in 
H9c2 cells. The possibility that PMA or FK might directly influence purified TG2 
activity was also studied. PMA and FK did not influence the activity of purified TG2, 
suggesting that these protein kinase activators do not directly interact with TG2. 
Extracellular signal-regulated kinases (ERK 1 and 2) are one of the major mitogen-
activated protein kinase (MAPK) families that have a protective role in 
cardiomyocytes (Abe et al., 2000; Sugden & Clerk, 2001). The phosphorylation of 
ERK1/2 by PKA and PKC activation via FK and PMA, respectively, has been 
reported (Nanzer et al., 2004; Wang et al., 2009). In the current work, a study of the 
effect of different protein kinase inhibitors in pERK1/2 activation has revealed that 
TG2 polyamine incorporation activity modulated by PMA and FK is a downstream 
target for PKA and PKC activation. Different protein kinase inhibitors induced 
significant decreases in TG2 activity and protein levels in conjunction with pERK 1/2 
reduction which was verified by Western blotting. Conversely, both TG2 specific 
inhibitors failed to block ERK1/2 activation.   
The results presented in this thesis demonstrate that PMA and FK treatments were 
able to increase the detectable TG2 protein level. These increases were prevented by 
protein kinase inhibitors. Although PMA/FK mediated TG2 incorporation activity was 
in correlation with increase of TG2 protein and mRNA levels, it is also likely that the 
activation of TG2 is not entirely due to induction of its gene. However, it is might be 
due to either TG2 protein being covalently modified (e.g. phosphorylation) or 
interaction with a regulatory protein induced by these kinase activators that increases 
its activity. The presented results have demonstrated that both PMA and FK induce a 
wide range of protein phosphorylation in H9c2 cells and this agrees with other studies 
(Jacquier-Sarlin et al., 1995; Teixeira et al., 2003; Bollag et al., 2005). Thus, it could 
be possible that these phosphorylation events result in conformational changes of 
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these target proteins or in altered affinity of specific proteins to recognise and bind to 
other proteins and thus affect regulation of TG2 activity. Phosphorylation of TG2 
itself may also alter anti-TG2 mAb binding to give a perceived increase in protein as a 
result of increased antibody binding. 
Polyamines are required for almost all cellular processes including cell signalling, 
phosphorylation, protein synthesis and gene expression (Igarashi & Kashiwagi, 2000). 
In cells, polyamine levels could be altered due to transportation, biosynthesis and 
degradation (Pegg, 1988; Giordano et al., 2010). When the concentration of 
polyamines in the cells or tissues is in the millimolar range, TG2 can catalyse the 
incorporation of these polyamines into intracellular proteins that act as specific acyl-
donor substrates (Jeon et al., 2003). This polyamination reaction can result in covalent 
modification of many proteins in intact cells and modulate the function and 
metabolism of such proteins. Although intracellular polyamine levels are < 1.0 mM in 
cardiac tissue (Wang et al., 2010), different stimuli may disturb polyamine 
homeostasis and thus crosslinking of intracellular proteins is unlikely to occur (Song 
et al., 2013). This can be verified by the present observations in which TG2 amine 
incorporation was more dominant than TG2 crosslinking activity.  
Interestingly, using a cell permeable biotinylated substrate of TG2 (biotin-X-
cadaverine) it is possible to visualise the protein targets of TG2 activity after 5 min 
following activation of PKA and PKC with pharmacological activators. The results 
were comparable to PMA- and FK-induced amine incorporation activity observed in 
vitro. Increases in transglutaminase activity were seen as early as 5 min following 
stimulation with PMA or FK, and the effect was maximal by 10 min in both in vitro 
and in situ activity. This suggests that no intermediate steps may be beyond these 
early responses for the activation of the transglutaminase. However, as TG2 is a 
calcium-activated enzyme (Griffin et al., 2002), it is possible that direct release of 
intracellular calcium following treatment with protein kinase activators is responsible 
for the activation of transglutaminase. It may be that there are areas of the cytoplasm 
where Ca
2+
 ions are released that may have elevated levels of Ca
2+
 sufficient to drive 
protein crosslinking as well. Indeed, PMA has been reported to stimulate, ATP-
dependent calcium transport within 2 min in neutrophil plasma membranes (Lagast et 
al., 1984) and cause a dose-dependent influx of calcium in human red blood cells 
(Andrews et al., 2002). Moreover, both PKA and PKC activation are responsible for 
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increases of cytosolic calcium ion levels from extra- (via voltage-gated channels) and 
intracellular (mobilisation in ER) sources in rat PC12 pheochromocytoma cells 
(Dermitzaki et al., 2004). From the data presented, it appears that PMA and FK-
induced TG2 activity depends on the continued presence of calcium. Therefore, it 
would be interesting to confirm these observations in situ by pre-treating H9c2 cells 
with the intracellular Ca
2+
 chelator (BAPTA) prior to PMA and FK stimulation 
(Robinson & Dickenson, 2001) or to follow the release of Ca
2+
 using Ca
2+
 fluo-dyes. 
The use of different and differentiating cardiomyocytes cell lines would determine 
whether the effects of PMA and FK on in situ TG activity are a common observation 
in heart tissue.  
However, given the covalent nature of biotin-X-cadaverine incorporation into protein 
substrates, it was unexpected to observe that in situ TG2 activity reversed to basal 
level after 20 min. Explanations of this result could be that the biotin-cadaverine 
labelled proteins were either targeted for degradation or that they were rapidly 
expelled from the cell. Further results implicated the latter, since labelled proteins 
were detected in the culture medium. However, it cannot be ruled out the possibility 
that these two processes occur simultaneously. Another explanation could be that the 
concentration of endogenous polyamines in the H9c2 cells were increased and 
accumulated after 10 min treatments with PMA and FK; thus, during the incubation 
time some of these free endogenous polyamines exported outside the cells resulting in 
an apparent reduction of TG2 activity over time and depletion of biotin-cadaverine 
labelled proteins. The prolonged treatment of HL-60 cells with PMA resulted in an 
increased level of the polyamines spermidine and putrescine but decreased levels of 
spermine (Gavin et al., 2004). This also suggests that PMA treatment may result in the 
degradation of endogenous polyamine (spermine) in H9c2 cells. Therefore, it would 
be of value to determine the concentration of different polyamines in H9c2 cells 
before and after PMA and FK treatments at different time point using high-pressure 
liquid chromatography (Wang et al., 2010). 
This is of interest, as TG2 activity has not been detected in cardiomyocyte culture 
medium before, yet this finding has been supported by another study that also 
detected TG2 activity in normal human and glaucomatous cultured trabecular 
meshwork cells and tissues (Tovar-Vidales et al., 2008).  
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Role of TG2 in PMA and FK-induced cytoprotection  
Recent evidence suggests that TG2 has a cardioprotective role against ischaemia and 
reperfusion-induced cell death by regulating ATP synthesis in cardiomyocytes 
(Szondy et al., 2006). Since TG2 activity appears to be regulated by protein kinases 
associated with cardioprotection (PKA and possibly PKC) this study investigated 
whether it plays a role in PMA and FK-induced cytoprotection. The data presented 
have shown for the first time that inhibition of TG2 activity decreased PMA and FK-
mediated cytoprotection against H2O2-induced oxidative stress.  
The role of TG2 in modulating protection induced by PMA and FK against oxidative 
stress was addressed using different cytotoxic measurement approaches. Firstly, the 
morphological changes in H9c2 cells were monitored before and after PMA and FK 
treatments in the presence and absence of TG2 inhibitors. The pseudopodia of the 
cells retracted and both granules and were formed in the presence of H2O2. These 
effects were attenuated by PMA and FK and but more pronounced in the presence of 
Z-DON TG2 inhibitor. Secondly, cell viability following H2O2 exposure was assessed 
by monitoring MTT reduction and lactate dehydrogenase (LDH) release. The fact that 
H2O2 exposure resulted in morphological alteration, cell survival reduction and LDH 
release from H9c2 cardiomyocytes had already been reported (Liang et al., 2010). As 
expected, pre-treatment with PMA and FK reversed H2O2-induced inhibition of MTT 
reduction and release of LDH. Finally, the DNA fragmentation in cells was evident 
when exposed with H2O2 alone and in cells pre-incubated with Z-DON. The TG2 
inhibitors R283 and Z-DON blocked PMA and FK-induced cytoprotection suggesting 
a protective role for TG2 in mediated PKC and PKA-induced cell survival. Although, 
Z-DON treatment decreased caspase-3 activation, it did not secure cells from death. 
This suggests that the complete inhibition of caspase-3 by TG2 inhibitor results in a 
shift of cell death from apoptosis to necrosis, similar to previous reports on ATP 
depletion stimulated B lymphocyte apoptotic cell death (Lemaire et al., 1998). It 
would also be of interest to confirm this protection by measuring another endpoint 
e.g. ROS production.  
Although, the protective effect of PMA and FK against oxidative stress induced by 
H2O2 has not previously reported in H9c2 cardiomyocytes, the results of this study are 
in agreement with other studies that document the protective effects of these agents 
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against cell injury induced by H2O2 in neural cells (Kamata et al., 1996; Ginés et al., 
2010; Jin et al., 2010; Park et al., 2012). Thus, it is possible that both of these protein 
kinase activators can induce cardioprotection against oxidative stress. However, it is 
important to note that both PMA and FK induce a robust increase in ERK1/2 
activation in H9c2 cells. The ERK1/2 pathway is also a prominent protein kinase 
associated with cardioprotection (Hausenloy & Yellon, 2004) and hence the 
cardioprotective effects of PMA and FK observed in H9c2 cells may involve ERK1/2. 
The results in the current study indicated that cells pre-treated with PMA and FK in 
the presence of H2O2 showed a significant increase in ERK activation compared to 
control, and H2O2 treated cells. In the presence of Z-DON this activation did not show 
significant attenuation. This suggests that the ERK pathway might not be involved in 
cardioprotection modulated by TG2 activation. On the other hand, up-regulation of 
pAKT has also been shown to be associated with cardioprotection mechanism against 
ischaemia-reperfusion injury in animals (Hausenloy & Yellon, 2006). However, 
pAKT (PKB) activation showed a significant increase in cells pre-treated with PMA 
and FK in the presence of H2O2, which was also significantly decreased in the 
presence of Z-DON. These results suggest that PMA and FK activate pAKT signalling 
under H2O2 induced oxidative stress and the possibility that TG2 could modulate this 
protective effect through pAKT signalling was supported by the reversal of this effect 
in the presence of Z-DON.  
Figure 7.1 shows the proposed cascade of signalling events in H9c2 cardiomyocytes 
involved in cardioprotection modulated by TG2 activation using data presented in this 
thesis and other literature. This proposed model (Fig. 7.1) indicates that the beneficial 
effects of PMA and FK in protecting cardiac cells from H2O2-induced cell injury 
require AKT activation mediated by TG2 activity as demonstrated by using theTG2 
inhibitor Z-DON. 
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Figure 7.1 Proposed cascade of signalling events in H9c2 cardiomyocytes 
involved in cardioprotection modulated by TG2 activation  
 
Forskolin (FK) activates adenylate cyclise (AC) to generate cAMP, stimulating both 
PKA and PI3/Akt activities (Wang & Yang, 2009). Upon activation of PKC by PMA, 
both the MAPK/ERK and PI3/Akt pathways are induced (Lallemend et al., 2005) and 
possibly mediated by TG2 activation resulting in protection of myocardial cells from 
H2O2 induced cell death and DNA degradation. ? Sign for an unknown pathway. 
 
Although the PI3/Akt signalling mediated-PKC activation is not a classical pathway, 
it could be linked by a non-receptor tyrosine kinase PYK2 that can be phosphorylated 
and activate the PI3/Akt pathway (Sayed et al., 2000; Shi & Kehrl, 2001; Sarkar et al., 
2002). Alternatively, the activation of this pathway could be due to oxidative stress 
(e.g. induced by H2O2) in H9c2 cells (Hong et al., 2001; Singla et al., 2008). 
Obviously, further studies exploring the effect of inhibitors for PKA, PKC, ERK1/2 
and pAKT would either confirm or eliminate the involvement of these exact kinases 
in PMA and FK-mediated cytoprotection in H9c2 cells. These pathways may also 
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contribute to TG2-mediated protection against H2O2 in response to PMA and FK 
treatments. In order to identify the mechanism by which TG2 protects cells against 
H2O2 induced stress, an ideal approach is to inhibit each of the pathways, separately 
and see whether TG2 is still protective. The diminishing of the pathways could be 
achieved by several means dependent on the pathway such as using specific inhibitors 
for these affected kinases or using small interfering RNA (Milhavet et al., 2003) to 
knock down important proteins involved in specific pathways. 
In spite of indecision surrounding the precise identity of the protein kinases involved 
in PMA and FK-induced cytoprotection, it is apparent that TG2 activation is involved 
in their cardioprotective actions. The phosphorylation of TG2 by PKA has several 
consequences, including the promotion of protein-protein interactions and 
enhancement of TG2 kinase activity, both of which might underlie its protective role 
(Mishra & Murphy, 2006; Mishra et al., 2007). For example, the phosphorylation of 
TG2 at Ser
216
 by PKA forms a binding site for the adaptor protein 14-3-3 (Mishra & 
Murphy, 2006). Interestingly, 14-3-3 proteins regulate various cellular functions 
including signalling pathways that are associated with cell survival (Mackintosh, 
2004). Although not associated with PKA phosphorylation and independent of its 
transamidating activity, TG2-mediated protection of neuronal cells against hypoxia 
and glucose deprivation-induced cell death through its interaction with hypoxia 
inducible factor 1β (HIF1β) which in turn reduces HIF1 signalling (Filiano et al., 
2008). It would be interesting in future work to identify TG2 interacting proteins in 
cardiomyocytes following PMA and FK stimulation. 
TG2 also has serine/threonine kinase activity and it has been involved in 
phosphorylation of insulin-like growth factor-binding protein 3, p53 and 
retinoblastoma protein in vitro (Gundemir et al., 2012). Both retinoblastoma and p53 
proteins are important regulators of apoptosis and thus it is believable that they are 
associated with TG2- modulated cardioprotection in H9c2 cells. Furthermore, the 
anti-apoptotic effects of TG2 implicate the crosslinking of retinoblastoma protein 
(Boehm et al., 2002) and hence it would be interesting to determine if retinoblastoma 
protein is a TG2 substrate in H9c2 cells. Moreover, the phosphorylation of TG2 by 
PKA at Ser
216
 appears to play an important role in TG2 mediated activation of NF-κB 
and PKB in fibroblast cells (Wang et al., 2012). Again, both of these signalling 
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pathways are associated with cardioprotection (Mishra et al., 2003; Hausenloy & 
Yellon, 2007) and it is possible they are regulated by TG2 in H9c2 cardiomyocytes 
following FK stimulation. This would need to be confirmed by an in vivo assay. In 
summary, TG2 is able of eliciting several pro-cell survival pathways related to 
cardioprotection that are either independent of its transamidating activity that require 
the prior phosphorylation by PKA or depend on its protein kinase function.  
The activity of TGs are inhibited by GTP/GDP and evidence suggests that TG2 when 
bound to GTP/GDP functions as a G-protein (known as Gαh; (Mhaouty-Kodja, 
2004)). Indeed, several members of the G-protein coupled receptor (GPCRs) family 
including the 1B-adrenergic receptor, thromboxane A2 receptor and oxytocin 
receptor couple to Gαh when activated, promoting exchange of GDP for GTP 
(Gundemir et al., 2012). Activated Gαh-GTP stimulates phospholipase C1 promoting 
phosphoinositide hydrolysis and stimulating increases in intracellular Ca
2+ 
(Gundemir 
et al., 2012). An increasing number of membrane-bound receptors belonging to the 
GPCR superfamily have been implicated in cardioprotection including the adenosine 
A1 receptor and members of the adrenergic receptor family (Sanada et al., 2011). 
These receptors trigger cardioprotection via the activation of signalling pathways 
involving PKC and PKA (Sanada et al., 2011). Indeed the data presented in this study 
have shown that the selective adenosine A1 receptor agonist N
6
-cyclopentyadenosine 
and the non-selective β-adrenergic receptor agonist isoprenaline trigger in situ 
increases in TG2 activity in H9c2 cells and is reversed by the inhibitor Z-DON. On-
going work is currently exploring the role of TG2 in cardioprotection triggered by the 
adenosine A1 receptor.  
In the current study, it has shown that TG2 activation prior to H2O2-induced oxidative 
stress is cytoprotective. There is growing evidence in the literature that oxidative 
stress promotes the up-regulation of TG2, which may promote cell survival or 
apoptosis depending on cell type (Caccamo et al., 2012). Interestingly, oxidative 
stress up-regulates TG2 expression in rat neonatal cardiomyocytes, contributing to 
H2O2-induced apoptosis (Song et al., 2011). It is worth noting that in this study it was  
observed an increase in TG2 activity in H9c2 cells following H2O2 stimulation. The 
present results have shown that oxidative stress induced by H2O2 results in stimulation 
of the biotin amine incorporation but not the protein crosslinking TG2 activity in 
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H9c2 cells, as shown by in situ and in vitro assays. This is in agreement with previous 
studies, which have reported that oxidative stress via H2O2 could not elevate in vitro 
TG2 activity, which depends on the cell type and the existence of specific cellular 
factors (Shin et al., 2004; Park et al., 2010). However, when the oxidative stress 
followed pre-treatment with PMA but not FK, there was a statistically significant 
increase in TG2 catalysed biotin cadaverine incorporation detected in vitro and in situ 
with both treatments. Both in vitro and in in situ, different TG2 inhibitors also 
reversed this activation. This suggests that this activity was due activation of 
endogenous TG2 in H9c2 cells and that this may contribute to cytoprotection.  
There were no correlations between the in vitro activation but not in situ and TG2 
protein level in response to H2O2 alone or in pre-treatment cells by PMA but not FK. 
This confirms the previous suggestion by Shin et al. (2004) in which there is not 
always any correlation between TG2 protein level and its activity (Jeon et al., 2004). 
This suggests that the level of TG2 activation is dependent on cell and stress types 
(Shin et al., 2004) possibly due to Ca
2+
 level. Until now, the molecular mechanisms 
by which intracellular TG2 is regulated are not clear. Some TG family members have 
been reported to undergo proteolytic cleavage to activate the intracellular enzymes 
(Lorand & Graham, 2003); no proteolytic activation has been reported in the case of 
TG2 regulation (Jeon & Kim, 2006). However, phosphorylation of TG2 by PKA and 
TG2 SUMOylation in response to oxidative stress has been reported (Mishra et al., 
2007; Luciani et al., 2009). In this study, therefore, it is possible that TG2 is 
posttranslationally modified by these kinases. Further work will be undertaken to 
establish whether TG2 is modified by a posttranslational modification such as 
phosphorylation mediated by protein kinases A and C. 
Despite the fact that TG2 is unlikely to be localised in the endoplasmic reticulum 
(Lorand & Graham, 2003; Iismaa et al., 2009), in this study, TG2 activity was shown 
to target mitochondria and endoplasmic reticulum proteins. Significantly, the 
likelihood, that TG2 functions to facilitate survival or death could be highly 
dependent on its cellular localisation and substrate accessibility (Esposito & Caputo, 
2005; Park et al., 2010). It is worth mentioning that a recent study by Szondy and his 
group suggests that the abolition of TG2 in knockout mice resulted in a serious failure 
of ATP production and a significant increase in heart infarct size (Szondy et al., 2006). 
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This suggests the involvement of TG2 catalytic activity in the posttranslational 
modification of some essential mitochondrial regulatory proteins (Szondy et al., 
2006). Although there is no report of TG2 translocation onto different organelle
 
membranes, the interaction of isoforms of PKC with different organelles depends on 
the signal transduction and cell types (Schechtman & Mochly-Rosen, 2001). This may 
explain the co-localisation of TG2 onto the endoplasmic reticulum and mitochondria 
(Fig. 4.3.11). Therefore, it is possible that TG2 is transiently localised to the 
mitochondria or endoplasmic reticulum, where it can interact with and modify 
substrates, which may potentially play a role in cardioprotection. It will be of value in 
future studies to determine TG2 activity in each cellular organelle (mitochondria and 
endoplasmic reticulum) of heart tissue/cells to further explore its function modulated 
by PKA and PKC activation. Hence, it is interesting to speculate that TG2, when 
activated promotes cell survival if activated prior to an oxidative insult, whereas it 
may participate in cell death when activated following exposure to the stress stimulus. 
Future experiments will seek to address this potential dual role of TG2 in 
cardiomyocytes.     
TG2 substrates induced by PKA and PKC activation in H9c2 cells  
 
Most cells take up polyamines (Seiler et al., 1996) and biotin-X-cadaverine has been 
used to label cells and visualise proteins that are targeted by transglutaminase (Perry 
et al., 1995). Using this cell permeable biotinylated substrate of TG2, it is possible to 
visualise the protein targets of TG2 activity after 5 min treatment following oxidative 
stress or activation of PKA and PKC with pharmacological activators. Many intra and 
extra-cellular proteins can interact with TG2 acting as substrates that are modulated 
by its activities (Esposito & Caputo, 2005). This interaction may be important for 
those cellular proteins to perform their biological functions. The recognition of 
proteins that act as TG2 substrates is of critical importance for studying TG2's 
biological role in different cell types and tissues (Facchiano et al., 2006).  
Posttranslational modifications of proteins through incorporation of polyamines or 
crosslinking mediated by TG2 have been implicated  in a wide range of physiological 
functions, including ECM stabilisation and formation (Grenard et al., 2001), 
angiogenesis progression (Wang et al., 2013), cell adhesion and survival regulation 
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(Wang et al., 2011) and apoptosis (Rossin et al., 2012). Therefore, the biotin-X-
cadaverine labelled proteins in treated H9c2 cells were captured with CaptAvidin 
beads and analysed by LC-MSMS. Twenty-five proteins were identified as TG2 
substrates and some of these protein targets were confirmed by immunofluorescence 
staining and Western blotting techniques. These targets include cytoskeletal 
organising proteins, chaperone proteins, Ca
2+ 
and phospholipid binding proteins and 
proteins involved in membrane transport processes. 
These data suggest the association of TG2 with the ER, since ER chaperone proteins 
HSP 90 and a novel TG2 substrate 78 kDa glucose-regulated protein were also among 
identified TG2 substrates targeted by this activity.  Proteomic analysis of human 
CaCo-2 intestinal epithelial cells also revealed that HSP 90 was a TG2 substrate 
located on the ER (Orrù et al., 2003). The 78 kDa glucose-regulated protein is one of 
many ER chaperones that play a significant role in cardioprotection (Glembotski, 
2008; Yang et al., 2011). Several mitochondrial matrix proteins have been shown to be 
TG2 substrates and were identified in the current and other studies, including HSP 70, 
HSP 90 organising protein, prohibitin (Orrù et al., 2003; Park et al., 2010) and two 
more novel mitochondrial proteins malectin, and serpin H1. Indeed, the involvement 
of these essential proteins in the modulation of TG2 activity induced by PKC and 
PKA signalling pathway suggests a role for this activity in cardioprotective cellular 
responses. 
Several cytoskeleton organising proteins were identified as TG2 substrates in the 
current study; among them α-actinin and tubulin. Both of these proteins have an 
essential role in the contractile function of smooth muscle cells modulating 
cytoskeleton restructuring (Fultz et al., 2000). Alpha actinin is also known as a marker 
for the Z-line of the sarcomere and the translocation of PKCɛ to this region is of 
importance to cardioprotection promotion (Robia et al., 2001). This suggests that the 
depletion of amine incorporation into α-actinin by TG2 inhibitors may affect the 
translocation and activation of PKCɛ, eliminating its protective effects. The 
polyamination of tubulin by TG2 has been reported in neuronal cells both in vitro and 
in vivo, in which the inhibition of transglutaminase activity or polyamine synthesis 
result in a significant decrease in neuronal microtubule stability (Song et al., 2013). 
Cardiac-microtubules support intracellular transport, facilitate cell growth, and form a 
basis for cardio morphology (Gregorio & Antin, 2000; Schweitzer et al., 2001; Severs 
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et al., 2006). Thus, it may be that polyamination of these cytoskeleton proteins is 
essential for cardiomyocyte microtubule stabilisation and thus necessary for unique 
cardiomyocyte structures and functions. Further confirmation will be necessary to 
verify these candidates as genuine substrates of TG2.  
Endomembrane vesicle trafficking proteins including the Arf-GAP -containing protein 
1 and Ras-related protein Rab-35 were also shown to be TG2 substrates in H9c2 cells. 
This finding suggests a possible role of TG2 mediated by PMA and FK in organising 
the actin cytoskeleton (Randazzo et al., 2000) and regulating intracellular vesicle 
trafficking (Takai et al., 2001) as well as exosome secretion (Hsu et al., 2010).  
The present data support the hypothesis that TG2 catalyses the posttranslational 
polyamination of target substrates involved in cytoskeletal organisation, protein 
folding machinery or endomembrane vesicle trafficking, and that this is likely to 
modify the physical-chemical properties of these target proteins. In turn, this is likely 
to influence their interactions with other proteins and control their biological activity 
with respect to cardioprotection.  
In the current study, TG2-mediated changes to a specific substrate protein mediated 
induced by protein kinase activators have not always been linked to its cellular 
function. It would be of interest to make this correlation via identification of these 
TG2 substrates in vivo in combination with a structural and functional proteomic 
approach. This could help in identification of these TG2 substrate proteins in relation 
to physiology and cardiac disease, allowing one to explore the crosslinking or 
interaction in such conditions as normal verses ischaemic or preconditioned cells or 
tissues, and normal verses differentiated cells or even cells undergoing necrotic or 
apoptotic processes. In addition, would also be of interest to screen for differences in 
TG substrates between various stimuli. 
In conclusion, the results presented in this thesis demonstrate that TG2 activity is 
modulated in H9c2 cells by PMA- and FK-mediated signalling pathways. Importantly, 
the study has shown for the first time that inhibition of TG2 attenuates PMA and FK-
mediated cytoprotection against H2O2-induced oxidative stress suggesting a 
cardioprotective role for this multi-functional enzyme. This TG2 transamidation 
activity is mainly a polyamine incorporation activity that results in posttranslational 
modification of intercellular proteins. The main target proteins labelled following 
activation by these protein kinase activators are involved in cytoskeletal organising, 
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protein folding machinery or endomembrane vesicle trafficking. Overall, this study 
has made a significant contribution to the understanding of the intracellular roles of 
TG2 polyamine incorporation activity, which remains largely an unploughed field. 
Moreover, it has revealed the relationship between PKC, PKA, their receptors and 
TG2 transamidation activity in cardiomyocytes. Figure 7.2 summarizes proposed 
mechanisms of TG2 activation modulated by PKA and PKC, protecting cardiac cells 
from H2O2-induced cell injury based on the data presented in this and other published 
work. 
Future work aims to identify TG2 substrates in H9c2 cells following PMA and FK 
stimulation by 2D-PAGE and to compare the effect of each treatment on these 
substrates by linking them to their cellular function, the potential regulation of TG2 
activity by GPCRs associated with cardioprotection and to explore further the 
potential mechanisms of TG2-mediated cardioprotection. In addition, it is of 
importance to measure calcium release before and after each treatment and 
determination of TG2 activity in subcellular fractions. In the future, it may be possible 
to exploit the new set of information for the treatment of ischaemic heart disease 
using heart tissue. 
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Figure 7.2 Hypothetical model of proposed mechanisms of TG2 activation 
modulated PKA and PKC protecting cardiac cells from H2O2-induced cell injury 
based on the data presented in the current study and other published data 
 
Forskolin (FK) and PMA increase TG2 polyamine incorporation activity through an 
unknown mechanism possibly involving elevated Ca
2+
 (Lagast et al., 1984; Andrews 
et al., 2002; Griffin et al., 2002; Dermitzaki et al., 2004), cAMP elevation (Szondy et 
al., 2006; Obara et al., 2012) or phosphorylation of TG2 or its substrates proteins 
(Mishra & Murphy, 2006; Mishra & Murphy, 2006; Mishra et al., 2007). The 
increased TG2 polyamine incorporation activity results in posttranslational 
modification of intracellular proteins (Fesus & Piacentini, 2002; Park et al., 2010; 
Gundemir et al., 2012). The main target proteins by of TG2 activation are cytoskeletal 
organising, protein folding (HSPs) or endomembrane vesicle trafficking proteins. 
Oxidative stress induced by H2O2 promotes cell death and apoptosis increased levels 
of ROS (Lee et al., 2003), decreased mitochondrial ATP production (Lennon et al., 
1991; Lelli et al., 1998) or TG2 overexpression (Song et al., 2011). The pre-exposure 
of cells to PMA and FK induces cell survival pathways resulting in cytoprotection 
against H2O2 through ERK/PI3 phosphorylation (Lallemend et al., 2005; Wang et al., 
2009) and TG2 polyamine incorporation activity. The TG2 inhibitors block these 
protective effects (TG2 activity and pAKT but not pERK) resulting in cell death.   
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CHAPTER IX:  
APPENDICES 
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9. Appendices  
Protein kinase activator stimulated protein phosphorylation in H9c2 cells  
Initial experiments concentrated on evaluation of phosphorylation events in H9c2 
cells via different protein stains after treatment with protein kinase activators.  
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Figure 8.1 Quantification of protein phosphorylation in response to PMA in 
H9c2 cells by Pro.Q diamond phospho-stain and SYPRO Ruby protein stain  
H9c2 cell lines were incubated with 1 µM PMA for the times indicated and were then 
harvested, lysed and denatured at 95°C in hot Laemmli buffer. Lysates were resolved 
by SDS-PAGE and proteins were revealed with Pro-Q Diamond phosphoprotein stain 
(A) and subsequently with SYPRO Ruby total protein gel stain (B). Protein marker 
lane 1, Control (0 min) lane 2, 1 μM PMA treated H9c2 cells in time course; lanes 3-
7, respectively. (C) Densitometry was carried out in Adobe Photoshop CS4 and values 
plotted as relative intensity versus the treatment incubation time. Results represent 
mean ± SEM of the optical density ratio from three independent experiments. Data are 
expressed as the percentage of phosphorylation of proteins at basal level in the 
untreated cells (0 min). *P < 0.05,***P <0.001. Proteins showing increased 
phosphorylation are highlighted by red circles. 
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Figure 8.2 Quantification of protein phosphorylation in response to FK in H9c2 
cells by Pro.Q diamond phospho-stain and SYPRO® Ruby protein stain  
 
H9c2 cell lines were incubated with 10 µM FK for the times indicated and were then 
harvested, lysed and denatured at 95°C in hot Laemmli buffer. Lysates were resolved 
by SDS-PAGE and proteins were revealed with Pro-Q Diamond phosphoprotein stain 
(A) and subsequently with SYPRO Ruby total protein gel stain (B). Protein marker 
lane 1, Control (0 min) lane 2, 10 μM FK treated H9c2 cells in time course; lanes 3-7, 
respectively. (C) Densitometry was carried out in Adobe Photoshop CS4 and values 
plotted as relative intensity versus the treatment incubation time. Results represent 
mean ± SEM of the optical density ratio from three independent experiments. Data are 
expressed as the percentage of phosphorylation of proteins at basal level in the 
untreated cells (0 min). *P < 0.05,**P <0.01. Proteins showing increased 
phosphorylation are highlighted by red circles.
 
The results demonstrate (Fig. 8.1) an increase in band intensity of phpophoproteins in 
PMA treated samples over time compared to the control cells (0 min). The increase 
was most prominent after 5 & 10 min (Fig. 8.1a). In addition, when samples were 
subsequently stained for protein with SYPRO Ruby stain (Fig. 8.1b), the ratio of 
protein phosphorylation was determined from both stains and calculated relative to 
control. This shows an increase in protein phosphorylation of the samples that were 
treated with PMA at the early time points (Fig. 8.1c). 
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This was also true when H9c2 cells were treated with FK as a protein kinase A 
activator (Fig. 8.2).  
Western blot analysis of phosphorylated protein  
Western blots of H9c2 cell extracts treated with PMA or FK in different time points 
were probed with anti-phosphoserine (Fig. 8.3a) and anti-phosphothreonine antibodies 
(Fig. 8.3b). In general, the results demonstrate an increase in band intensity of 
proteins containing either phosphoserine or phosphothreonine in treated samples over 
time compared to the control cells (0 min). Interestingly, on the filter paper that was 
probed with anti-phosphoserine (Fig. 8.3a) there was a slight increase in band 
intensity ~74 kDa that corresponded to standard TG2 in comparison to control and 
one more band in 50 kDa. However, when membrane was stripped and re-probed with 
phosphothreonine antibodies, TG2 the standard no longer appeared but a new band 
corresponding to ~70 kDa was detected. Another western blot of the sample probed 
with anti-phosphotyrosine antibodies (Fig. 8.3c). This showed an increase in band 
intensity of proteins that corresponded to size of~100 kDa and ~77 kDa over the 
incubation time. 
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Figure 8.3 Detection of protein bound phospho-tyrosine, phospho-serine and 
phospho-threonine in PMA and FK treated H9c2 cells 
H9c2 cell lines were incubated with 1 μM PMA or 10 μM FK for the times indicated 
and were then harvested, lysed and denatured at 95°C in hot Laemmli buffer. Lysates 
were loaded and resolved by SDS-PAGE and transferred onto nitrocellulose 
membrane filters. Filters were then blocked and probed with (A) anti-phosphoserine, 
(B) anti-phosphothreonine (C) anti-phosphotyrosine. Protein marker lane 1, control 
(untreated cells = 0 min) lane 2, PMA treated H9c2 cells in time course lanes 3-5 
respectively and FK treated H9c2 cells in time course lanes 6-9 respectively and TG2 
lane 10.  
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Identification and fractionation of acyl-donor TG2 substrates 
A)                                  
 
 
 
 
 
 
 
B) 
 
 
 
       
 
 
          
Figure 8.4 TG2-mediated labelling of PMA/FK treated H9c2 cells with the acyl-
acceptor probe biotin-X-cadaverine  
PMA/FK treated biotin-X-cadaverine labelled H9c2 proteins were fractionated on 
CaptAvidin beads; equal amounts of bound and unbound materials were resolved by 
SDS-PAGE and analysed by Western blotting. The resultant blots of H9c2 proteins 
were probed with ExtraAvidin peroxidase. A) biotin-X-cadaverine proteins isolated 
with CaptAvidin beads from PMA treated cells.  B) biotin-X-cadaverine proteins 
isolated with CaptAvidin beads from FK treated cells. 
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Figure 8.5 Identification of TG2 substrate proteins in PMA treated H9c2 cells 
from 2D-PAGE 
H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine for 4h. They were then 
treated with 1 µM PMA for 5 min. The biotin-cadaverine labelled proteins were 
isolated with CaptAvidin beads, subjected to 2D-PAGE and the spots aligned to those 
on western blots (see Fig 6.2.5). Spots of interest were extracted, digested with trypsin 
and subjected to mass spectrophotometry. The numbered spots were identified as (1) 
78 kDa glucose-regulated protein, (2) tubulin, (3) annexin; A2, (4) actin, (5) voltage-
dependent anion-selective channel protein 1, (6) α-actinin, (7) vimentin and (8-9) 60S 
ribosomal protein L5.
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 Mascot Search Results 
1) Protein View 
Match to: VDAC1_RAT Score: 194 
Voltage-dependent anion-selective channel protein 1 OS=Rattus norvegicus GN=Vdac1 PE=1 SV=4 
 
Nominal mass (Mr): 30737; Calculated pI value: 8.62 
NCBI BLAST search of VDAC1_RAT against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Rattus norvegicus 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 44% 
 
Matched peptides shown in Bold Red 
 
     1 MAVPPTYADL GKSARDVFTK GYGFGLIKLD LKTKSENGLE FTSSGSANTE  
    51 TTKVNGSLET KYRWTEYGLT FTEKWNTDNT LGTEITVEDQ LARGLKLTFD  
   101 SSFSPNTGKK NAKIKTGYKR EHINLGCDVD FDIAGPSIRG ALVLGYEGWL  
   151 AGYQMNFETS KSRVTQSNFA VGYKTDEFQL HTNVNDGTEF GGSIYQKVNK  
   201 KLETAVNLAW TAGNSNTRFG IAAKYQVDPD ACFSAKVNNS SLIGLGYTQT  
   251 LKPGIKLTLS ALLDGKNVNA GGHKLGLGLE FQA 
2) Protein View 
Match to: ACTB_RAT Score: 185 
Actin, cytoplasmic 1 OS=Rattus norvegicus GN=Actb PE=1 SV=1 
 
Nominal mass (Mr): 41710; Calculated pI value: 5.29 
NCBI BLAST search of ACTB_RAT against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Rattus norvegicus 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 31% 
 
Matched peptides shown in Bold Red 
 
     1 MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK  
    51 DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE  
   101 HPVLLTEAPL NPKANREKMT QIMFETFNTP AMYVAIQAVL SLYASGRTTG  
   151 IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF  
   201 TTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI  
   251 GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS  
   301 GGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS  
   351 TFQQMWISKQ EYDESGPSIV HRKCF 
 
 
Figure 8.6 An example of Mascot fingerprinting reports for some of identified 
TG2 substrates 
Report shows fingerprinting of 1) voltage-dependent anion-selective channel protein 
1, and 2) actin, cytoplasmic 1, the score and % sequence coverage are highlighted in 
yellow. 
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